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Purpose.

5-HMF is a potential antisickling agent forming a Schiff-adduct with

hemoglobin (Hb). In-vitro studies were designed to identify the metabolic pathways of 5HMF in human hepatic cytosol, to assess inter-species differences in its hepatic
metabolism, and to predict in-vivo PK properties. Moreover, metabolism of 5-HMF in
human RBCs was investigated. Finally, in-vitro studies were done to characterize 5-HMF
binding kinetics with human Hb and albumin (HSA).

Methods. NAD+ reduction was monitored at 340 nm in human hepatic cytosol for 5-HMF
(26 mM) and prototypical ADH and ALDH substrates in the presence or absence of their
inhibitors. Furthermore, concentration-dependency studies were performed for 5-HMF
(1.5-96 mM) in mouse, rat, dog, and human hepatic cytosol and fitted by Michaelis
Menten (MM) model. In-vitro-in-vivo-extrapolation (IVIVE) was performed using the
well-stirred model. Moreover, metabolic studies of 5-HMF (12-142 mM) in human RBCs
were done under similar conditions.
Time- and concentration-dependent binding studies were conducted for 5-HMF (5 µM-5
mM), in Hb (217 μM) and HSA (6 3 and 202 μM) solutions. Ultrafiltered 5-HMF
concentrations were measured by a validated HPLC-UV assay. After correction for
nonspecific binding, rate constants, binding affinity, and capacity were estimated by
nonlinear regression.

Results. In human hepatic cytosol, 5-HMF followed MM kinetics with Km: 218(±74) mM
and was mainly inhibited by the ALDH inhibitor. In all animal species, 5-HMF exhibited
millimolar Km values and is expected to have low hepatic extraction, high oral
bioavailability, and first-order PK for relevant blood concentrations. The IVIVE-predicted
in-vivo half-lives for 5-HMF were adequate for the mouse and dog but overestimated for
humans. In RBCs, 5-HMF had Clintin-vitro of 0.34(± 0.02) ml/min/ml RBCs scaled-up to 9.9
ml/min/kg.
Time-dependent binding of 5-HMF was demonstrated for both Hb and HSA. Steady-state
studies revealed saturable Hb binding and non-saturable HSA binding.
xxx

Conclusions. 5-HMF is an ALDH/ADH substrate in hepatic cytosol. Across animal
species, 5-HMF is expected to be a low-hepatic-extraction-ratio drug with high oral
bioavailability. 5-HMF is subject to RBCs metabolism in human. 5-HMF is expected to
show fast association with, but slow dissociation from its drug target, Hb, which may lead
to a prolonged in-vivo PD effect.
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CHAPTER 1
1
INTRODUCTION

1.1

Sickle Cell Disease

1.1.1 Prevalence

Sickle cell disease (SCD) is one of the most common inheritable genetic diseases
worldwide (Niscola 2009) (Wahl 2009). SCD is affecting 1 in every 375 African-American
births in the USA, 100,000 patients in the general USA population, and it has an estimate of 2025 million patients in the world (Aliyu 2008) (Driscoll 2007) (Bolaños-Meade 2009) (Field
2009). The frequency of SCD is becoming more uniform through the world because of the
immigration of patients to countries with low SCD incidence history (Niscola 2009).
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1.1.2 Pathogenesis

The pathogenesis of the disease reveals a substitution of the normal GAG codon with
GTG resulting in the expression of sickled hemoglobin (HbS) rather than adult hemoglobin
(HbA), where glutamic acid amino acid is replaced by valine amino acid at the sixth position of
β-globin protein in patients with SCD (Niscola 2009) (Smiley 2008) (Wahl 2009). The resultant
HbS is less stable and less soluble than the normal HbA (Niscola 2009). Consequently, the
typically flexible doughnut shape of red blood cells (RBCs) is altered to stiff crescent-like RBCs,
in which Hb is likely to polymerize upon uploading its oxygen content (Vekilov 2007).
Furthermore, patients with SCD might be affected by other hemoglobin abnormalities, such as
thalassemia, and the resultant syndrome is dependent of the accompanying defect (Niscola
2009).
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1.1.3 Complications

The quality of life of SCD patients ranges from normal asymptomatic life to one with
frequent hospitalization (Niscola 2009). Besides leading to anemia as a result of abnormal RBCs
destruction, SCD is associated with other complications due to the abnormal shape of RBCs.
Infection is an important problem faced by SCD patients and can be severe enough to cause
death, e.g. pulmonary infections. Furthermore, the tendency of HbS to polymerize upon
deoxygenation results in vascular occlusion (Driscoll 2007). Because of that, acute
manifestations like acute splenic sequestration and vaso-occlusive pain crises occur, which is the
predominant symptom in SCD patients (Niscola 2009). Niscola and co-workers reported that
while 39% of SCD patients had no pain crises, 5.2% of the patients had 3-10 annual pain
episodes (Niscola 2009). The pain crises were found more frequent in adults than in children and
were associated with higher hematocrit and lower fetal hemoglobin (HbF) percentage (Field
2009). Overall, approximately 90% of SCD patients’ hospitalizations are due to the pain
episodes that they encounter (Niscola 2009). Other consequences of RBC deformation are
chronic organ damage, cerebrovascular disease, and pulmonary hypertension (Smiley 2008)
(Driscoll 2007). Because of the chronic nature of SCD and frequent hospitalization, some
patients suffer from psychological illnesses as well (Niscola 2009).
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1.1.4 Sickle Cell Disease Treatments

1.1.4.1 Non-Opioid Analgesics

Mild to moderate pain is managed by acetaminophen and non-steroidal anti-inflammatory
drugs (NSAIDs) in a pathway that leads to desensitizing of the nociceptors responsible for pain,
with an advantage of the latter in having an anti-inflammatory effect (Niscola 2009). In severe
pain cases, these are combined with opioids to decrease the dose that would be required if
opioids were used alone (Field 2009) (Niscola 2009). On the other hand, NSAIDs inhibit the
basal levels of prostaglandin and may lead to renal and cardiovascular toxicity (Niscola 2009).
Moreover, aspirin is avoided in children due to the risk of Reye’s syndrome (Niscola 2009).

1.1.4.2 Opioids

Opioids represent an approach for providing an immediate relief of acute pain episodes
(Field 2009). The presence of multiple choices in this class acting on different opioid receptors,
ranging from weak agonists, e.g. codeine, to strong agonists, e.g. morphine, and formulated in
different dosage forms offers an advantage that encourages clinicians to prescribe them for SCD
patients (Niscola 2009) (Field 2009). However, the misuse of these drugs leading to drug
dependence is an immense disadvantage in their therapy (Niscola 2009). In addition, if not
cautiously administered, opioids may cause death by respiratory depression (Niscola 2009).
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1.1.4.3 Hydroxyurea

Currently, hydroxyurea is the only Food and Drug Administration (FDA) approved
therapeutic agent for the treatment of SCD (Charache 1997) (Lanzkron 2008). Its diseasemodifying properties are a result of its ability to induce HbF production by unclear mechanism
of action (Lanzkron 2008). HbF has a higher oxygen affinity than that of HbA (Lanzkron 2008).
The protective effect of a relatively higher fraction of HbF in some SCD patients is demonstrated
in lower pain episode rates, as discussed in Section 1.1.3 (Niscola 2009). In addition, a two-year
study with a maximum hydroxyurea daily dose of 35 mg/kg resulted in 3.5% increase in HbF
and a decrease in the annual rate of pain crises (Lanzkron 2008). Upon a seven-year follow-up, it
was observed that the mortality rate decreased by 40% (Lanzkron 2008). Unfortunately,
hydroxyurea was associated with reproductive toxicity in male mice and developmental toxicity
in rat and mice fetuses (Lanzkron 2008). In addition, chronic administration of this agent was
associated with leukemia, lymphoma, and skin hyperpigmentation (Lanzkron 2008).
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1.1.4.4 Stem Cell Transplant

Other therapeutic approaches are mainly supportive and do not cure the disease with the
exception of hematopoietic stem cell transplant, which is hindered by its eligibility criteria and
the availability of suitable donors (Lanzkron 2008) (Driscoll 2007). The age of the ideal
candidate for a bone marrow transplant is usually not more than 16 years and he should have
suffered a major complication of SCD, such as stroke, neuropathy, and retinopathy. In addition,
the donor should be a sibling having a matching lymphocyte antigen (Bolaños-Meade 2009).
Besides, considering that children are the ones who are undergoing this surgery, families are
often worried about the mortality rates and morbidities affecting their growth and development
(Bolaños-Meade 2009).

1.1.4.5 Blood Transfusion:

Blood transfusion is indicated for the management of anemia in SCD. The aim of blood
transfusion is to dilute HbS with normal blood and increase the life span of circulating RBCs
(Wahl 2009). Yet, many complications are associated with this procedure, such as
alloimmunization, infection, acute lung injury, and iron overload (Wahl 2009) (Porter 2007).
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1.1.4.6 Non-Pharmacological Interventions

Non-pharmacological and behavioral interventions constitute an important part in SCD
treatment. Massage and relaxation were reported to decrease the pain rate (Niscola 2009). In
addition, optimism and cognitive strategies are used to cope with pain and alter its perception in
SCD patients (Niscola 2009).
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1.2

5-HMF

1.2.1 Exposure to 5-HMF

5-HMF is a versatile ubiquitous compound, to which humans are exposed in industry,
food, and pharmaceutical formulations. As shown in Figure 1-1, 5-HMF is a small (MW: 126 D)
molecule with a pKa value of 12.8 (ACS 2009) that behaves as a neutral molecule at
physiological pH range.

The following are major areas, in which 5-HMF is involved:

1.2.1.1 5-HMF in Industry

As part of its utility, 5-HMF is used in the synthesis of resins, solvents, polymers, and
plant protective agents (NTP 1994). In addition, 5-HMF is produced from biomass and is
investigated as an alternative biofuel (Yong 2008). On the other hand, 5-HMF has a negative
industrial interaction since it is considered as a potent inhibitor for ethanologenic bacteria growth
and fermentation, which are used to produce ethanol (Liu 2006).
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Figure 1-1. 5-HMF structure
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1.2.1.2 5-HMF in Drug Formulations

Human exposure to 5-HMF can occur through cigarette smoke and pharmaceutical
syrups (NTP 1994). In addition, 5-HMF is found in pharmaceutical products mainly as a
degradation product. As a review for its inadvertent presence, 5-HMF concentration in parenteral
preparations was reported by Ulbricht et al. In this review, 5-HMF was detected at a
concentration of 10 mg/l (Ulbricht 1984) and at a range of 0.2-200 mg/l of 5-HMF in parenteral
solutions (Germond 1987). In addition, 5-HMF was identified in a study investigating impurities
in a morphine sulfate formulation as a result of including the carboxylate salt of opioids and/or
having an acidic formulation (Kelly 2003).
Surprisingly enough, 5-HMF is an active ingredient of a microsupplement product,
Sanopal (Matzi 2007). Currently, this product is marketed as a preoperative support for lung
resection. Moreover, 5-HMF was identified as a therapeutic moiety in traditional Chinese
medicines (Lin 2008) (Li 2005) (Xu 2007).
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1.2.1.3 5-HMF in Food

1.2.1.3.1 5-HMF FORMATION

5-HMF can be found in foods as a result of Maillard reaction, which is a non-enzymatic
reaction between free amino groups in protein and reducing sugars that is enhanced by high
temperature. Moreover, caramelisation (dehydration) of reducing sugars catalyzed by high
temperature and an acidic environment produces 5-HMF (Delgado-Andrade 2007) (M. P.
Murkovic 2006) (Gaspar 2009).
5-HMF consumption is affected by food selection and cooking processes (DelgadoAndrade 2007). In a study conducted by Delgado-Andrade et. al., 5-HMF levels were correlated
with thermal processing (frying vs. boiling) and sugar content (Delgado-Andrade 2007). It was
found that the long heating time and temperature over 90 °C favor the production of furfurals,
including 5-HMF (Cocchi 2008).
Along with 5-HMF, 5-methylfurfural (5-MF) and 2-furfural (2-F) are found in food as a
result of the Maillard reaction (Gaspar 2009). These compounds were identified as structural
analogs for 5-HMF by the National Toxicology Program (NTP) at NIH (NTP 1994). In addition,
5-hydroxymethyl-2-furoic acid (HMFA), which is an identified major metabolite of 5-HMF, was
found in food along with 5-HMF (M. B. Murkovic 2007). A peak concentration of around 0.2
mg/g and 0.9 mg/g coffee of HMFA and 5-HMF, respectively, were formed during a roasting
process. The fact that HMFA levels peaked after the 5-HMF peak suggested that HMFA is a
degradation product of 5-HMF (M. B. Murkovic 2007). However, further investigations
proposed an alternative for the production of HMFA (M. B. Murkovic 2007).
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1.2.1.3.2 5-HMF CONSUMPTION IN FOOD

5-HMF is found in various types of food such as coffee, honey, biscuits, bread, juice,
dried fruits, honey-wines, and cereals (Janzowski 2000) (Gaspar 2009) (Kahoun 2008) (Fallico
2008) at concentrations ranging between 300-1900 mg/kg (M. P. Murkovic 2006). Moreover, 5HMF is present in traditional drinks such as barley tea, which is a common drink in Japan
(Kulkarni 2008). Table 1-1 lists a number of foods with the estimated concentrations of 5-HMF
and its primary metabolite (if data available). Considering its abundant presence, it is estimated
that the daily consumption of 5-HMF ranges between 30-150 mg (Husøy 2008), which is within
the reported acceptable daily intake of 2.5 mg/kg (Germond 1987). Furthermore, 5-HMF levels
have been monitored in honey as an indicator for its quality with respect to overheating and
aging (Gaspar 2009) (Fallico 2008). In addition, a limit of 0.08 mg/g of 5-HMF was reported to
indicate potential adulteration (M. B. Murkovic 2007). Moreover, 5-10 mg/l and 25 mg/l are the
recommendations by the International Federation of Fruit Juice Processors for 5-HMF
concentration in fruit juice and fruit concentrate, respectively (Gaspar 2009).
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Table 1-1. 5-HMF and HMFA concentrations in food.

Food

5-HMF Content HMFA Content
( mg/kg)
( mg/kg)

Reference

Dried apricot

30-780

-

(M. P. Murkovic 2006)

Dried pear

100

-

(M. P. Murkovic 2006)

Dried Peach

40

-

(M. P. Murkovic 2006)

Dried plum

1600-2200

-

(M. P. Murkovic 2006)

Dried plum jam

1100-1200

-

(M. P. Murkovic 2006)

Dried date

1000

-

(M. P. Murkovic 2006)

Dried fig

1

-

(M. P. Murkovic 2006)

Dried pineapple

280

-

(M. P. Murkovic 2006)

Dried apple

80

-

(M. P. Murkovic 2006)

Bread with dried fruits

450

-

(M. P. Murkovic 2006)

Baby food

22

-

(M. P. Murkovic 2006)

Coffee (ground, roasted)

300-1900

-

(M. P. Murkovic 2006)

Whole wheat biscuit

0.16

0.18

(Husøy 2008)

Biscuits with chocolate and
nuts

0.07

0.08

(Husøy 2008)

Cappuccino with added
sugar, instant powder

1.72-143

0.23-17.2

(Husøy 2008)

Coffee instant

91.3-3060

5.6-174

(Husøy 2008)

Ground coffee

262-547

40.3-130

(Husøy 2008)

Bread

0.06-0.14

ND.07

(Husøy 2008)

Narwegian brown cheese

0.08-0.21

ND

(Husøy 2008)

Rasberry jam

0.08

ND

(Husøy 2008)

Honey

0.34

0.05

(Husøy 2008)

Dark beer

13.3

ND

(Husøy 2008)

Chocolate with nuts

ND

ND

(Husøy 2008)

Wine

0.84 g/l

-

(M. B. Murkovic 2007)

Dried plum juice

1.6 g/l

-

(Gaspar 2009)

1.2- 4.6 g/l

-

(Gaspar 2009)

Balsamic vinegar
ND: not detected

13

1.2.2 5-HMF Mechanism of Action and Pharmacodynamics in Sickle Cell Disease

Safo reported that 5-HMF is a potent agent in reducing the sickling of RBCs containing
HbS (SS cells) (Safo 2004). The antisickling action of 5-HMF originates from its ability to form
a Schiff base adduct through binding to the N-terminal α-valine amino acid (Abdulmalik 2005)
(Safo 2004).
Upon preincubation of 5-HMF in SS cells suspension (haematocrit= 20%), a left-shift in
oxygen equilibrium curve (OEC) was observed, shown in Figure 1-2, as a result of increased
affinity to oxygen (O2) in a dose-dependent manner (Abdulmalik 2005) (Safo 2004).
1, 2, and 5 mM of 5-HMF were added to suspensions of RBCs containing HbS (SS cells)
(the concentration of SS cells was not specified) and incubated for an hour under air, after which
they were exposed to hypoxic conditions for 5 hours. Samples were taken at 0, 1, 2, 3, and 5
hours to investigate the percentage of sickled cells using computer analysis (Abdulmalik 2005).
5-HMF added immediately before exposing the cells to the hypoxic conditions was associated
with lower survival of cells in comparison to those pre-incubated with 5-HMF, as shown in
Figure 1-3. This might be attributed to the notion that Hb adduct with aldehydes takes
approximately an hour to form (Abdulmalik 2005).
The adduct formation in an in-vivo system was indicated by the appearance of a new peak
in transgenic mice blood using anion-exchange chromatography at 215 nm after an oral
administration of 5-HMF. 100% and 70% of Hb-adduct were formed in the transgenic mice after
an hour of the oral administration of 100 and 50 mg/kg of 5-HMF, respectively. The peak
remained for 3 hours followed by a gradual decrease. The peak was finally disappeared at 6
hours (Abdulmalik 2005). It should be noted that for in-vitro determination of Hb-adduct, cation
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exchange chromatography along with detection at 410 nm were used, as shown in Figure 1-4
(Abdulmalik 2005).
Further analysis was performed on the data reported by Abdulmalik et. al. in transgenic
mice (Abdulmalik 2005). Concentrations of free hemoglobin, 5-HMF plasma concentrations, and
the adduct formed over time were combined in a semi-quantitative plot, as shown in Figure 1-5.
It is observed that there was a lag-time between the peak plasma concentration and that for the
adduct.
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Figure 1-2. Left-shift in oxygen equilibrium curve upon incubation with 5-HMF. (Abdulmalik
2005)
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Figure 1-3. In-vitro increased survival of RBCs with 5-HMF preincubation. (Abdulmalik 2005)
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Figure 1-4. Hb-adduct formation. (Safo 2004)
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Figure 1-5. Hb-adduct concentration vs 5-HMF plasma concentration. Data taken from
(Abdulmalik 2005)
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Figure 1-6 shows a linear regression analysis that was performed on 5-HMF
pharmacological effect versus the reported concentration. The pharmacological effects were the
inhibition of in-vitro RBCs sickling (6A) and the change in oxygen affinity (pO50) (6B). These
effects were reported in suspensions of RBCs containing HbS that were pre-incubated for one
hour with 0, 1, 2, and 5 mM of 5-HMF and exposed to hypoxic conditions (4% O2) for 5 hours
(Abdulmalik 2005). The inhibition of sickling and the change in pO50 were proportional to the
concentration of 5-HMF in the RBCs suspension. Thus, if a shift of 5-10 mmHg in pO2 is
therapeutically targeted, a blood concentration of 1-2 mM (120-240 µg/ml) of 5-HMF would be
required. This is supported by the results reported by Safo for in-vitro experiments, where 1 mM
and 2 mM of 5-HMF were used and resulted in a shift of -6.6 mmHg and -10.8 mmHg in pO2,
respectively (Safo 2004). In concordance with that, a preliminary projection of a therapeutic 5HMF IV dose was made as 0.8-1.5 g achieving 100-200 µg/ml blood concentration (Venitz
2006).
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Figure 1-6. Blood PD after pre-incubation with 5-HMF. Estimated from (Abdulmalik 2005) (Safo 2004).
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6

1.2.3 1.2.3 Other 5-HMF Pharmacological Activities

Although 5-HMF occurs in herbs and fruits known to exhibit antioxidant effects, 5-HMF
was reported not to have antioxidant activity (Prior 2006). On the other hand, a micronutrient
supplement that contains 5-HMF along with α-ketoglutaric acid (α-KG) was reported to decrease
oxidative stress and increase exercise capacity of athletes though they were declared to have no
doping effect (Matzi 2007). Hence, its effectiveness as a pre-operative support for lung resection
surgeries indicated by lung cancer was investigated (Matzi 2007). The pharmacological 5-HMF
effect in this aspect was attributed to its ability to consume and interact with oxygen, hydroxyl,
and superoxide radicals (Matzi 2007).
It was reported that 5-HMF inhibits interleukins-1 β expression together with the tumor
necrosis factor α (Michail 2007). Consequently, 5-HMF was involved in phase II clinical studies
in combination with other substances as a cytostatic agent (Michail 2007). This might be related
to the ability of 5-HMF to selectively inhibit terminal deoxynucleotidyltransferase (TdT) with an
IC50 of 5 .5 µM and DNA p oly merase λ with an IC50 of 26.1 µM in a competitive manner
(Mizushina 2006). Mizushina et. al. reported that all of the investigated changes in the structure
of 5-HMF resulted in activity loss (Mizushina 2006). This pharmacological activity of 5-HMF is
relevant as an anticancer agent knowing that the inhibition of DNA polymerases is targeted by
antitumor drugs (Miura 2004) and that TdT overexpression is reported in acute lymphocytic and
myelocytic leukemias (Di Santo 2006). TdT is mainly expressed by the developing T and Blymphocytes in bone marrow and thymus (Di Santo 2006). On the other hand, DNA polymerase
λ is expressed mainly in human ovaries, testis, and fetal liver (Di Santo 2006).
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5-HMF was extracted from Dictyophora indusiata mushroom and proved to have antityrosinase activity. The mode of action was found through non-competitive inhibition of the
enzyme with an ID50 of 0.98 mM that might be related to the formation of Schiff-base (Sharma
2004). In this study, mushroom tyrosinase was used for this assay (Sharma 2004). Tyrosinase
enzymes are involved in many important functions as melanin synthesis and undesired enzymatic
browning of vegetables and fruits upon post harvest damage (Sharma 2004).
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1.2.4 5-HMF Pharmacokinetics

Following is an elaborate summary of the ADME properties for 5-HMF as described in
the literature:

1.2.4.1 Oral Absorption and Bioavailability

Only 17% of a 100 mg/kg oral dose of 5-HMF was detected in mice intestine after 5
minutes of administration, which rapidly decreased to 1% by 60 minutes (Czok, Tolerance of 5hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970). This rapid
disappearance indicated a rapid and complete absorption of 5-HMF assuming negligible
chemical and metabolic degradation.
The intestinal absorption of 5-HMF was investigated using Caco-2 cell lines. Breakfast
cereals were used as a source of 5-HMF in addition to a 5-HMF standard (Delgado-Andrade
2008). 5-HMF was subjected to stomach and intestinal digestion through continuous in-vitro
mixing with gastric juice followed by intestinal enzymes and bile acids. This process was
followed by assessment of 5-HMF concentration in the solution before adding it to the apical
chamber of Caco-2 cell lines. It was found that only 13-56% of the 5-HMF content in the cereals
was detected in the soluble fraction of the digest. When the digestion process was applied to 5HMF standard, only 61% of the initial 5-HMF concentration was detected in the soluble fraction
of the digest. Then, the concentration of 5-HMF in the basolateral side was measured after 2
hours of incubation. It was observed that 5-HMF did not affect the integrity of Caco-2
monolayer. 17-68% of the 5-HMF spiked test solutions was detected in the basolateral side.
Breakfast cereals had only 24-32% transported through the cell lines. In this study, 5-HMF was
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suggested to be transported in the intestine through passive diffusion and transporters (DelgadoAndrade, Estimation of hydroxymethylfurfural availability in breakfast cereals. Studies in Caco2 cells 2008).
High oral bioavailability was pointed out by Abdulmalik et al. (Abdulmalik 2005),
implying high fraction absorbed (fabs) and low first-pass effect. In addition, the low value of the
apparent clearance (CLTot/Foral), estimated in that study, indicated a high Foral value and low firstpass effect unless the actual clearance value was so low. The absolute Foral is calculated with
reference to an IV administration of the drug, as illustrated by Equation 1-1, for the same dose
(Hurst, 2007):

Foral =

AUCoral
AUCIV

...............................................................................................................Equation 1-1

Where, Foral is a composite of the drug fraction absorbed through the GI (not metabolized,
degraded, and/or subject to efflux transporters) (fg) and the fraction that escapes the pre-systemic
hepatic metabolism (fh). Thus, Foral can also be described by Equation 1-2 (Hurst, 2007):

Foral = fg × fh ….…………………………………..……..………..………………Equation 1-2
5-HMF is probably a low hepatic-extraction ratio drug. Thus, fh is probably high (>80%).
The structure 5-HMF seems to be relatively stable to degradation in the GI and appears to be
highly permeable. Unfortunately, the role of transporters in 5-HMF disposition has not yet been
characterized. However, considering the structure of 5-HMF and assuming that 5-HMF can be
classified as a class I BCS drug, transporters should not play a major part in its disposition.
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Hence, we postulate that fg is around 90%. Consequently, 72% is the value projected for the oral
bioavailability (Foral) of 5-HMF.

1.2.4.2 Distribution

5-HMF distribution in the body was investigated by assessing the concentration-time
profiles of 5-HMF related radioactivity in rodent tissues studied by Godfrey et al (Godfrey
1999): it was observed that 5-HMF peak levels in various tissues were achieved before 2 hours
post-administration of 100 and 500 mg/kg doses, suggesting a rapid distribution into most
physiological compartments. In addition, liver and kidney had the largest tissue/blood partition
coefficient (AUC48 ratio) in rats and mice, as evident in Table 1-2. This might be attributed to the
fact that these organs not only act as distribution compartments, but also are elimination sites
with relatively high blood supply.
Germond and co-workers investigated the distribution of 5-HMF using whole animal
autoradiography in rats after oral and intravenous administration of [14C]5-HMF (Germond
1987). After one hour of oral administration, most of the radioactivity was found in the bladder,
kidney, and liver with little radioactivity detected in the stomach and small intestines and the
lowest radioactivity detected in the nervous system (Germond 1987). Again, this supports the
conclusion of rapid distribution and emphasize the importance of kidney and liver in the
elimination of 5-HMF. On the other hand, a higher concentration was observed in the nervous
system after intravenous administration (0.1% of the administered dose) and the radioactivity in
the stomach, but not in the small intestine, was absent (Germond 1987). The radioactivity was
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distributed uniformly in other organs (1-2% of radioactivity). Another point, the authors pointed
out the discrepancy in almost complete recovery of 5-HMF related-radioactivity observed in this
study and what was reported in earlier studies, summarized in by Ulbricht et al., in which only
around 50% of 5-HMF was recovered and the unrecovered part was assumed to undergo
covalent protein binding (Germond 1987). Germond et al. attributed this discrepancy to the
ineffectiveness of the extraction method used in the previous studies, in which the glycine
conjugate was not extractable (Germond 1987).
Further analysis of a study carried-out by Czok (Czok, Tolerance of 5hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970) observed a
bixeponential decline of 5-HMF in rat plasma after an IV injection of 100 mg/kg. The volume of
distribution (Vdcc) of 6.6 L/kg estimated for Czok is 10 fold higher than the anticipated 5-HMF
Vd that is equivalent to total body water. The volume of distribution at pseudosteady-state
(Vdpss), 7.2 L/kg, was similar to Vdcc. The same biphasic pattern was observed in mice after
IV bolus injection of 100 mg/kg (Monien 2009). The Vdcc was estimated to be 0.55 L/kg
(Monien 2009). This is equivalent to total body water as would be expected considering 5-HMF
polar structure. On the other hand, the Vdpss was 7.7 L/kg (Monien 2009).
As far as plasma protein binding is concerned, in-vitro interaction of 5-HMF with
intracellular Hb was similar when 5-HMF was incubated in plasma or RBC suspension in saline
(Abdulmalik 2005). Therefore, the fraction of 5-HMF bound to plasma protein is anticipated to
be low. Furthermore, the small molecular size and hydrophilic characteristics of 5-HMF support
the notion of low plasma protein binding.
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Table 1-2. AUC48 tissue/blood ratio of 5-HMF in rats and mice. Estimated from (Godfrey
1999).
Mice
Dose (mg/kg)

Blood

Liver

Kidney

Muscle

Skin

Adipose

Brain

Testes

5

1

2.4

1.4

0.1

0.2

0.1

0.1

0.1

100

1

2.4

5.6

0.6

0.8

0.4

0.4

0.6

500

1

1.8

4.8

0.6

0.9

0.4

0.3

0.6

Rats
10

1

3.5

3.0

1.4

2.2

1.7

0.4

1.2

100

1

4.0

6.3

2.6

2.2

5.1

0.6

2.5

500

1

2.2

6.6

1.5

1.5

1.1

0.4

1.0
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1.2.4.3 Metabolism

On the other hand, Godfrey and co-workers reported in a mass balance study conducted
in rodents (mouse and rat) that the total radioactivity recovery within 48 hours after 5-HMF
administration (5-500 mg/kg) by oral gavage was 80-92%, mostly (>70%) eliminated as
metabolites in the urine (Godfrey 1999).
N-(5-hydroxymethyl-2-furoyl)glycine (HMFG), 5-Hydroxmethyl-2-furoic acid (HMFA),
and 2,5-Furan dicarboxylic acid (FDCA), shown in Figure 1-7, were identified as metabolites in
the urine of rodents, with HMFA accounting for approximately 80% of the metabolites (Godfrey
1999).
These results are concurred by the fact that two major metabolites were identified by
Germond et al. as HMFA and HMFG, with the ratio of HMFA to HMFG increased from 1 to 18
with increasing the administered doses (Germond 1987). The ratio decreased when glycine was
administered indicating the importance of its availability in the formation of HMFG (Germond
1987). The conjugation of glycine was proposed to occur in kidney, since this metabolite was
only found in kidney homogenate (Germond 1987). Its note worthy, that HMFA, but not 5-HMF
or HMFG, was extracted from liver homogenate (Germond 1987) and that 44-67% of 5-HMF
administered to dogs, rabbits, and chickens were excreted as HMFA in the urine (NTP 1994).

29

HO

O
O

O

HO

HO

O

O

O
NH

O

OH

OH

O

HMFA

FDCA

HMFG

I

II

III

Figure 1-7. Major metabolites of 5-HMF in rodents (Godfrey 1999).
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In humans, it was reported that the total recovery of 5-HMF in urine was 46% and 14%
after 6 hours of oral administration of dried plum juice and dried plums as metabolites (Prior
2006). Likewise, 74% and 38% of the administered dose was recovered in the urine as HMFA
and FDCA of parenterally fed human neonates exposed to 5-HMF as a hydrolysis product of
fructose upon sterilization process of fructose solutions (E. B. Jellum 1973).
The above-mentioned study involved six healthy women volunteers who administered
dried plum juice and dried plums after an overnight fast in a randomized cross-over clinical
study (Prior 2006). The amount of 5-HMF was estimated as 497 mg (3.9 mmol) and 61.2 mg
(0.5 mmol) in the dried plum juice and dried plums, respectively. In addition to the baseline
sample, blood was sampled at 0.25, 0.5, 1, 2, 3, 4, and 6 hours post administration. Moreover,
urine was collected at the baseline and every two-hour period up to six hours. Bioanalysis was
performed using HPLC-MS/MS and HPLC-UV (Prior 2006). The analysis was focused on peaks
that appeared in the plasma of those administered the dried plum products and was not in the
control group (Prior 2006).
HMFA, compound I in Figure 1-7, was identified as the major metabolite of 5-HMF
excreted in the urine accounting for 36.9% of 5-HMF dose (1.5 mmol/6 hrs). In addition, HMFA
was detected in the urine of controls at levels of 0.006 mmol/6 hrs. The area under the curve of
the plasma concentration-time profile for HMFA was 0.32 mmol/l.hr (Prior 2006). The reported
plasma concentration-time profile for HMFA was used in the estimation of the pharmacokinetics
parameters, as summarized in Table 1-3.
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Figure 1-8. Potential metabolites of 5-HMF. (Prior 2006)
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Table 1-3. Pharmacokinetics parameters of HMFA in humans.
Parameter

Value

AUC6hrs (mM.hr)

0.316

AUC∞ (μM.hr)

0.328, reported 0.318

t1/2 (min)

69

Ke (min-1)

0.01

Urinary clearance of unchanged drug (ml/min)

80
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(5-Carboxylic acid-2-furoyl)glycine, compound IV in Figure 1-8, was identified as a
metabolite of 5-HMF in urine with 0.168 mmol excreted in 6 hours (4.2% of 5-HMF dose). This
compound was also found in one of the control urine (Prior 2006). This metabolite was not
detected in murine studies after oral administration of 5-HMF (Germond 1987) (Godfrey 1999).
Moreover, N-(5-hydroxymethyl-2-furoyl)glycine, compound III in Figure 1-7, was
identified as a metabolite in the urine accounting for 3.6% of 5-HMF dose (0.137 mmol/6 hrs).
This metabolite was observed in urine earlier after oral administration of 5-HMF in rats and mice
(Germond 1987) (Godfrey 1999).
Furthermore, 5-hydroxymethyl-2-furoylaminomethane, compound V in Figure 1-8, was
identified as a metabolite for 5-HMF with small amounts excreted, which was 1.8% of 5-HMF
dose. This compound was also detected in 50% of the controls excreted urine (Prior 2006). This
metabolite was not detected in murine studies after oral administration of 5-HMF (Germond
1987) (Godfrey 1999).
In this study, the ratio of compound I to III was twofold higher with the administration of
dried plum juice compared to dried plums, which is supported by Germond et al. observation that
the proportion of excreted compound III decreased with the increase in the administered dose
(Germond 1987) (Godfrey 1999).
Although compound II in Figure 1-7 was not detected in the study (Prior 2006), Godfrey
et al. observed this metabolite in rats and mice (Godfrey 1999).
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All of the above suggests that oxidation is the main biotransformation pathway of 5HMF, is most likely by oxidoreductase enzymes; ALDH and ADH. The major metabolite,
HMFA, implies that ALDH plays a crucial rule in 5-HMF detoxification. Besides the liver, these
enzymes are found in stomach, kidney, erythrocytes, etc (Satre 1994) (Sládek 2003).
Recently, 5-sulfoxymethylfurfural (SMF) was detected in mice plasma after the I.V.
bolus administration of 100 mg/kg 5-HMF (Monien 2009). SMF was reported as a carcinogenic
and mutagenic compound, however, the AUC ratio of SMF to 5-HMF was 0.017% (Surh 1994)
(Monien 2009).
ADH involvement in the formation of a primary metabolite was reported to happen only
by yeast. 5-HMF was metabolized by ethanolgenic yeast to 2,5-bis-hydroxymethyl furan, shown
in Figure 1-9, with a preference to the presence of NADPH as a cofactor in the redox reaction,
which was observed at 222 nm with a total disappearance of 5-HMF after 48 hours of incubation
(Liu 2006).
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Figure 1-9. 2,5-bis-hydroxymethyl furan (Lin 2008)
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In general, a drug is considered a low hepatic extraction-ratio drug if less than 20% of
what enters the liver, through the hepatic artery and portal vein, is lost upon leaving the liver. As
mentioned above, 5-HMF is highly metabolized with the metabolic clearance (Clmet) accounting
for more than 70% of total clearance (Cltot) in rats (Godfrey 1999). Stating that 5-HMF had high
oral bioavailability in mice indicates that it is a low hepatic extraction-ratio drug (Abdulmalik
2005). The apparent clearance (Cltot/F) of less than 5 ml/min/kg in mice, reported by Abdulmalik
and co-workers, is much less than the liver blood flow in mice (around 280 ml/min/kg) (Davies
1993). Knowing that this value as a clearance might have been overestimated, because of the
unknown oral bioavailability (Foral), provides us with more confidence in considering 5-HMF as
a low hepatic extraction-ratio drug. When this apparent value was allometrically scaled to
human, assuming it represents the true clearance, it was around 5% of the hepatic blood flow.
However, this allometric scaling did not account for the differences in the metabolic enzymes
expression and activity between human and animals (Venitz 2006).
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1.2.4.4 Excretion

As a small molecule with a neutral structure at physiological pH range, it was anticipated
that 5-HMF is freely filtered in the kidney and that it is subject to tubular reabsorption (Venitz
2006). However, only 12 mg of unchanged 5-HMF was excreted in urine after administration of
1 g of 5-HMF to rabbits (Lang 1970). This is in agreement with detecting 0.73% of the 5-HMF
amount consumed by healthy volunteers in their urinary excretion as unchanged 5-HMF (M. P.
Murkovic 2006). This study was conducted in seven healthy volunteers, in whom the urinary
excretion of unchanged 5-HMF was investigated after administering 24 mg of 5-HMF in plum
jam after an overnight fast (M. P. Murkovic 2006). Figure 1-10 shows the amount excreted in
urine over time. The total of the average amounts of unchanged 5-HMF excreted over the 6
hours was 176 µg. Unfortunately, the metabolites were not investigated in this study. However,
the presence of the sulfated metabolite was investigated but it was not detected in urine (M. P.
Murkovic 2006).
More than 60% of the 5-HMF dose was eliminated in rodents urine, mainly as
metabolites (~90%) (Godfrey 1999). In the studies performed by Germond, Jellum, and Godfrey,
the urinary excretion of unchanged 5-HMF was not reported. Both Godfrey et al. and Jellum et
al. stated clearly that 5-HMF was not detected in the urine (Godfrey 1999) (E. B. Jellum 1973).
Germond and co-workers suggested that the kidney might contribute to the metabolism of 5HMF by adding the glycine moiety to its carboxylic metabolite. Blood concentrations, reported
by Godfrey et al. for the oral administration of 5-HMF in rodents, were used to estimate the
exposure parameters of 5-HMF by non-compartmental analysis, as shown in Table 1-4.
The values for the apparent clearance (Cltot/F) indicated higher bioavailability and/or lower
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Figure 1-10. Unchanged 5-HMF excretion in human urine over time after administering 24 mg
of 5-HMF in plum jam.
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elimination rate of 5-HMF in rat compared to that in mice. The estimated parameters were
compared to those reported by Abdulmalik et al. for the 100 mg/kg dose in mice, as shown in
Table 4. In this study, the blood sampling schedule included seven time-points after the pre-dose
sample from 30 minutes to 6 hours (Abdulmalik 2005), while Godfrey reported concentrations
for four time points from 2 hours to 48 hours (Godfrey 1999). A discrepancy was noted in the
estimate of the apparent clearance and the AUC reported by Abdulmalik et al.. Hence, the
trapezoidal AUC (AUCtrap) was re-estimated for the concentration-time profile. The estimated
AUCtrap was not similar to the reported value, as shown in Table 1-5.
Czok reported lower 5-HMF plasma concentrations in rats after I.V. injection of 100
mg/kg (Czok, Tolerance of 5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic
effects. 1970). Using non-compartmental analysis, the initial t1/2 was estimated as 4.8 minutes
and the terminal t1/2 was 11 minutes with a total clearance of 446 ml/minute/kg, which is 10 fold
higher than the apparent clearance estimated for Godfrey study. The findings are concurred by a
recent study carried-out by Monien and co-workers (Monien 2009). The distribution t1/2 after an
I.V. bolus of 100 mg/kg in mice, was 1.7 minute and the terminal t1/2 was 28 minutes with a total
clearance of 190 ml/minute/kg after HPLC-MS/MS analysis of mice plasma (Monien 2009). In
beagle dogs, 5-HMF was administered as 5 g/hour infusion (Klimmek 1978), and the
pharmacokinetic parameters for it were summarized in Table 1-6.
In addition, in a mass balance study, 0-330 mg/kg of [C14]5-HMF was administered to
rats by both stomach tube and tail vein injection (Germond 1987). When 5-HMF administered
through stomach tube, less than 1% was recovered as radioactivity in the expired air. The
remaining activity, which accounted for around 85% of the radioactivity, was recovered in the
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urine after 8 hours of administration (Germond 1987). Hence, it is postulated that at least 70% of
5-HMF is orally absorbed and is subject to extensive metabolism.
Table 1-4. Comparison of exposure parameter estimates in rats and mice in blood (n= 4).
Estimated from (Godfrey 1999)
Dose (mg/kg)
Rats

Mice

5

100

500

10

100

500

AUC48hrs (µg/ml*min)

2071

8679

52005

159

2109

22877

ClTot/F (ml/min/kg)

2.4

11.5

9.6

62.8

47.4

21.9
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Table 1-5. Comparison of the exposure parameters for oral administration of 100 mg/kg in mice.
Estimated from
Godfrey et al.,
1999

Estimated from
Abdulmalik et al.,
2005

Reported by
Abdulmalik et al.,
2005

AUC∞
(µg/ml*min)

2,109

22,680

412 ± 25

Cltot/F
(ml/min/kg)

47.4

4.4

4.2 ± 0.3
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Table 1-6. Pharmacokinetics parameters for IV infusion of 5 g/hour infusion to beagle dogs
(n=7).
Parameter

Value

AUC120min (μg/ml.min)

3503

AUC∞ (μg/ml.min)

7959

t1/2 (min)

123.5

Ke (min-1)

0.006

CL (ml/min)

628.2

Vd (l)

112.0
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As a conclusion, renal elimination contributes mainly to the elimination of drug
metabolites. However, the kidney contribution to the unchanged drug elimination is minimal in
the light of evidence that 5-HMF is highly metabolized and no 5-HMF was detected in the urine.
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1.2.4.5 BCS Classification

The Biopharmaceutics Classification System (BCS) classifies drugs according to their
solubility, dissolution, and permeability properties of the drug substance in the highest strength
of their immediate release drug product (Wu 2005). The calculated solubility of 5-HMF, shown
in Figure 1-1, is 48 g/l at 25 °C (ACS 2009), which means that up to 12 g of 5-HMF can be
dissolved in 250 ml of aqueous media (pH 1-7.5 at 37 °C) as defined by the FDA (Wu 2005).
This estimated solubility is based on the assumption that the solubility of 5-HMF is constant
between 25-37 °C. 12 g is much larger than the proposed human dose of around 1.5 g 5-HMF
(Venitz 2006) and probably the highest strength dose will be less than 12 g. Thus, 5-HMF can be
considered as a highly soluble drug substance.
It is assumed in this case that other components in the formulation will not significantly
decrease the dissolution of the dosage form. Hence, it is predicted that ≥ 85% of the labeled
amount of 5-HMF will be dissolved in 900 ml buffer using apparatus I or II (FDA 2000). As far
as permeability is concerned, a drug is considered to be highly permeable if it was proven that at
least 90% of the administered dose is orally absorbed in humans. The intravenous (IV) reference
dose or mass balance study can prove that (FDA 2000). Unfortunately, except for what was
reported by Jellum et al. (E. B. Jellum 1973), where 5-HMF was administered intravenously, no
in-vivo human study had 5-HMF administered intravenously. However, 46% recovery of HMFA
in urine of healthy volunteers after administering dried plum juice (Prior 2006) indicates that at
least 46% was absorbed through the gastrointestinal tract. If this value is compared to what was
reported by Jellum regarding 36-73% recovery of 5-HMF metabolites in urine after parenteral
administration of 5-HMF, it indicates that 5-HMF has high oral bioavailability.
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The calculated log D value of 5-HMF equals -0.45 (ACS 2009) over a pH range of 1-10
and its small molecular weight (MW: 126 D) makes it a candidate for passive diffusion in the
gastrointestinal tract (Hurst 2007). Germond and co-workers reported that 95-100% of the
radioactivity was recovered in urine within 24 hours of oral and intravenous [14C]-5-HMF
administration to rats (Germond 1987). The doses ranged between 0.8-330 mg/kg administered
for two rats at each dose level (Germond 1987). This indicates that≥90% is orally absorbed in
rats. If a similar absorption behavior is found in human, 5-HMF can be classified as a class I
drug according to the BCS. However, although it was mentioned in this study that 5-HMF was
administered both orally and intravenously; the AUC after IV administration was not reported.
This prevents from calculating the absolute bioavailability in order to draw any informed
conclusion regarding 5-HMF oral bioavailability. Abdulmalik et al. stated that 5-HMF had high
oral bioavailability and achieved high levels in whole blood samples of mice (Abdulmalik 2005).
A mass balance study by Godfrey et al. reported 61-77% and 70-82% recovery of
cumulative radioactivity in urine in mice and rats, respectively, after oral gavage of doses
ranging between 5-500 mg/kg (Godfrey 1999). This indicates that at least 61% and 70% of 5HMF is absorbed mice and rats, respectively. Assuming that there is no significant difference in
the disposition of 5-HMF between human and rodents, 5-HMF might be classified as
intermediate to high permeability drug in human. As a conclusion, 5-HMF was recognized to be
highly metabolized in the above studies indicating that 5-HMF can be classified as a class I drug
according to the Biopharmaceutics Drug Disposition Classification System (BDDCS) (Wu
2005). Thus, 5-HMF can be classified as either class I (high solubility, high permeability) or
class III (high solubility, low permeability) drug according to the BCS.
The following points summarize the preclinical findings in rodents:
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•

A rapid distribution to physiological compartments was observed with the highest AUC
tissue-to-blood ratios achieved in the kidney and liver. Plasma protein did not affect 5HMF interaction with Hb.

•

Metabolism was recognized as the major route of elimination for 5-HMF. Three
metabolites were identified in the urine with HMFA as the primary one.

•

There is a variation in the apparent clearance estimated for animals in the discussed
studies. This complicates drawing any conclusion regarding bioavailability and clearance
mechanism of 5-HMF.
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1.2.5 5-HMF Toxicity

There is no epidemiological study relating 5-HMF to cancer, in neither a positive nor in a
negative direction (NTP 1994).

1.2.5.1 In-vitro

Incubation of 5-HMF with RBCs did not cause any toxicity, when investigated through
morphology, pumps, and transporters function of RBCs (Abdulmalik 2005). In another study,
0.07, 0.74, and 7.4 mM of 5-HMF were incubated with blood cells to investigate changes in the
metabolic activity (Nässberger 1990). While the heat output increased by 60% in RBCs, a
significant reduction in the heat output was observed in the granulocytes. On the other hand, no
adverse effects were observed in thrombocytes (Nässberger 1990).
5-HMF present in light colored caramel resulted in colonic aberrant cryptic foci initiation
and promotion in rats (X. C. Zhang 1993). However, upon conducting a statistical study on this
work carried-out by Zhang et. al, it was found that 5-HMF had only a borderline significant
effect in producing the aberrant cryptic foci (Minkin 1994).
Moderate carcinogenicity was induced by incubation of 5-HMF in cell lines for an hour
at a concentration of 115 mM (Janzowski 2000). Also, at a high 5-HMF concentration (120
mM), a weak mutagenic effect was observed in-vitro (Janzowski 2000). However, DNA damage
was not observed (Janzowski 2000). In addition, 5-[(sulfooxy)-methyl]furfural, a chemically
synthesized derivative of 5-HMF was mutagenic adverse events, while another derivative, 5(chloromethyl)furfural, was mutagenic and cytotoxic (Surh 1994).
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1.2.5.2 In-vivo

1.2.5.2.1 HUMAN

5-HMF was administered in a clinical regimen as 720 mg/day subdivided into three doses
to preoperative patients for 10 days with no apparent side effects (Matzi 2007). Furthermore, 5HMF at concentrations normally encountered in parenteral solutions are not considered toxic
(Ulbricht 1984).

1.2.5.2.2 DOG

5 g/hour and 50 mg/hour of 5-HMF were infused to beagle dogs in 0.9% sodium chloride
(Klimmek 1978). An increase in lactate concentration, pO2, and heart rate and a decrease in
pCO2, and pH to around 7.06 was observed with the infusion of 5 g/hour. On the other hand, no
changes were observed in the haematocrit, electrolytes, creatinine, bilirubin, and enzyme
activities (Klimmek 1978).

1.2.5.2.3 RABBIT

When 400 mg of 5-HMF was given twice daily for a week through subcutaneous
injection to rabbits, no adverse effects were observed (Rasmussen 1982).
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1.2.5.2.4 RAT

The LD50 in rats ranged between 2.5-5 g/kg when 5-HMF was administered through oral
route (NTP 1994) (Janzowski 2000). 250 mg/kg of 5-HMF was fed to rats for 40 weeks without
affecting their weights or the histological characteristics of liver, kidney, heart, spleen, and testes
(Lang 1970). On the other hand, it was reported that 5-HMF showed some evidence of
carcinogenicity in female mice at gavage doses of 188 and 375 mg/kg/day, while no evidence of
carcinogenicity was reported for similar doses in rats or male mice up to 750 mg/kg doses in a
two-year toxicity study. In addition, respiratory and olfactory epithelium degeneration was
observed in this study (NTP, TR-554 Toxicology and Carcinogenesis Studies of 5(Hydroxymethyl)-2-Furfural (CAS No. 67-47-0) in F344/N Rats and B6C3F1 Mice (Gavage
Studies) 2008).
In a study aimed to find an association between the erectile dysfunction in renal failure
and the increase in the glycation products, the levels of 5-HMF were measured in the penile
tissue as an indicator of glycation products, which resulted from non-enzymatic reaction between
sugars and free amino groups in proteins. A significant increase in 5-HMF levels was found in
rats with induced renal failure in comparison to the control (Usta 2002).
In addition, 5-HMF is used as a measure of glycated proteins in diabetes and cataracts
after being released by acid hydrolysis of the glycated proteins. A significant higher level of the
released 5-HMF was estimated in diabetic rats with cataracts in comparison to non-diabetic rats
(Turk 1997).
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1.2.5.2.5 MICE

No lethal effects were observed upon oral administration of 5-HMF up to 2 g/kg (Czok,
Tolerance of 5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970).
On the other hand, the LD50 was 0.84 g/kg through an intraperitoneal route (Czok, Tolerance of
5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970). A slightly
lower LD50 of 0.75 g/kg was estimated when 5-HMF was administered through an I.V. route
(Czok, Tolerance of 5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects.
1970). Gastrointestinal movements and bile secretion were increased with the increase in 5-HMF
oral dose administered (50, 100, 200 mg/kg). In addition, 5-sulfoxymethylfurfural (SMF), a
carcinogenic and mutagenic compound, accounted for 17 ppm of 5-HMF AUC in mice plasma
after an I.V. bolus administration of 100 mg/kg 5-HMF (Monien 2009) (Surh 1994).
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1.2.6 5-HMF in Humans

Despite the fact that 5-HMF is reported to be involved in clinical trials as anticancer
agent and micronutrients, a shortage of literature for studies characterizing or predicting its PK in
human is apparent. Moreover, the variation in the estimated in-vivo animal exposure parameters
emphasizes the need for preclinical studies exploring the PK of 5-HMF.
720 mg/day of 5-HMF along with α-ketoglutaric acid (α-KG) divided into three doses
were given to a study group (n=16) in a randomized prospective study involving 32 lung cancer
patients undergoing lung resection surgery (Matzi 2007). The micronutrient supplement was
given for 10 days before the surgery. The study group had a significant improvement in their
exercise capacity and did not suffer from oxidative stress after the surgery as indicated by their
carbonyl protein and isoprostane levels (Matzi 2007).
A study in seven healthy volunteers investigated the urinary excretion of unchanged 5HMF after administering 1.2 mg/g of 5-HMF in 20 g of plum jam after an overnight fast.
Volunteers were three females and four males with a wide age range between 18-45 years (M. P.
Murkovic 2006).
Another study involved six healthy women volunteers aged between 65-70 years who
administered dried plum juice and dried plums after an overnight fast in a randomized cross-over
clinical study (Prior 2006). The amount of 5-HMF was estimated to be 497 mg (3.9 mM) and
61.2 mg (0.5 mM) in the dried plum juice and dried plums, respectively (Prior 2006).
Moreover, a study investigated the presence of furan compounds in the urine of healthy
volunteers using gas chromatography and mass spectroscopy (Mrochek 1972). 2,5furandicarboxylic acid with a total amount between 3-5 mg/24 hours, 2-Furoylglycine, 5hydroxymethyl-2-furoic acid with a total amount between 1-25 mg/24 hours, were identified in
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the urine of these healthy human. On the other hand, 5-hydroxymethyl-2-furoyl glycine was
identified in a patient with chronic lymphocytic leukemia. Moreover, enhanced urinary excretion
of the above compounds were observed in two patients with lymphocytic leukemia. The excreted
amount of 2,5-furandicarboxylic acid in these patients reached 214 and 300 mg/24 hours
(Mrochek 1972).
In a paper presented by Michail et. al., it was stated that 5-HMF is under phase II clinical
studies in combination with other compounds for its anticytostatic activity (Michail 2007). In
addition, it was mentioned that a dose of 3 g 5-HMF/day was given to cancer patients in a pilot
study. 300 ng/ml was reported to be the approximate minimum concentration to characterize the
pharmacokinetic profile of 5-HMF considering the required number of half-lives (Michail 2007).
The only systemic exposure to 5-HMF was reported in parenterally fed human neonates
(n=2), who were exposed to 5-HMF as a hydrolysis product of fructose upon sterilization process
of fructose solutions (E. B. Jellum 1973).
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1.3

Aldehyde Dehydrogenase (ALDH)

ALDH is a potential enzyme in the metabolism of 5-HMF. Below is a description of its
structure, function, substrates, isoenzymes, expression, polymorphism, and pharmacogenetics.

1.3.1 1.3.1 Structure

ALDH1 and ALDH2 are the main ALDH isoenzymes studied in the liver. Both of these
are homotetramers with a total molecular weight of ~220-240 kDa (C. D. Cheung 2003) (A. R.
Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in
acetaldehyde metabolism 1996) (Agarwal 1992). In general, other ALDH isoenzymes are
homotetramers with few present as homodimers. Table 1-7 summarizes the quaternary structures
of ALDH isoenzymes.
Based on human ALDH1, Cys-302 and Glu-268 were reported to be involved in the
catalytic site, while Lys-192, Gly-245, Gly-250, Glu-399, and Phe-401 are important amino
acids for the binding of the cofactor NAD(P)+ (Manzer 2003). Consequently, inactive
isoenzymes were characterized by the presence of arginine amino acid in their active site instead
of cysteine (Manzer 2003).
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Table 1-7. Quaternary protein structure of ALDH isoenzymes (Marchitti 2008) (V. P. Vasiliou
2000)
Quaternary
Protein
Structure

Isoenzyme

Tetramer

ALDH1A1, ALDH1A2, ALDH1B1, ALDH1L1, ALDH1L2,
ALDH2, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1

Dimer

ALDH1A3, ALDH3A1, ALDH3A2, ALDH4A1

55

1.3.2 Function

In general, ALDH catalyzes an irreversible oxidation of aliphatic and aromatic aldehydes
into acids (C. D. Cheung 2003) (V. P. Vasiliou 2000). In conjunction with this irreversible
oxidation of aldehydes, the enzymatic reaction involves the reduction of a cofactor, nicotinamide
adenine dinucleotide, (NAD+) into NADH.
The main isoenzymes studied are ALDH1 and ALDH2 because of their well-known
function in acetaldehyde detoxification and converting it into acetic acid (Liao 1991) (Agarwal
1992) (Ricciardi 1983) (Klimmek 1978). Consequently, ALDH1A1 deficiency was associated
with alcohol injury in mice while increased expression of ALDH1A1 in brain contributed to
alcohol avoidance (Marchitti 2008). ALDH activity was proposed as an alcohol consumption
indicator since the activity of ALDH in RBCs was found to be significantly less in alcoholics
than teetotalers (Johnson 1992).
Hence, the role of ALDH is very important in detoxification processes. Besides alcohol,
this includes many compounds causing skin sensitization and present in flavors and fragrances,
such as cinnamaldehyde (C. D. Cheung 2003). While cinnamaldehyde might be present in the
fragrance, it can be formed because of cinnamic alcohol activation through metabolism (C. D.
Cheung 2003). Moreover, the cytosolic ALDH1A1 is involved in cyclophosphamide
detoxification (V. P. Vasiliou 2000) (Beedham 1997). While ALDH1A1 decreases the toxicity of
cyclophosphamide, it also causes resistance of tumors to cyclophosphamide in the case of its
high expression in targeted tumor tissue (Marchitti 2008). Hence, the metabolism of anticancer
drugs by ALDH contributes to the development of resistance to these drugs, especially where
there is an increase expression of ALDH in the tumor tissue (Beedham 1997) (V. N. Vasiliou
2005).
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In particular, it was fond that antineoplastic resistance is associated with an enhanced
expression of ALDH3A1 (V. P. Vasiliou 2000). While ALDH3A1 has low expression level in
healthy liver tissue, its expression increases in liver cancer cells since it contributes to cell
regulation by downregulating transcription factors (Marchitti 2008). Relevant to this aspect,
ALDH1A2 was reported to act as a tumor suppressor (Marchitti 2008).
On the other hand, the ALDH enzyme is essential for development and growth as they
catalyze the oxidation of retinal to retinoic acid, which is an essential compound for gene
expression (V. N. Vasiliou 2005). An ALDH1A2 knockout mice, dies in the early embryonic
stages due to its key role in retinoic acid metabolism and its function as an important regulator in
the development of organs including kidney, pancreas, forebrain, spinal cord, retina, spleen, and
lung (Marchitti 2008) (V. P. Vasiliou 2000). ALDH decreased activity is observed in cirrhosis
and can result in feminization due to its importance in retinal oxidation and androgen binding
role in testis (Marchitti 2008) (Ricciardi 1983).
Besides detoxicification, ALDH plays a role in the bioactivation of GABA
neurotransmitter and is involved in DNA repair and replication through catalyzing the formation
of tetrahydrofolate that is required for purine synthesis (Marchitti 2008) (V. N. Vasiliou 2005).
In addition, ALDH1 and ALDH3 were proposed to have a role in the transparency of
cornea since a reduced level of these enzymes was observed in cataract (Manzer 2003) (Marchitti
2008). It is thought that ALDH1A1 protects the eye from cataracts by oxidizing lipid
peroxidation products, thus decreasing oxidative stress caused by aging and UVB exposure
(Marchitti 2008) (Manzer 2003). This is supported by the notion that lipid peroxidation products,
such as malondialdehyde and 4-hydroxynonenal, are substrates for ALDH (Manzer 2003).
Moreover, ALDH acts as an antioxidant by producing NAD(P)H and scavenging free radicals
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through its cysteine, sulfhydryl, and methionine groups (Marchitti 2008). On the other hand,
some of the ALDH isoenzymes, which are present in the cornea have no metabolic capacity and
thought to contribute only structurally to the transparency of cornea (Manzer 2003) (Sophos
2003) (V. N. Vasiliou 2005).
Other than its famous role in aldehydes oxidation, ALDH catalyzes ester hydrolysis and
ALDH2 acts as a nitrate reductase, thus activating nitroglycerine (Marchitti 2008). Furthermore,
in addition to their catalytic activity, ALDH function as binding proteins for endogenous
moieties as androgen in human genital tissues and exogenous substances as acetaminophen
(Sophos 2003) (V. N. Vasiliou 2005).
An advantageous outcome for the absence of ALDH1A1 was noticed in knockout mice,
where a protection against insulin resistance and diet-induced obesity was observed (Marchitti
2008).
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1.3.3 Substrates

Aldehydes are known to be very reactive compounds due to the presence of the highly
electrophilic carbonyl group, for which they are related to carcinogenicity (Beedham 1997) (V.
N. Vasiliou 2005). Inside the human body, they are generated from carbohydrates, amino acids,
lipids, and neurotransmitters (Marchitti 2008). On the other hand, human exposure to aldehyde
might be through exogenous sources, such as environmental acetaldehyde and formaldehyde and
through intended exposure while ingesting ethanol, food flavors, and anticancer medications
(e.g. cyclophosphamide and ifosfamide) (Marchitti 2008). Consequently, some aldehydes are
essential for biological process in the body while others are toxic (Marchitti 2008).
Generally, aliphatic aldehydes with longer carbon chains have higher affinity toward
ALDH than those with shorter chains (A. R. Klyosov, Possible role of liver cytosolic and
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). Some aromatic
aldehydes were also shown to have high affinity for ALDH with Km values less than 100 nM (A.
R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in
acetaldehyde metabolism 1996). In this aspect, naphthaldehydes have Km values in the single nM
range (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996). A substitution on benzaldehydes and
naphthaldehydes did not significantly affect their affinity to ALDH whether the addition was an
electropositive or electronegative group (A. R. Klyosov, Possible role of liver cytosolic and
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). On the other hand,
modification in the structure to make it more hydrophilic especially at the ortho-position,
decreased the affinity toward ALDH with around 10 fold or more activity (A. R. Klyosov,
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Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde
metabolism 1996).
High affinity substrates for liver ALDH, such as cinnamaldehyde and benzaldehyde, have
been identified with a Km values less than 100 nM (A. R. Klyosov, Possible role of liver
cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). While
hyperbolic non-linear regression using the Michaelis Menten equation is usually used to estimate
the metabolic parameters, these low Km values make it difficult to determine the metabolic
parameters accurately (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial
aldehyde dehydrogenases in acetaldehyde metabolism 1996). Even with known substrates as
acetaldehyde and retinal, different affinity values were reported that vary as much as 100 fold
difference (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996). In addition, the Km value for certain
substrates was difficult to determine although the activity was observed (A. R. Klyosov, Possible
role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism
1996).
Consequently, for substrates having affinities in the nanomolar or subnanomolar range, a
more complicated procedure that involved the addition of another substrate to the reaction was
reported (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996). However, this procedure was deemed
complicated and does not provide an advantage over measuring the kinetics using the substrate
alone (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996).
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Acetaldehyde is a prototypical substrate for ALDH. In human, the Km value of cytosolic
ALDH toward acetaldehyde is 180 µM (A. R. Klyosov, Possible role of liver cytosolic and
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). In mice,
acetaldehyde Km was reported to be 0.9-5 µM and 0.8-1.4 mM in the mitochondrial fraction,
while it was 10-50 µM and 0.1-0.6 mM in the cytosol (Tomita 1990). This variation in the Km
values in addition to what was reported with more than a 20 fold range (22-483 µM) estimated as
the Km value for acetaldehyde in humans is attributed to difficulties in measuring the initial
velocities for low concentrations or variations in the enzyme or cell fraction purification
processes (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996). Likewise, acetaldehyde experiments are
difficult to carry on since the acetaldehyde boiling point is 21 °C. In addition, acetaldehyde
oxidation products formed in the presence of air interferes with oxidoreductase activity
measurement. Hence, redistillation of acetaldehyde under anaerobic conditions is recommended
before conducting the experiments to remove interfering substances (Yan 1987). Moreover,
acetaldehyde is not a high affinity substrate for all ALDH isoenzymes. Acetaldehyde is primarily
metabolized by ALDH2 with a Km< 1 µM (Marchitti 2008). ALDH1A1 is another isoenzyme
that contributes to acetaldehyde metabolism, for which the Km was estimated to be between 50180 µM (Marchitti 2008). Besides, ALDH1B has high affinity toward acetaldehyde with a Km of
30 µM (Marchitti 2008). On the other hand, the affinity of acetaldehyde toward ALDH3 is less
than that for ALDH1 and ALDH2, hence, its role in the metabolism of ingested ethanol is
minimal (Liao 1991). Likewise, ALDH1A2 does not seem to play an important role in
acetaldehyde oxidation since it has a relatively low affinity with a Km value of 650 µM
(Marchitti 2008).
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Other than acetaldehyde, retinal is an endogenous substrate for ALDH1 and an inhibitor
for ALDH2 (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996). Furthermore, lipid peroxidation products,
such as malondialdehyde and 4-hydroxynonenal, are substrates for ALDH enzyme (Manzer
2003). γ-aminobutyric acid represents another example of endogenous substrate for ALDH5A1
and ALDH9A1 (V. P. Vasiliou 2000). Table 1-8 lists some ALDH substrates.
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Table 1-8. ALDH substrates.
Km (mM)

vmax
(nmol/min/mg
protein)

Species

ALDH Enzyme
Source

Reference

4.7

20.2

Rat

Hepatic cytosol

(Gupta 2006)

6

8.4

Rabbit

Hepatic cytosol

(Gupta 2006)

1.7

33

Dog

Hepatic cytosol

(Gupta 2006)

0.7

32.5

Human

Hepatic cytosol

(Gupta 2006)

19.7

9

Rat

Hepatic cytosol

(Gupta 2006)

15.7

4.8

Rabbit

Hepatic cytosol

(Gupta 2006)

13
5.8

24.5
37.2

Dog
Human

(Gupta 2006)
(Gupta 2006)

1 to 2

-

Human

Methanol

6 to 150

-

Human

Ethylene glycol

13 to 220

-

Human

Benzyl alcohol

0.004 to 0.12

-

Human

Octanol

0.005 to 0.017

-

Human

16-HHA

0.007 to 0.026

-

Human

0.005 to 23

-

Human

Hepatic cytosol
Hepatic cytosol
Liver purified
enzyme
Liver purified
enzyme
Liver purified
enzyme
Liver purified
enzyme
Liver purified
enzyme
Liver purified
enzyme
Liver purified
enzyme
Liver cytosol
purified enzyme
(ALDH1)

Substrates

Ethanol

Propylene glycol

Ethanol

Cyclohexanol
5-Bromo-1-naphthaldehyde

2.5 ± 0.3

2 ± 0.2*
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Human

(Wagner 1983)
(Wagner 1983)
(Wagner 1983)
(Wagner 1983)
(Wagner 1983)
(Wagner 1983)
(Wagner 1983)
(A. R. Klyosov,
Possible role of
liver cytosolic

6-(Dimethylamino)-2naphthaldehydec

6.3 ± 1.8

20 ± 5*

Human

Liver cytosol
purified enzyme
(ALDH1)

5-Nitro-1-naphthaldehyde

11 ± 5

4.2 ± 0.6*

Human

Liver cytosol
purified enzyme
(ALDH1)

Fluorene-2-carboxaldehyde

54 ± 6

46 ± 5*

Human

Liver cytosol
purified enzyme
(ALDH1)
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and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde

p-(Dimethylamino)benzaldehyde

60 ± 20

16 ± 2*

Human

Liver cytosol
purified enzyme
(ALDH1)

4-Methoxy-1-naphthaldehyde

200 ± 20

34 ± 5*

Human

Liver cytosol
purified enzyme
(ALDH1)

Indole-3-acetaldehydec

310 ± 20

86 ± 2*

Human

Liver cytosol
purified enzyme
(ALDH1)
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dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism

1996)

Trans-cinnamaldehyde

400 ± 40

59 ± 5*

Human

Liver cytosol
purified enzyme
(ALDH1)

p(Dimethylamino)cinnamaldehyde

900 ± 200

62 ± 5*

Human

Liver cytosol
purified enzyme
(ALDH1)

7-(Dimethylamino)coumarin-4carboxaldehydec

1420 ± 230

60 ± 10*

Human

Liver cytosol
purified enzyme
(ALDH1)

Phenylacetaldehyde

5500 ± 1200

380 ± 40*

Human

Liver cytosol
purified enzyme
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(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of

(ALDH1)

Phenanthrene-9-carboxaldehyde

9400 ± 800
2700 ± 700

<4*

Human

Liver cytosol
purified enzyme
(ALDH1)

Acetaldehyde

0.18 ± 0.10

-

Human

Liver cytosol
purified enzyme
(ALDH1)

4.5 ± 0.3 x 10-3

-

Human

Liver cytosol
purified enzyme
(ALDH1)

Propanal
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liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial

Pentanal

0.16 ± 0.03 x
10-3

Hexanal

0.041 ± 0.002 x
10-3

Heptanal

0.018 ± 0.002 x
10-3

Human

Liver cytosol
purified enzyme
(ALDH1)

-

Human

Liver cytosol
purified enzyme
(ALDH1)

-

Human

Liver cytosol
purified enzyme
(ALDH1)

-
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aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde

Octanal

0.012 ± 0.002 x
10-3

-

Human

Liver cytosol
purified enzyme
(ALDH1)

Decanal

-6

2.9 ± 0.4 x 10

-

Human

Liver cytosol
purified enzyme
(ALDH1)

Retinal

0.99-1.3 x 10-3

-

Human

Liver cytosol
purified enzyme
(ALDH1)

0.32 ± 0.08

-

Human

Liver mitochondria

Formaldehyde
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metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,

purified enzyme
(ALDH2)

Acetaldehyde

Propanal

Pentanal

0.20 ± 0.02 x
10-3

-6

95 ± 5 x 10

34 ± 2 x 10

-6

-

-

-
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Human

Liver mitochondria
purified enzyme
(ALDH2)

Human

Liver mitochondria
purified enzyme
(ALDH2)

Human

Liver mitochondria
purified enzyme
(ALDH2)

Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and

Hexanal

30 ± 5 x 10

-6

-

Human

Liver mitochondria
purified enzyme
(ALDH2)

Heptanal

27 ± 4 x 10-6

-

Human

Liver mitochondria
purified enzyme
(ALDH2)

Human

Liver mitochondria
purified enzyme
(ALDH2)

Octanal

28 ± 4 x 10

-6

-
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mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases

Decanal

22 ± 3 x 10-6

-

Human

Liver mitochondria
purified enzyme
(ALDH2)

Retinal

<100 x 10-6

-

-

ALDH1A1

Acetaldehyde

0.9-5 x 10-3
0.8-1.4

-

Mouse

Mitochondrial
fraction

Acetaldehyde

10-50 x 10-3
0.1-0.6

-

Mouse

Cytosol
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in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(Marchitti 2008)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism
1996)
(A. R. Klyosov,
Possible role of
liver cytosolic
and
mitochondrial
aldehyde
dehydrogenases
in acetaldehyde
metabolism

1996)
*% Relative to acetaldehyde
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1.3.4 Isoenzymes and Expression

250 genes under the ALDH superfamily were identified in different species (V. P.
Vasiliou 2000). Out of these genes, 16 genes were identified in human (V. P. Vasiliou 2000) and
transcriped into around 20 families. Each family consists of enzymes having at least 40% of
similarity in their sequence, symbolized by an Arabic number. If more than 60% of sequence
similarity exists, these enzymes are categorized under the same subfamily indicated by a letter
(Sophos 2003) (V. N. Vasiliou 2005). For example, ALDH1L2 has 72% homology with
ALDH1L1 and ALDH3B2 has 83% similarity with ALDH3B1 (Marchitti 2008). In addition,
ALDH1B shares 75% of homology with ALDH2 (Marchitti 2008). There is around 68%
positional identity between ALDH1 and ALDH2 (Agarwal 1992). It is noteworthy that when 145
ALDH proteins aliened, only Gly-245, Gly-299, Glu-399, and Phe-401 were the amino acids
conserved among these proteins (Manzer 2003).
With respect to their subcellular expression, ALDH are expressed in all cell components
(Marchitti 2008). However, the majority of the isoenzymes are located in the cytosol followed by
mitochondria as shown in Table 1-9. For instance, ALDH2 is mainly present in mitochondria
while ALDH1 and ALDH3 are present in the cytosol (C. D. Cheung 2003).
In the body, ALDH are widely distributed in tissues (Marchitti 2008). While ALDH
isoenzymes are abundant in the liver, as shown in Table 1-10, it is also expressed in different
parts of the body. Even though the main isoenzymes, ALDH1-3, are expressed in liver, they are
present in extrahepatic tissues (C. D. Cheung 2003). For example, ALDH1 and ALDH3 are
expressed in cornea (Manzer 2003). Moreover, the expression of some ALDH enzymes increases
in tumor tissues as a response for oxidative stress (Gaspar 2009).

74

Table 1-9. Subcellular locations of ALDH isoenzymes (Marchitti 2008) (V. P. Vasiliou 2000)
Subcellular Location

Isoenzyme

Cytosol

ALDH1A1, ALDH1A2, ALDH1A3, ALDH1L1, ALDH1L2,
ALDH3A1, ALDH3B1, ALDH3B2, ALDH7A1, ALDH8A1,
ALDH9A1

Mitochondria

ALDH1B1, ALDH2, ALDH4A1, ALDH5A1, ALDH6A1,
ALDH7A1, ALDH18A1

Nucleus

ALDH3A1, ALDH7A1

Microsomes, peroxisomes

ALDH3A2
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Table 1-10. Tissue expression of ALDH isoenzymes.
Isoenzyme

Expression

Reference

ALDH1A1

Highest in liver but also present in eye lens, brain (dopaminergic neurons)
kidney, lung, hematopoietic stem cells, red blood cells, genital tissues
Androgen-inducible protein
Highly conserved

(V. P. Vasiliou 2000)
(Marchitti 2008)

ALDH1A2

Intestine, testis, lung, kidney, liver, brain, and retina.

(Marchitti 2008)

ALDH1A3

Salivary glands, stomach, breast, kidney, nasal mucosa, eye, olfactory
bulbs, hair follicles, forebrain, and cerebral cortex.

(Marchitti 2008)

ALDH1A6

kidney, salivary glands, and stomach

(V. P. Vasiliou 2000)

ALDH1B1

Liver, kidney, muscle, heart, placenta, cornea, testis, and brain.

(V. P. Vasiliou 2000)
(Marchitti 2008)

ALDH1L1

Mainly in liver, pancreas, and kidney. Also in lung, prostate, brain,
muscle, thymus, ovary, and testis. Downregulated by xenobiotics as
acetaminophen and methotrexate

(Marchitti 2008)

ALDH1L2

Spleen

(Marchitti 2008)

Liver, brain, heart, lung, leukocytes, and hair roots

(V. P. Vasiliou 2000)
(Yamamoto 1993)
(Marchitti 2008)

ALDH2
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ALDH3A1

Cornea, stomach, lung, skin, esophagus
Inducible by cortisone and xenobiotics (e.g. polycyclic aromatic
hydrocarbons) and cancers. Can be downregulated by progesterone

(V. P. Vasiliou 2000)
(Marchitti 2008)
(Liao 1991)

ALDH3A2

Liver, kidney, stomach, intestine, muscle, skin, lung, pancreas, heart,
brain, and placenta.

(V. P. Vasiliou 2000)
(Marchitti 2008)
(Liao 1991)

ALDH3B1

Mainly in liver and kidney and in lesser amounts in lung and brain.

(Marchitti 2008)

ALDH3B2

Salivary glands, lung, brain, liver, kidney, and prostate.

(Marchitti 2008)

ALDH4A1

Liver, muscle, and kidney.

(Marchitti 2008)

ALDH5A1

Mainly in brain but also present in liver, pituitary, muscle, heart, and ovary

(V. P. Vasiliou 2000)
(Marchitti 2008)

ALDH6A1

Mainly in liver, kidney, heart, and to a less extent in muscle and brain

(V. P. Vasiliou 2000)
(Marchitti 2008)

ALDH7A1

Heart, liver, and kidney

(Marchitti 2008)

ALDH8A1

Liver, kidney mainly and moderately in brain, spinal cord

(Marchitti 2008)

ALDH9A1

Liver, kidney, muscle, and brain

(V. P. Vasiliou 2000)
(Marchitti 2008)

ALDH18A1

Pancreas, ovary, testis, and kidney.

(Marchitti 2008)
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Despite the fact that a particular ALDH isoenzyme might be expressed in more than one
tissue, its activity might be different from one tissue to another. An example of that is shown in
Table 1-11 for ALDH2 enzyme.
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Table 1-11. ALDH activity in human tissues relative to that in liver. (Yin 1994)

ALDH2

Liver

Lung

Esophagus

Stomach

Colon

Rectum

100

2.8

2.8

12

3.8

4.0
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1.3.5 Polymorphism and Pharmacogenetics

Nine of 16 ALDH genes identified in humans are polymorphic and appear to play an
important role in human development and neurological health (V. P. Vasiliou 2000).
Consequently, this genetic mutation is associated with metabolic diseases having neurological
manifestations, such as hyperprolinemia, where the increase in proline levels is associated with
seizures and mental retardation, Sjogren-Larsson syndrome (SLS), and cancer (V. N. Vasiliou
2005) (V. P. Vasiliou 2000). Moreover, a manipulation in the ALDH1 genes led to death of mice
at their midgestational stage (V. P. Vasiliou 2000). In addition, ALDH deficiency is investigated
as a contributing factor in Alzheimer disease (V. N. Vasiliou 2005). Table 1-12 summarizes
diseases associated with ALDH polymorphism and deficiency. The importance of ALDH
enzymes is evident by the diseases caused by mutations in its isoenzymes.
A well-known pharmacogenetic issue that is associated with ALDH is alcoholism. While
familial history is an important factor in alcoholism because of environmental and cultural
issues, the inheritance of ALDH polymorphism is another factor in familial trends in alcoholism
where ALDH polymorphism is thought to be protective against alcoholism (Agarwal 1992). In
mice, acute alcohol intoxication affected the activity of ALDH2 but not ALDH1 (Tomita 1990).
The loss of ALDH2 activity might be a consequence of a point mutation in the ALDH2 gene,
which is common among Asian populations who are not alcoholics (48% vs 12%) (Thomasson
1991) (Beedham 1997). This mutation causes sensitivity to alcohol consumption in 50% of
Orientals and 40% of American Indians since they lack the activity of ALDH2 causing slower
metabolism of acetaldehyde (Liao 1991) (Agarwal 1992) (Yamamoto 1993). Consequently,
persons with ALDH2 deficiency suffer from aversive reactions including, facial flushing, nausea,
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and palpitation as a result of catecholamine and kinins release (Thomasson 1991) (Beedham
1997) (Hatake 1990) (Agarwal 1992). ALDH2 deficient population are characterized by the
presence of ALDH2*1/ALDH2*2 and ALDH2*2/ ALDH2*2 alleles (Yamamoto 1993). The
difference between ALDH2*1 and ALDH2*2 involves an alteration of a single base, where
guanine is replaced by adenine (Yamamoto 1993). Consequently, this point mutation results in
the expression of lysine in the 14 position from the C-terminus instead of glutamic acid (Agarwal
1992). Moreover, alcohol flushing syndrome is associated with alcohol related cancer and
hypertension (V. N. Vasiliou 2005) (V. P. Vasiliou 2000). Nevertheless, this polymorphism has
an advantage through protecting against alcoholism (V. P. Vasiliou 2000). On the other hand,
flushing in Caucasian population is due to several mutations leading to ALDH1 activity decrease
(Agarwal 1992).
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Table 1-12. Diseases associated with ALDH polymorphism and deficiency.
ALDH
Isoenzyme

ALDH1A1

ALDH1A2
ALDH1A3

ALDH2

ALDH1L1

Disease
Increased the likely risk of ethanol-induced cancers
Decreased the likely risk of alcoholism
Lower expression levels: Down’s syndrome.
Testicular feminization
Parkinson Disease
Schizophrenia
Spina bifida
Congenital diaphragmatic hernia
Alcohol-induced toxicity in liver and eye lens
Congenital diaphragmatic hernia
Downregulated in breast cancer
Increased risk of ethanol-induced cancers (esophageal and
upper aerodigestive tract cancers)
Decreased risk of alcoholism
Increased DNA damage in polyvinyl chloride workers
who smoke.
A decrease in nitroglycerin efficiency
Myocardial infarction, and hypertension
Late onset Alzheimer disease
Parkinson disease
Decrease reproductive efficiency
Imbalances in tetrahydrofolate
Increased risk of methanol toxicity
Increased or decreased risk of postmenopausal breast
cancer
Downregulated in pancreas, liver, prostate, ovarian, and
lung cancers

ALDH3A1

Susceptibility to cataract upon UV exposure

ALDH3A2

Sjögren-Larsson syndrome
Preterm birth

ALDH3B1

Mutation is associated with paranoid and schizophrenia

ALDH4A1

Type II hyperprolinemia

ALDH5A1

4-hydroxybutyric aciduria

ALDH6A1

Developmental delay
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Reference

(V. P. Vasiliou
2000)
(Marchitti 2008)

(Marchitti 2008)
(Marchitti 2008)

(V. P. Vasiliou
2000)
(Marchitti 2008)

(Marchitti 2008)

(Marchitti 2008)
(V. P. Vasiliou
2000)
(Marchitti 2008)
(Marchitti 2008)
(V. P. Vasiliou
2000)
(Marchitti 2008)
(V. P. Vasiliou
2000)
(V. P. Vasiliou
2000)

1.3.6 Similarities between Species

ALDH activity was observed in the liver of rat, rabbit, dog, monkey, cow, sheep, and pig
(Deitrich 2007). In addition, ALDH was studied in the lung and kidneys of rat, rabbit, dog, and
monkey (Deitrich 2007). Nevertheless, the expression, structure, presence of isoenzymes,
catalytic activity, and inhibition sensitivity are factors that contributes to the differences
observed between species with respect to ALDH activity. Hence, similarities between species
ALDH1 enzyme was studied through its activity in metabolizing acetaldehyde and other
compounds (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde
dehydrogenases in acetaldehyde metabolism 1996). In addition, human, hamster, and rat liver
homogenates were compared using agarose gel electrophoresis (A. R. Klyosov, Possible role of
liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996).
Such studies demonstrated that there is a high similarity (91%) in ALDH1 between human and
horse (Agarwal 1992).
Although rodents are used for investigating ADH and ALDH activities assuming
similarity in of these enzyme to the isoenzymes present in human (A. R. Klyosov, Possible role
of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism
1996), the cytosolic fraction for human liver was characterized by the presence of ALDH1 while
the hamster and rat cytosolic fraction contained three isoenzymes of ALDH (A. R. Klyosov,
Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde
metabolism 1996). In addition, rodents’ cytosolic ALDH1 enzyme exhibits more basic character,
lower molecular weight (120000-150000) than human ALDH1 (230000-240000) and are
presumed to be dimeric in contrast to the tetrameric human ALDH1 enzyme (A. R. Klyosov,
Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde
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metabolism 1996). Furthermore, it was found that human cytosolic ALDH1 is different from
rodents’ ALDH1 in its catalytic activity toward acetaldehyde (A. R. Klyosov, Possible role of
liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996).
With respect to isoenzyme expression, rabbits express ALDH1 in the cornea rather than
ALDH3 that is expressed in the cornea of human, pigs, baboon, bovine, sheep, rat, and mice
(Manzer 2003).
1.3.7 ALDH in RBCs

A tetramer ALDH enzyme has been characterized in human RBCs (Inoue 1979) (Rawles
1987) (Ueshima 1993). Similarities between this enzyme and human cytosolic enzyme in the
liver were reported including their sensitivity to acetaldehyde and disulfiram along with their
optimum pH (Inoue 1979) (Rawles 1987). The physiological function for ALDH in RBCs is not
known, however, it is thought to contribute to the metabolism of the acetaldehyde fraction that
escapes liver metabolism (Rawles 1987). During a study conducted by Ueshima et. al., one
subject out of 16 subjects had no expression of ALDH in his RBCs (Ueshima 1993). With the
exception of that subject, ALDH activity was estimated as 25 nmol NADH/minute/g hemoglobin
(Ueshima 1993). The same group conducted an in-vitro study, in which acetaldehyde was added
at a concentration of 0.1 mM to 1 ml of heparinized blood and measured over 14 minutes by gas
chromatography. Approximately 60-70% of the added acetaldehyde disappeared within the 14
minutes, while only 20% disappeared in the person with ALDH deficiency (Ueshima 1993). At
the physiological concentration of Mg+2, it inhibited ALDH probably by decreasing the rate of
enzyme-NADH dissociation rate (Rawles 1987). Hence, while diluting the RBC matrix to
conduct metabolic studies, the inhibitory effect of Mg+2 will be diluted. Hence, the activity of the
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enzyme will be overestimated (up to 6-fold as implied by Rawles et al.) upon extrapolating the
in-vitro activity to its corresponding in-vivo value.
ALDH activity decreased upon storage of RBCs at 4, -20, -70 °C (Johnson 1992).
Addition of sucrose at 40 g/l concentration increased ALDH stability upon storage at -20 °C
(Johnson 1992). Lactate dehydrogenase might interfere in the results but can be inhibited by
oxalate (Johnson 1992). It is noteworthy that ALDH activity was not observed in rat blood
(Deitrich 2007).
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1.4

Alcohol Dehydrogenase (ADH)

ADH is a potential enzyme in the metabolism of 5-HMF. Below is a description of its
structure, function, substrates, isoenzymes, expression, polymorphism, and pharmacogenetics.

1.4.1 Structure

ADH is an 80 kDa dimeric-enzyme that catalyzes an interconversion reaction between
alcohol and aldehydes (Agarwal 1992) (C. D. Cheung 2003). Each subunit contains two zinc
molecules and is consisted of around 374 amino acids (Yin 1994) (Agarwal 1992) (Liao 1991).
There are seven structural genes encoding for the subunits of ADH, namely; α, β, γ, π, x, and µ
(Liao 1991) (Agarwal 1992) (Ricciardi 1983) (Yin 1994). These subunits are the basis for the six
identified mammalian classes, which are ADH1 through ADH6 (C. D. Cheung 2003).

1.4.2 Function

ADH catalyzes the interconversion of alcohols and their corresponding aldehydes,
including primary, secondary, and tertiary alcohols that are primarily aliphatic in nature and to a
lesser degree are cyclic (Agarwal 1992). ADH is involved in the metabolism of endogenous
compounds, such as retinol, bile acid, and steroids (Agarwal 1992). Likewise, ADH catalyzes the
bioconversion of xenobiotics, like food flavors and digoxin (Agarwal 1992). Ethanol is one of
the most studied substrates, for which ADH is significantly responsible for converting it to
acetaldehyde (Liao 1991) (Agarwal 1992) (Yin 1994). Besides its known function in the
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oxidation of aliphatic and aromatic alcohol, it was reported to have aldehyde dismutase function
transferring aldehydes into acids (C. D. Cheung 2003).

1.4.3 Substrates

The Km for ethanol was determined between 0.049-4.2 mM for class I ADH while it was
30 mM for Class II, IV, V. Class III does not seem to be involved in ethanol metabolism (Yin
1994).

1.4.4 Isoenzymes and Expression

ADH1-2 are predominantly expressed in liver while ADH3 is present in liver and
extrahepatic tissues (C. D. Cheung 2003). With respect to extrahepatic tissues, ADH is expressed
in stomach with 20% of ingested ethanol metabolized there (Liao 1991). The γ ADH is the
predominant isoenzyme in the gastrointestinal tract with small amounts of β ADH present (Liao
1991). In addition, ADH2 is also present in leukocytes (Yamamoto 1993). Table 1-13
summarizes ADH activities in human tissue relative to liver.
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Table 1-13. ADH activities in human tissue relative to liver (Yin 1994)

ADH1

Liver

Lung

Esophagus

Stomach

Colon

Rectum

100

2.1

26

8.2

7.2

10
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1.4.5 Polymorphism and Pharmacogenetics

There is 90% similarity in enzymes with the same class and 60% between the enzymes
from different classes (Yin 1994). Genetic polymorphism that is associated with ADH occurs in
β1, β2, β3 and γ1, γ2 genes of ethnic groups (Liao 1991) (Yamamoto 1993) (Yin 1994).
Particularly, polymorphism in β and γ subunits of ADH2 and ADH3, respectively, are thought to
be responsible for the genetic part that accounts for up to 50% of the three-fold difference in
alcohol metabolism observed in different populations (Thomasson 1991). This polymorphism in
ADH2 and ADH3 were more frequent in non-alcoholic Chinese when compared to alcoholics
Chinese (Thomasson 1991). Non-alcoholic populations have ADH with higher capacity to
metabolize ethanol since they have the ADH2*2 allele with β2 subunit, which has a higher
enzymatic activity in comparison to the wild ADH2*1 allele with β1 subunit (Thomasson 1991)
(Ricciardi 1983). However, it was shown later that a significant higher acetaldehyde
concentration in the blood of individuals who are homozygous for ALDH2*2 in comparison to
those who are homozygous for ADH2*2 (Yamamoto 1993) (Ricciardi 1983). The frequency of
ADH 2*2 in Japanese and Chinese was found to be around 69%-85% while it was 20% in Swiss
population (Yamamoto 1993) (Agarwal 1992) (Ricciardi 1983). Table 1-14 shows the frequency
of ADH polymorphism in different population.
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Table 1-14. ADH polymorphism in different population (Yin 1994)
ADH21

ADH22

ADH23

ADH31

ADH32

Orientals

0.30

0.70

0

0.90

0.10

Caucasian

0.90

0.10

0

0.60

0.40

African-American

0.84

0

0.16

0.85

0.15

American Indian

1.00

0

0

0.41

0.59

Taiwanese Aborigines

0.09

0.91

0

0.99

0.01
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1.4.6 Similarities between Species

ADH1 is present in mouse, rat, guinea pig, and human liver and skin (C. D. Cheung
2003). However, its expression level is dependent on the developmental stage, as shown in rat
and mice (C. D. Cheung 2003). On the other hand, it was shown that ADH2 is not expressed in
mouse, rat, guinea pig skin but expressed their livers and the liver and the skin of humans (C. D.
Cheung 2003). The vmax determined for ADH in human skin was lower than that for rodents and
guinea pig although their intrinsic clearance (vmax/Km) values were similar (C. D. Cheung 2003).
In addition, Gupta reported different Km and vmax values ranging between 0.8-14 mM and
0.05-2.8 mmol/min, respectively, for in-vivo ethanol metabolism, mediated by ADH, in rat,
rabbit, dog, and human (Gupta 2006). Besides, Cheung and co-workers observed that the
cytosolic ADH of rodents had a lower metabolic efficiency of ethanol metabolism than that of
human (C. D. Cheung 2003).
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1.5

Blood Composition

Blood is a connective tissue that safeguards living cells in the body by delivering oxygen
and nutrients as well as getting rid of toxins (Rhoades 1996). Blood is confined to the blood
vessels and heart compartments (Rhoades 1996). Figure 1-21 shows the main components of
sedimented blood layers. The average viscosity of an adult blood is 4.5-fold higher than water
(Rhoades 1996).

1.5.1 Plasma

Plasma is a transparent fluid that carries blood platelets, cells, and proteins (Rhoades
1996). Upon fractionation of blood, plasma is separated from the blood cells and platelets. When
fractionated, plasma is mainly composed of water (93%) that contains proteins, organic, and
inorganic substance (Rhoades 1996). Plasma proteins regulate the osmotic pressure of blood,
which controls the exchange of substances between blood and interstitial fluid (Rhoades 1996).
In addition, it acts as a reservoir for amino acids and as a buffering agent to keep the slightly
alkaline environment of blood (Rhoades 1996). A well-known function of plasma proteins is the
transport of endogenous substances, such as hormones and the otherwise insoluble fat (Rhoades
1996). Moreover, exogenous material exemplified by drugs can bind to plasma proteins
(Rhoades 1996).
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1.5.2 Red Blood Cells

Approximately 5000 million RBCs exist in each milliliter of the blood (Rhoades 1996).
RBCs (erythrocytes) originates from the bone marrow through the erythropoiesis process
(Rhoades 1996). In contrast to other cells in the body, mature RBCs do not contain a nucleus and
are anchored by a cytoskeleton that is connected to the inner membrane of RBCs (Rhoades
1996). They are characterized by their flexibility, which allow them to pass through blood
vessels regaining their biconcave shape, after bending and twisting (Rhoades 1996). In addition,
their distinct shape increases their main function efficiency, which involves gases exchange,
because it maximizes the surface area to volume ratio (Rhoades 1996).
Unfortunately, the flexibility and the doughnut shape of RBCs are impaired in genetic
diseases like sickle cell anemia. Table 1-15 lists the differences between normal RBCs and
sickled RBCs.
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Table 1-15. Differences between normal and sickled RBCs.
Sickled RBCs relative to Normal RBCs

Reference

Increased

(Hebbel 1991)

5-50%

(Hebbel 1991)

Dehydrated

(Hebbel 1991)

Increased

(Hebbel 1991)

Present

(Hebbel 1991)

Increased Na+
Decreased K+

(Hebbel 1991)

10 fold increase in total Ca+2

(Hebbel 1991)

Phospholipid destabilization
Adducts with malondialdehyde

(Hebbel 1991)

Decreased

(Hebbel 1991)

Decreased stability and solubility

(Hebbel 1991)

Reticulocytes
Abnormally dense RBCs
Water content
Mean cell hemoglobin
concentration (MCHC)
Irreversible sickled RBCs
Monovalent cations
Ca+2
Lipid bilayer
Strength and flexibility
Hemoglobin
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1.5.3 White Blood Cells (WBCs)

Approximately 7 to 10 million WBCs are present in each one milliliter of whole blood
(Rhoades 1996). WBC types are distinguished by the shape of their nuclei and the presence or
the absence of granulated vesicles (Rhoades 1996). WBCs need staining for differentaion
purposes since they do not contain coloring molecules in contrast to RBCs (Rhoades 1996).
Besides the blood stream, WBCs are found in the lymphatic system and connective tissues
(Rhoades 1996). Their general function is defense against toxins and foreign substance entering
the body (Rhoades 1996). As part of the immune system, they produce antibodies against and
engulf invading bacteria (Rhoades 1996).

1.5.4 Platelets

Platelets (thrombocytes) are membrane bounded cell fragments that lack nuclei (Rhoades
1996). There are approximately 150-350 million platelets in each milliliter of blood (Rhoades
1996). Their main function is concerned with decreasing blood loss in injuries by playing a role
in blood vessel contraction and blood coagulation at the site of injury (Rhoades 1996).
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1.5.5 Blood Proteins
Albumin and α-acid glycoprotein (AAG) are involved in drug binding. There are other
proteins present in plasma at low concentration, such as lipoproteins, C-reactive proteins and are
thought to have a minimal contribution to drug binding (Routledge 1986). The overall
concentration of albumin and globulins in the blood are regulated to keep a constant total
concentration with a variant albumin/globulin ratio depending on the health status of the patient.

1.5.5.1 Albumin

Albumin accounts for 60% of plasma proteins, thus represents the most abundant protein
in plasma and it is a main contributor to the osmotic pressure of blood (Rhoades 1996). Hence, a
decrease in its concentration, because of malnutrition or liver disease, results in a fluid shift from
the blood compartment into interstitial fluid (Rhoades 1996). Albumin is a single chain peptide
protein with a molecular weight of 66,478 Da (Sigma-Aldrich n.d.). Human serum albumin
solubility is 50 g/l (Sigma-Aldrich n.d.). Although albumin concentration is relatively stable, 3550 g/l, it can decrease in disease states, such as renal and hepatic failures (Corti 1994).
Nevertheless, changes in the concentration are less than two fold of the normal concentration.
This concentration stability in addition to the fact that albumin has low affinity, high capacity of
binding make drugs binding to albumin less susceptible to variations (Routledge 1986).

96

1.5.5.2 Hemoglobin

Hemoglobin (Hb) is a tetramer protein that is soluble in water at a concentration of 20 g/l
(Sigma-Aldrich n.d.). The molecular weight of hemoglobin is 64,677 Da (Sigma-Aldrich n.d.).
The average concentration of hemoglobin in blood is 150 g/l (2.3 mM) (Dixon 1997), while the
average normal mean corpscular hemoglobin concentration (MCHC), i.e. concentration of
hemoglobin in erythrocytes, is 340 g/l (5.3 mM) (Clark 1989). Hemoglobin is major carrier of
oxygen in the body and the absence of this function requires the heart to pump around 80
l/minute since only a small percentage of oxygen is dissolved in blood (Sladen 1981).
Hemoglobin is known for its cooperativety in binding to oxygen, as described by Hill, with
conformational changes facilitating this binding (Riggs 1998). Upon oxygen binding to the heme
groups in hemoglobin, it destabilizes salt bridges in the quaternary structure of hemoglobin
leading to an increase in the affinity to oxygen that appears in the sigmoidal shape of oxygen
saturation curve (Sladen 1981). This curve is characterized by the P50 value, which represent the
oxygen pressure achieving 50% saturation of hemoglobin. The typical P50 value in healthy
individuals is 26.5 mmHg (Sladen 1981). However, the P50 is affected by temperature and
organic and inorganic ligands, such as proton ions (H+), carbon dioxide (CO2), and 2,3
diphosphoglycerate (2,3-DPG). While the increase in CO2 and 2,3-DPG concentration is
associated with an increase in the P50 (right-shift in the oxygen saturation curve), the increase in
the pH affects the P50 inversely (left-shift in the oxygen saturation curve). The concentration of
2,3-DPG is approximately 4 mM inside the RBCs and doubling its concentration has a major
effect oxygen curve resulting a P50 of 37 mmHg (Sladen 1981). The decrease in hemoglobin
affinity toward oxygen is a result of 2,3-DPG salt bridging interaction between the β–chains
(Safo 2004).
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1.5.5.3 AAG

The molecular weight of AAG is 40,000 Da and it has an acidic pKa. The concentration
of albumin is approximately 100 times more than AAG (Routledge 1986). Its physiological
function of this acidic protein is not clear but it can contribute to immunological and repair
processes (Routledge 1986). Hydrophobic rather than electrostatic interactions are mainly
involved in drugs binding to AAG (Routledge 1986). AAG does not significantly contribute to
the binding of acidic drugs, which are more attracted to human serum albumin. Propranolol and
disopyramide are examples of drugs bound to AAG (Routledge 1986). AAG is present in both
plasma and extra-vascular space (Routledge 1986). AAG concentration is affected by
environmental conditions more than hereditary factors (Routledge 1986). Since the concentration
of AAG differs according to the health status, drug binding to this protein is associated with
variability (Routledge 1986). For example, the concentration of AAG increases in infections,
obese subjects, and in subjects on anticonvulsant therapy while it has lower levels in patients
with nephrotic syndrome (Routledge 1986). Besides, AAG is characterized by a low capacity,
high affinity binding interaction and subject to saturation (Routledge 1986).
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CHAPTER 2
2
HYPOTHESES, SPECIFIC AIMS, AND SIGNIFICANCE

2.1

Hypotheses

The main objective of this research is to help predict human in-vivo PK of 5-HMF using
in-vitro-in-vivo extrapolation (IVIVE). The results will be useful in determining a non-toxic and
biologically relevant dosage regimen to be used in phase I clinical trials. Therefore, the
hypotheses guiding this research are as follows:
•

In hepatic cytosol:
– 5-HMF is subject to ALDH- and ADH-mediated metabolism.
– Significant species differences in 5-HMF disposition exist among mouse, rat, dog,
and human.

•

In human blood:
– 5-HMF is subject to ALDH-mediated metabolism.
– 5-HMF demonstrates a time- and a concentration-dependent binding to Hb.
– 5-HMF demonstrates a time- and a concentration-dependent binding to HSA.
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2.2

Specific Aims

In order to test the hypotheses specified in section 2.1, the following specific aims are
proposed in this research project:
1.

To review the available literature on the physiochemical properties, PK, and
PD of 5-HMF, as a potential antisickling agent.

2.

To optimize the experimental conditions needed to investigate 5-HMF
metabolism and binding in blood and hepatic cytosol.

3.

To develop and validate an assay method for the quantitation of 5-HMF in neat
solution, human plasma, and human RBCs.

4.

To identify the metabolic pathways of oxidative 5-HMF metabolism in human
hepatic cytosol.

5.

To determine the in-vitro affinities and metabolic capacities of 5-HMF in
mouse, rat, dog, and human hepatic cytosol.

6.

To perform IVIVE of hepatic metabolism for 5-HMF in mouse, rat, dog, and
human hepatic cytosol and compare it with published data.

7.

To determine the in-vitro affinity and metabolic enzyme capacity of 5-HMF in
human RBCs.

8.

To perform IVIVE for 5-HMF metabolism in human RBCs and compare it
with published data.

9.

To investigate the time-dependent kinetics of 5-HMF binding to human
hemoglobin and serum albumin.

10.

To determine the steady-state concentration-dependent parameters of 5-HMF
binding to human hemoglobin and serum albumin.
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11.

To develop a PK model that combines both hemoglobin binding and RBC
metabolism of 5-HMF to explain its disposition in blood.

2.3

Significance

Sickle cell disease is classified as the most common inherited disease in the world
(Howard 2009). The susceptibility of HbS to polymerize upon deoxygenation is severe enough to
decrease the life expectancy of patients with this disease to 45-55 years (Howard 2009).
Moreover, sickle cell disease is accompanied with a decrease in the quality of life of the patient
and their families because of the recurring and unpredictable pain episodes and other chronic and
acute complications related to obstruction of blood vessels by sickled RBCs (Howard 2009).
Bone marrow transplantation represent a cure for this disease, however, it is hindered by the
having a suitable donor and the eligibility of the patient for this procedure (Bolaños-Meade
2009). The only treatment that specifically targets pathophysiology of sickle cell disease is
hydroxyurea, through stimulating the production of HbF, which has higher oxygen affinity
(Lanzkron 2008). Consequently, hydroxyurea decreases the fraction of hemoglobin that is
susceptible to polymerization at certain oxygen pressure. Yet, hydroxyurea toxicities mire its
use, especially in children (Lanzkron 2008). Therefore, there is an apparent need for having a
curative and a relatively safe treatment for this disease. Besides, none of the current therapeutic
approaches prevents the polymerization of HbS that precedes sickling of RBCs. In the process of
searching for an agent targeting the pathophysiology of SCD, 5-HMF was found to reduce RBCs
sickling in rodents though increasing the affinity of HbS to oxygen (Safo 2004). Consequently,
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less HbS exists in the deoxygenated state at any specific oxygen pressure, therefore, 5-HMF
decreases HbS polymerization. An attractive fact about 5-HMF, with regard to its safety, that 5HMF is found constitutively in food such as coffee, dried fruits, and traditional Chinese
medicines (Lin 2008) (Janzowski 2000). In addition, 5-HMF is an adulteration product in honey,
beer, fruit juice, and glucose infusion solutions (Godfrey 1999).
Despite the long history of 5-HMF research, the literature is scarce with respect to studies
fully characterizing its human PK. 5-HMF was dosed to different animal species, rodents, dogs,
rabbits, and chickens, with the oral route being the method of administration in most of the
studies (Klimmek 1978) (Rasmussen 1982) (Godfrey 1999) (Czok, Tolerance of 5hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects 1970) (Germond
1987) (NTP 1994) (NTP 2008). In addition, 5-HMF was administered orally to humans in three
clinical studies without elaborating its PK properties (Prior 2006) (Matzi 2007) (M. P. Murkovic
2006). Differences in the estimated half-life and systemic clearance were found between and
among species in the reported studies. Furthermore, 5-HMF oral bioavailability was not
evaluated by a simultaneous administration of 5-HMF through systemic and oral routes.
In studies with the radiolabeled molecule, 5-HMF was shown to be extensively
metabolized and the metabolites were mainly excreted in urine, however, the metabolic pathways
were not identified (Godfrey 1999) (Germond 1987). Moreover, the metabolic affinity and
capacity were not characterized along with any relevant differences and/or similarities among
species. Furthermore, extra-hepatic metabolism was not investigated as a potential contributor
for the overall clearance.
On the other hand, 5-HMF was reported to bind to hemoglobin by transient covalent
binding to form a Schiff base (Safo 2004). However, the kinetics of this binding was not studied;
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including the expected time to equilibrium and extent of binding. In addition, binding to the
major serum protein, albumin, was not investigated to explore its interaction with hemoglobin
binding.
Consequently, 5-HMF stability in human blood was investigated using a validated
HPLC-UV assay in human plasma, where a decrease in 5-HMF concentration over time was
observed. In addition, experiments were performed to evaluate the metabolic stability of 5-HMF
in human hepatic cytosol. A concentration-dependent increase in nicotinamide adenine
dinucleotide (NADH) formation was demonstrated, indicating the involvement of ALDH/ADH
enzymes in the metabolism of 5-HMF. Hence, as a part of this research, the mechanistic basis
behind 5-HMF metabolism in human hepatic cytosol was explored. In addition, this research
intended to evaluate 5-HMF metabolic properties in hepatic cytosol of human, dog, rat, and
mouse. These properties were compared among species to evaluate any similarities or variations.
Furthermore, metabolism in human RBCs was studied as a potential source of extra-hepatic
metabolism. More to the point, time- and concentration dependency studies were carried-out in
human serum albumin and hemoglobin solutions. The overall objective of these in-vitro studies
was to support first-time-in-human phase I studies with 5-HMF as a part of its development as
antisickling agent.
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CHAPTER 3
3
DEVELOPMENT AND VALIDATION OF HPLC ASSAY METHODS

3.1

Introduction

A number of analytical methods for the quantification of 5-HMF were described in the
literature, as summarized in Table 3-1. The lowest reported concentration is listed in Table,
except where indicated, since the LLOQ was not reported in most of these analytical methods.
However, most of these were dedicated for the determination of 5-HMF in non-biological
matrices. Other methods measured 5-HMF as a hydrolysis product of glycosylated RBCs and
plasma proteins. Although few assay methods in biological matrices were reported, complex or
tedious sample preparation was utilized in these. Hence, the need to a simple and a sensitive
bioanalytical assay method was pointed-out to determine 5-HMF concentration in biological
matrices involved in potential future clinical and animal studies. It is noteworthy that 5-HMF
was investigated in a pilot study, which employed cancer patients with a dose of 3 g/l/day of 5HMF. The minimum concentration of 5-HMF in plasma in that study was anticipated to be
around 2.4 µM (Michail 2007).
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Table 3-1. 5-HMF literature-reported assays
Matrix

Method

Lowest Reported
Concentration
(µM)

(Coco 1996)

Honey

HPLC-UV/VIS

0.008 mg/kg (LOD)

(Drifield 2005)

Honey

HPLC-UV

1.4 mg/kg (LOD)

Intravenous nutrition
and urine

GC-MS

NA

(Standefer 1983)

RBC (HbA1)

Colorimetric
spectrophotometry

~ ≥19.8

(Menez 1984)

RBC (HbA1)

HPLC-UV

0.50

Plasma (glycosylated
protein)`

HPLC-UV

0.50

Tissues (including
whole blood) and urine

HPLC-UV and HMFderived radioactivity

Whole blood and
plasma

HPLC-UV

~ 23.8

Plasma

HPLC-UV

2.4 (LLOQ)

Author

(E. B. Jellum
1973)

(Sampietro 1987)

(Godfrey 1999)

(Abdulmalik 2005)
(Michail 2007)
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~ 0.16 in blood
~ 0.013 µg/g brain

3.2

Methods

3.2.1 Materials and Reagents

1. Mobile Phase for 5-HMF Assay Method in Plasma and RBCs:
- 93.5% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
- 6.2% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ)
- 1% Acetic acid, glacial, > 99% (Sigma, Milwaukee, WI)
- 0.3 % Tetrahydrofuran, HPLC grade (Burdick and Jackson, Morristown, NJ)
2. Mobile Phase for HMFA Assay Method in Human Hepatic Cytosol:
- 83% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
- 17% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ)
- Tetrabutylammonium iodide, 99% (Sigma, St. Louis, MO)
3. 5-Hydroxymethyl-2-furfural (5-HMF) Stock Solution:
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
4. 2-Furfuraldehyde (2F) Stock Solution:
- 2-Furfural (Sigma, St. Louis, MO)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
5. Acetylfuran (AF) Stock Solution:
- Acetylfuran (Sigma, St. Louis, MO)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
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6. 5-Methyl-2-furfuraldehyde (MF) Stock Solution:
- 5-Methyl-2-furfural (Sigma, St. Louis, MO)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
7. 5-Hydroxymethyl-2-furoic Acid (HMFA) Stock Solution:
- 5-Hydroxymethyl-2-furoic Acid (Toronto Research Chemicals, Inc., North York,
On.Canada)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
8. Furan-2,5-dicarboxylic Acid (FDCA) Stock Solution:
- Furan-2,5-dicarboxylic acid (Toronto Research Chemicals, Inc., North York,
On.Canada)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
9. SPE Conditioning:
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
10. SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4:
- Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
11. SPE Eluting Solution: 50% Methanol:
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ)
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory)
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3.2.2 Equipment

1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips
(Microman, Rainin Instruments, Oakland, CA).
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West
Chester, PA).
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA).
4. Vortex (Vortex-Genie, VWR, West Chester, PA).
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).
6. pH meter (Corning, Glendale, AZ).
7. Balance (Fisher Scientific A 250, Pittsburgh, PA).
8. Oasis HLB cartridge, 1 cc/ 30 mg (Waters).
9. Centrifuge 5804-R (Eppendorf, Hauppauge, NY).
10. Glass vials with caps, 1 ml (Waters, Milford, MA).
11. UV detector (Shimadzu, AV-10, Columbia, MA).
12. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA).
13. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA).
14. 717 plus autosampler (Waters, Milford, MA).
15. 600 Multisolvent controller (Waters, Milford, MA).
16. Empower 2 software (Waters, Milford, MA).
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3.2.3 Preparation of Solutions

– Mobile Phase for 5-HMF Assay Method in Plasma and RBCs (1 L):
935 ml water, 62 ml methanol, 10 ml acetic acid glacial, and 3 ml
tetrahydrofuran were mixed to prepare the mobile phase.

– Mobile Phase for HMFA Assay Method in Human Hepatic Cytosol (1 L):
2 g of tetrabutylamonium iodide were dissolved in 830 ml water mixed with
170 ml methanol.

– 5-Hydroxymethyl-2-furfural (5-HMF) Stock Solution, 39.6 mM
20 mg of 5-hydroxymethyl-2-furfural (M.W.: 126.11 Da) in 4 ml of water.

– 2-Furfuraldehyde (2F) Stock Solution, 12.1 mM.
11.6 mg of 2-furfural (M.W.: 96.08 Da) was added to 10 ml of water.

– Acetylfuran (AF) Stock Solution, 9.97 mM.
10.1 mg of acetylfuran (M.W.: 110.11 Da) was added to 10 ml of water.

– 5-Methyl-2-furfuraldehyde (MF) Stock Solution, 10.1 mM.
11.1 mg of 5-methyl-2-furfural (M.W.: 110.11 Da) was added to 10 ml water.
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– 5-Hydroxymethyl-2-furoic Acid (HMFA) Stock Solution, 1.41 mM.
2 mg of 5-hydroxymethyl-2-furoic acid (M.W.: 142.11 Da) was added to 10 ml
water.

– Furan-2,5-dicarboxylic acid (FDCA) Stock Solution, 12.8 mM.
10 mg of furan-2,5-dicarboxylic acid (M.W.: 156.09 Da) was added to 5 ml water.

– SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4
One tablet of phosphate-buffered saline was added to 200 ml of water.

– SPE Eluting Solution: 50% Methanol.
25 ml of methanol was mixed with 25 ml of water.
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3.2.4 Procedures

0.3 ml of plasma and 0.1 ml of thawed RBCs (after freezing at -80 °C) were diluted to 0.6
ml and 1.2 ml, respectively. 0.6 ml of the diluted sample was loaded into preconditioned (with
methanol and water) HLB (hydropilic-lipophilic balance) solid phase extraction cartridges. The
undesired impurities were washed with PBS and the sample was finaly eluted with 0.5 ml of
50% methanol in water. The extraction procedure is summarized in Table 3-2. Reference was
made to Michail and co-workers, with minor amendments, for the sample prepartion by solid
phase extraction (Michail 2007). However, the extract was injected directly into the HPLC-UV
system with satisfactiory results without including the tedious and time-cosumimg dervitization
step reported in that method.
The mobile phase for the analysis of 5-HMF in plasma and RBCs was prepared in an
identical way to that reported by Menez et al., where an isocratic mobile phase was prepared by
mixing water, methanol, acetic acid, tetrahydrofuran, 93.5:6.2:1:0.3, respectively, were mixed
and used in (Menez 1984). A UV scan was performed between 200 nm to 330 nm to check if the
mobile phase contributes to the absorbance measured at 285 nm. Figure 3-1 demonstrates that
the mobile phase absorbance is insignificant at that wavelength window.
10 µl of the extracted samples were injected into Zorbax C18 analytical column (150 x 4.6
mm) protected by a C18 guard column (12.5 mm x 4.6 mm) through an autosampler at 4 °C and
the mobile phase flowed at 0.75 ml/minute rate. 5-HMF peak was detected using Shimadzu 10
AV UV absorbance detector a at 285 nm.
Another method was developed for the detection of the metabolite HMFA in the presence
of the parent compound 5-HMF in human hepatic cytosol. 0.2 ml of hepatic cytosol reaction
mixture was diluted with 1 ml ice-cold acetonitrile. Then, 0.15 ml of the mixture was diluted
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further with 0.65 ml ice-cold water. 10 µl of the diluted samples was injected directly into
HPLC. The mobile phase was a mixure of water and methanol, 87:13, respectively. In addition,
0.2% w/v tetrabutylammonium iodide was added an ion-pairing agent. The flow ratewas 1
ml/minute though Zorbax C18 analytical column (150 x 4.6 mm) protected by a C18 guard column
(12.5 mm x 4.6 mm). HMFA peak was detected using Shimadzu 10 AV UV absorbance detector
a at 260 nm.
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Figure 3-1. UV spectrum for the mobile phase.
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Table 3-2. Solid phase extraction procedure

Solvent

Volume (ml x times)

Minimum centrifuge
speed (rpm) – time (min)

Methanol

1x2

400-2

Water

1x2

400-2

Loading

Plasma (diluted one fold) or RBCs
suspension (diluted 6 folds)

0.6 x 1

400-7

Washing

Phosphate buffer saline pH 7.4

1x2

700-5

50% methanol in water

0.5 x 1

400-5

Step

Conditioning

Elution
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3.3

Method Validation

3.3.1 5-HMF in Human Plasma

A summary of the 5-HMF assay method in human plasma is described in Table 3-3. In
addition, representative chromatograms of 5-HMF in human plasma are shown in Figures 3-2, 33, 3-4, 3-5, 3-6, and 3-7.
To ensure the suitability and reliability of the developed method for the intended
measurements, validation of this analytical method in human plasma was evaluated through the
following:

3.3.1.1 Recovery

The response of extracted samples at low, medium, and high concentrations was
compared to the response of unextracted known concentrations that represent 100% recovery.
The efficiency of extraction was reproducible with a CV less than 4% and a recovery of more
than 78%. Moreover, the recovery at the LLOQ was determined to be 84% with a CV not
exceeding 1%, as summarized in Table 3-4.
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Table 3-3. 5-HMF assay descriptive summary.
Type of assay

HPLC-UV

Sample preparation

Solid phase extraction of diluted plasma by Oasis HLB cartridges (Waters)

Detector

Shimadzu 10 AV Absorbance Detector

LC pump

Waters 600E Multisolvent Delivery System

LC column

Zorbax Rx C18, 80 Ao, 150 mm x 4.6 mm, 5 μm
(Agilent, Serial # USDU010028)

Guard column

C18, 12.5 mm x 4.6 mm
(Agilent, Serial # USCI042710)

Detection

UV at 285 nm

Autosampler temperature

4 °C

Flow rate

0.75 ml/minute

Regression algorithm

Linear, weighted 1/X

Sample volume and matrix

0.3 ml of plasma diluted with water to a total volume of 0.6 ml. The 0.6 ml
diluted sample is extracted to 0.5 ml sample using HLB cartridges

Mobile phase

Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3)

Injection volume

10 µL

Chromatographic run time

10 minutes

Calibration curve range

0.16 – 158.6 µM

LLOQ

0.16 µM

Quality control levels

0.48, 15.9, 126.9 µM
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Figure 3-2. Representative chromatogram of 5-HMF standard in mobile phase.
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Figure 3-3. Representative chromatogram of individual human plasma blank.
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Figure 3-4. Representative chromatogram of LLOQ concentration.
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Figure 3-5. Representative chromatogram of low QC concentration.
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Figure 3-6. Representative chromatogram of mid QC concentration.
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Figure 3-7. Representative chromatogram of high QC concentration.
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Table 3-4. 5-HMF recovery in human plasma.

Concentration (µM)

R1

R2

R3

Mean

CV

0.16

85

84

85

84

0.9

0.48

75

81

79

78

3.7

15.9

105

108

109

107

1.9

126.9

107

108

111

109

1.9
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3.3.1.2 Accuracy

Within-assay accuracy was determined for six replicate measurements at four different
concentrations, in addition to the LLOQ. The mean deviation from the nominal value was used
as a measure of accuracy in the analytical range (DFN). The DFN did not exceed 15% at any of
these concentrations including the LLOQ, as shown in Table 3-5. 1/X weighted linear regression
was used in the calibration curve.
Inter-assay accuracy was determined at three levels with twelve replicates at each
concentration, as summarized in Table 3-6. The accuracy was deemed acceptable as per the FDA
guidance for industry “Bioanalytical Method Validation” criteria, with no more than 15% DFN
for the selected concentrations and 20% as the DFN at the LLOQ.

3.3.1.3 Precision

The analysis was applied repeatedly at three levels with twelve replicates at each
concentration to evaluate the between-run repeatability, as summarized in Table 3-6. Within-run
precision was determined for six replicates, shown in Table 3-5, at four concentrations in the
analysis range. To measure the repeatability of the method with time, three different runs were
analyzed. The FDA guidance for industry “Bioanalytical Method Validation” criteria was used
as a reference, with no more than 15% coefficient of variation (CV) for the selected
concentrations and ≤ 20% as a CV at the LLOQ.
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Within the expected range of concentrations, the method produced satisfactory results
without the use of an internal standard. In addition, sample preparative procedure did not
diminish the recovery of 5-HMF. Consequently, an internal standard was deemed unnecessary.

3.3.1.4 Selectivity

As shown in Table 3-6, six sources of plasma were analyzed to test for interferences and
to investigate the ability to differentiate and quantify 5-HMF in the presence of other endogenous
components in the extracted plasma. The chromatograms for these are shown in Figures 3-8, 3-9,
3-10, 3-11, 3-12, and 3-13. The ratio of the average area response of six replicates at the LLOQ
concentration to that of six blank sources was 5.5.
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Table 3-5. 5-HMF intra-run accuracy and precision in human plasma.

Concentration
(µM)

R1

R2

R3

R4

R5

R6

Mean

CV

0

848

145

1028

705

1175

886.5

798

44.9

0.16

4522

4131

4359

4357

4518

4405

4382

3.3

-11.8

0.32

7080

7788

6609

7128

4936

6933

6746

14.3

7.5

0.48

10006

10256

10084

9678

10358

9911

10049

2.4

4.3

15.9

283536

281470

286576

282973

284034

286408

284166

0.7

14.6

126.9

2716556

2454494

2391176

2404352

2387093

2415976

2461608

5.2

5.6
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DFN%

Table 3-6. 5-HMF inter-run accuracy and precision in human plasma.
0.16 µM

0.48 µM

15.9 µM

126.9µM

R1

4348

10139

337282

3021407

R2

3964

10051

343673

3041115

R3

4410

9997

346116

3147102

R1

4522

10006

283536

2716556

R2

4131

10256

281470

2454494

R3

4359

10084

286576

2391176

R4

4357

9678

282973

2404352

R5

4518

10358

284034

2387093

R6

4405

9911

286408

2415976

R1

4825

12182

334845

2412090

R2

5907

13063

341995

2409259

R3

6510

13016

336680

2426958

Mean

4688

10728

312132

2602298

CV

16.0

11.7

9.4

11.4

DFN%

-18.6

-2.8

4.4

-0.1

First run

Second run

Third run
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Figure 3-8. Individual human plasma chromatogram (blank 1).
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Figure 3-9. Individual human plasma chromatogram (blank 2).
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Figure 3-10. Individual human plasma chromatogram (blank 3).
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Figure 3-11. Individual human plasma chromatogram (blank 4).
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Figure 3-12. Individual human plasma chromatogram (blank 5).
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Figure 3-13. Individual human plasma chromatogram (blank 6).
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In addition, three structurally related compounds, along with potential metabolites,
namely, 5-hydroxymethylfuran-2-carboxylic acid (HMFA), and furan-2,5-dicarboxylic acid
(FDCA), were studied to investigate the selectivity of this bioanalytical method. The three other
compounds, named in Table 3-7, were reported to co-exist with 5-HMF in some infants dietary
products as a result of excessive heat exposure of the protein and carbohydrates during the
sterilization process of these products (Ferrer 2002). The absorbance of these compounds was
scanned between 200 nm to 330 nm as demonstrated in Figure 3-14. As evident in Table 3-7, the
calculated molar absorptivity and λmax indicates a potential interference of these compounds in
case of their presence in the sample if they are co-eluted with 5-HMF. Consequently, the
compounds were injected separately into the HPLC column and in a mixture along with 5-HMF
under the same chromatographic conditions of this analytical method. The chromatogram for the
mixture is shown in Figure 3-15 below.
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5-HMF

FDCA
HMFA

2F

MF

AF

Figure 3-14. Furan carboxylic acids and furfurals UV spectrum.
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Table 3-7. Molar absorptivity of furan carboxylic acids and furfurals.

λmax (nm)

ε (AbsU/M/cm)
λmax

285 nm

5-HMF

283.8

19913

19452

5-Hydroxymethyl)furan-2-carboxylic acid (HMFA)

256.7

12854

817

Furan-2,5-dicarboxylic acid (FDCA)

265.4

18692

3430

Acetylfuran (AF)

274.4

11843

12224

5-Methylfuran-2-carbaldehyde (MF)

292.3

15785

5473

2-Furfural (2F)

276.9

12022

11748
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2F
HMF

AF

MF

HMFA
FDCA

Figure 3-15. Furan carboxylic acids and furfurals chromatogram.
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The relationship between these compounds’ logP values, calculated via ChemSketch
(ACD Labs), vs their retention factors (k’) was plotted in Figure 3-16. The k’ values were
calculated according Equation 3-1 and are listed in Table 3-8. tR´ in Equation 3-1 was calculated
according to Equation 3-2, where the mobile phase retention time (tM) was estimated to be 3.1
minutes. A positive trend was observed with increasing the hydrophobicity of the compounds
relative to their retention time (tR). However, the slope for the linear regression model was not
significant (p-value > 0.05).

k’= tR´/tM… … … … … … … … … … … … … … … … … … … … … . . … … … … . … … … . … Equation 3 − 1
tR´= tR - tM… … … … … … … … … … … … … … … … … … … … … . . … … … … . … … … … Equation 3 − 2
The insignificant model might be due to the small number of compounds incorporated in
this relationship. In addition, considering the structure of 2-furfural, the calculated logP value
seemed higher than what is expected. This calculated logP for 2-furfural is higher than that for
acetylfuran although the latter has an additional methyl group. Therefore, the assigned logP
value appears to be overestimated for 2-furfural. Moreover, FDCA was retained in the column to
a greater extent than what is predicted using its logP value. The pH of the mobile phase is 3 and
FDCA should be mainly unionized at that pH, which might increased its lipophilic
characteristics. Unfortunately, we were not able to obtain a pka values for these compounds.
Consequently, the compounds with acidic were excluded from the group and the relationship was
re-plotted in Figure 3-17. An improvement in the association was observed, however, the slope
remained insignificant.

138

15

Retention Factor (k')

FDCA
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MF
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5-HMF
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-0.5

0

0.5

Calculated logP

Figure 3-16. Furan carboxylic acids and furfurals calculated logP vs k’.
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1

1.5

8

MF

Retention Factor (k')

6
AF
4

5-HMF

2F

2

0
-0.5

0

0.5

Calculated logP
Figure 3-17. Furfurals calculated logP vs k’.
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1

1.5

Table 3-8. 5-HMF and its metabolites along with structurally related furfurals calculated logP and retention properties.
Compound Name

Structure

Calculated logP

Retention time (min)

k'

-0.45 ± 0.27

6.6

1.1

-0.55 ± 0.33

7.1

1.3

-0.02 ± 0.41

45.0

13.5

0.52 ± 0.31

17.6

4.7

0.73 ± 0.26

9.6

2.1

1.19 ± 0.26

22.2

6.2

O

5-HMF

O
HO

H

HO

O
O

HMFA

OH
HO

FDCA

O
O

O

OH
O
O

AF

CH3
O
O

2F

H
O

MF

H3C

O
H
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After the exclusion of acids from the correlation between the logP and the corresponding
retention factor (k’) for the compounds, shown in Figure 3-17, the r value increased from 0.18 to
0.79. Equation 3-3 describes the relationship between k’ and logP in this HPLC system.

k’= 2.6*(logP) + 2.2… … … … … … … … … … … … … … … … … … … … … . . … … … … . Equation 3 − 3
The use of logP value as a factor affecting the retention of the compounds is based on the
partitioning properties of these compounds between the hydrophobic C18 stationary phase and the
hydrophilic mobile phase. However, secondary hydrogen bonding interactions with the free
silanol groups might have existed. A change in the column to one with better end capping quality
to minimize the secondary interactions might result in an improved relationship between the logP
and the retention properties.
Both UV absorptivity and retention properties, summarized in Table 3-9, can potentially
cause an interference in 5-HMF analysis if the compounds happened to coexist with 5-HMF in
the sample. The interference of FDCA in this assay method is not expected due to the difference
in the retention time between FDCA and 5-HMF. On the other hand, as shown in the
chromatogram, HMFA and 5-HMF peaks overlap. In the presence of equimolar amounts of
HMFA and 5-HMF, it will be difficult to recognize the presence of HMFA since 5-HMF
absorption at 285 is 23.8 times higher than HMFA. Nevertheless, HMFA is not expected to
survive the extraction method since the washing solution is PBS with a pH of 7.4, at which
HMFA is expected to be fully ionized and washed away.
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Table 3-9. HPLC-UV selectivity contributors of furfurals.
λmax (nm)

Rt (min)

5-HMF

283.8

6.6

5-Hydroxymethylfuran-2-carboxylic acid (HMFA)

256.7

7.1

Furan-2,5-dicarboxylic acid (FDCA)

265.4

45.0

Acetylfuran (AF)

274.4

17.6

2-Furfural (2F)

276.9

9.6

5-Methylfuran-2-carbaldehyde (MF)

292.3

22.2
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3.3.1.5 Calibration Curve

The relationship between 5-HMF concentrations in plasma and the UV detector response
was modeled by a linear regression algorithm in the range of 0.16 – 158.9 µM, as demonstrated
in Figure 3-18. Three replicates were used to define the analytical relationship. As evident in
Table 3-10, all the concentrations (excluding the blank) in the defined analytical range were
within 92.6-104.4% of the nominal concentrations and did not exceed 7% in their coefficient of
variation.
The lowest value in the calibration curve, which is 0.16 µM, was deemed as the LLOQ.
The response of the blank at the retention time of 5-HMF, was not more than the 20% of the
LLOQ response at the specified retention time. The ratio of the average response of six replicates
at the LLOQ to that of the six sources of blanks was 5.5. The average of the analytical results for
a minimum of six replicates at the LLOQ had DFN value of 7.4 %. The CV at the LLOQ did not
exceed 5.7% as a measure of precision.
Due to the wide analytical range, a weighing factor of (1/X) was used in the established
linear model. All the individual calibration curves had significant slopes and non-significant
intercepts. The residual plot, shown in Figure 3-19, demonstrates over- and underestimation of
the values predicted by the linear regression when compared with the observations. The residuals
were distributed above and below the zero-line. Hence, the linear regression with a weighting
factor of 1/X was deemed as a suitable model to describe and interpolate the response associated
with 5-HMF analytical concentrations.

144

4e+6

Response

3e+6

2e+6

1e+6

0
0

20

40

60

80

100

120

140

Concentration (µM)
Figure 3-18. 5-HMF response-concentration curve in human plasma.
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Table 3-10. 5-HMF standard curve.
Concentration (µM)

R1

R2

R3

Mean

CV

Average DFN%

0.16

4348

3964

4410

4241

5.7

7.4

0.32

7328

7737

6732

7266

7.0

1.0

1.6

32592

32385

32873

32617

0.8

-1.7

3.2

62716

63458

63556

63243

0.7

-3.7

7.9

156979

153307

157812

156033

1.5

-4.4

31.7

649542

650343

663931

654605

1.2

0.6

79.3

1606296

1595854

1586900

1596350

0.6

-1.8

158.9

3251346

3283051

3322955

3285784

1.1

1.1

Slope

20364.9

20437.1

20611.2

20471.1

0.6

Intercept

782.0

594.3

568.3

697.5

18.0

r2

0.9999

0.9997

0.9995

0.9997

0.02
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Figure 3-19. Area residuals by the predicted area.
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3.3.1.6 Dilution Integrity

A solution was prepared at 7.9 mM of 5-HMF in the plasma matrix and then diluted with
the blank plasma matrix to 158.9 µM. Triplicates were analyzed in three different runs. The
results are shown in Table 3-11.

3.3.1.7 Stock Solution Stability

A solution of 15.8 µM of 5-HMF was analyzed using the HPLC method. Then, the
solution was left at RT for about 5.5 hours. After that, triplicates of that solution were reanalyzed
and compared to the measurement when freshly prepared. The 95% confidence intervals of the
means, shown in Table 3-12, were compared and were considered equivalent. The working
solution was deemed stable at RT for 5.5 hours.

3.3.1.8 Post-Preparative Stability

Triplicates of processed samples at low, mid, and high QC concentrations were kept in
the autosampler for around 48 hours and then reanalyzed. Their results were compared to those
freshly analyzed, as shown in Table 3-13. A null hypothesis (H0) of μ

fresh

≥ μ48 hrs in autosampler at

each concentration was tested using a paired t-test. In each case the p-value was greater than
0.05. Hence, the processed samples were considered stable for 48 hours residence-time in the
autosampler.
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Table 3-11. Accuracy and precision for diluted samples.

First run

Second run

Third run

R1

2898187

R2

3114074

R3

2992520

R1

3080501

R2

2973592

R3

3036628

R1

3160578

R2

3099857

R3

2962983

Mean

3035436

CV

2.6

DFN%

7.1
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Table 3-12. Working-solution stability at RT results.
Freshly prepared

After 5.5 hours at RT

R1

256105

263072

R2

260565

263659

R3

264585

268184

260418

264972

1.6

1.1

249881- 270956

258023- 271921

Mean
CV
95% Confidence interval
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Table 3-13. Short-term stability results.
0.48 µM

15.8 µM

126.9 µM

Fresh

After
autosampler
storage

Fresh

After
autosampler
storage

Fresh

After
autosampler
storage

R1

10139

11264

337282

379305

3021407

3402782

R2

10051

12425

343673

381153

3041115

3254875

R3

9997

10993

346116

389284

3147102

3359762

Mean

10062

11561

342357

383247

3069875

3339140

CV

0.7

6.6

1.3

1.4

2.2

2.3

Prob< t

> 0.05

> 0.05
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> 0.05

3.3.2 5-HMF in Rat, Mouse, and Dog Plasma

The same HPLC-UV assay method validated in human plasma was investigated for the
determination of 5-HMF in rat, mouse, and dog plasma. A descriptive summary of the method is
shown in Table 3-14.
To ensure the suitability and reliability of the developed method for the intended
measurements, validation of this analytical method in rat, mouse, and dog plasma was evaluated
through the following:

3.3.2.1 Accuracy

Within-assay accuracy was determined for six replicate measurements at three different
concentrations, in addition to the LLOQ, were determined. The DFN value was used as a
measure of accuracy in the analytical range. The absolute DFN value did not exceed 15% at any
of these concentrations including the LLOQ, as shown in Tables 3-15, 3-16, and 3-17.
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Table 3-14. 5-HMF assay descriptive summary in species plasma.
Type of assay:

HPLC-UV

Sample preparation:

Solid phase extraction of diluted Plasma by Oasis HLB cartridges (Waters)

Detector:

Shimadzu 10 AV Absorbance Detector

LC pump:

Waters 600E Multisolvent Delivery System

LC column:

Zorbax Rx C18, 80 Ao, 150 mm x 4.6 mm, 5 μm
(Agilent, Serial # USDU010028)

Guard column:

C18, 12.5 mm x 4.6 mm
(Agilent, Serial # USCI042710)

Detection:

UV at 285 nm

Autosampler temperature:

4 °C

Flow rate:

0.75 ml/min

Regression algorithm:

Linear, weighted 1/X

Sample volume and matrix:

0.3 ml of plasma suspension, extract to 0.5 ml sample

Mobile phase

Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3)

Injection volume:

10 µl

Chromatographic run time:

10 minutes

Calibration curve range:

Mouse: 1.6 – 158.9 µM, Rat: 1.6 – 158.9 µM, Dog: 0.16 – 158.9 µM

Lower limit of quantitation:

Mouse: 1.6 µM, Rat: 1.6 µM, Dog: 0.16 µM

Quality control levels:

Mouse: 2.4, 15.8, 126.9 µM, Rat: 2.4, 15.8, 126.9 µM, Dog: 0.48, 15.8, 126.9 µM
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Table 3-15. 5-HMF intra-run accuracy and precision in mouse plasma.
Concentration
(µM)

R1

R2

R3

0

6603

2209

6982

1.6

21363

21757

21323

23279

18398

2.4

34029

30138

27702

37173

15.8

174194

179427

174667

187060

126.9

R4

Mean

CV

5265

50.4

22461

21430

7.8

1.1

34145

35892

33180

10.8

6.9

183122

179418

179648

2.7

-9.4

1550036 1669814 1502977 1542189 1654157 1635667 1592473

4.3

1.0
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R5

R6

DFN%

Table 3-16. 5-HMF intra-run accuracy and precision in rat plasma.

Concentration
(µM)

R1

R2

R3

0

4470

4024

3558

1.6

24934

21537

20593

18901

19997

2.4

34530

35786

33950

35969

15.8

192685

199316

214060

126.9

1638235

1729048

1783345

R4

Mean

CV

4017

11.4

19795

20960

10.2

-3.8

34698

35574

35085

2.3

7.7

212831

221287

199441

206947

3.4

-4.3

1665379

1908818

1679190

1734003

5.8

0.4

155

R5

R6

DFN%

Table 3-17. 5-HMF intra-run accuracy and precision in dog plasma.

Concentration
(µM)

R1

R2

R3

0

772

805

416

1.6

4516

4255

4531

3647

5158

2.4

8226

9775

9346

9709

15.8

217652

227034

229274

126.9

1732705

1730375

1995461

R4

Mean

CV

664

32.5

3428

4256

14.9

-1.8

8746

9588

9232

6.7

3.8

232000

247277

204856

226349

6.3

-1.6

1795253

1870952

1851862

1829435

5.5

0.2
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R5

R6

DFN%

3.3.2.2 Precision

Within-run precision was determined for six replicates, shown in Tables 3-15, 3-16, and
3-17 at four concentrations in the analysis range including the LLOQ. The FDA guidance for
industry “Bioanalytical Method Validation” criteria were considered for acceptance with no
more than 15% coefficient of variation for the selected concentrations and 20% as CV at the
LLOQ.

3.3.2.3 Selectivity

As shown in Tables 3-15, 3-16, and 3-17, pooled plasma blank from at least six different
sources were analyzed to test for interferences and to investigate the ability to differentiate and
quantify 5-HMF in the presence of other endogenous components in the extracted plasma.
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3.3.3 5-HMF in Human RBCs

An HPLC-UV assay was developed for the determination of 5-HMF in human RBCs. A
descriptive summary of the method is shown in Table 3-18. In addition, representative
chromatograms are shown in Figures 3-20, 3-21, 3-22, and 3-23.
To ensure the suitability and reliability of the developed method for the intended
measurements, validation of this analytical method in human RBCs was evaluated through the
following:

3.3.3.1 Recovery

The response of the extracted samples at low, medium, and high concentrations was
compared to the response of unextracted known concentrations that represent 100% recovery.
The efficiency of the extraction was reproducible with a CV less than 4% at each concentration.
The CV was 17% through the calibration range with a recovery mean of 75.7%. The variability
might be due to the big range (approximately 500 fold range) that can cause a difference in the in
the performance of the extraction cartridges. Moreover, the recovery at the LLOQ was
determined to be 80% with a CV not exceeding 3%, as summarized in Table 3-19.
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Table 3-18. 5-HMF assay descriptive summary in human RBCs.
Type of assay:

HPLC-UV

Sample preparation:

Solid phase extraction of diluted RBCs by Oasis HLB cartridges (Waters)

Detector:

Shimadzu 10 AV Absorbance Detector

LC pump:

Waters 600E Multisolvent Delivery System

LC column:

Zorbax Rx C18, 80 Ao, 150 mm x 4.6 mm, 5 μm

Guard column

C18, 12.5 mm x 4.6 mm

Detection:

UV at 285 nm

Autosampler temperature:

4 °C

Flow rate:

0.75 ml/min

Regression algorithm:

Linear, weighted 1/X

Sample volume and matrix:

0.1 ml of RBCs suspension, extracted to 0.5 ml sample

Mobile phase

Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3)

Injection volume:

10 µL

Chromatographic run time:

10 minutes

Calibration curve range:

4.3 – 2379 µM

Lower limit of quantitation:

4.3 µM

Quality control levels:

9.5, 47.6, 1903 µM
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Figure 3-20. Representative chromatogram of individual human RBCs blank.
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Figure 3-21. Representative chromatogram of the LLOQ concentration.
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Figure 3-22. Representative chromatogram of low QC concentration.
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Figure 3-23. Representative chromatogram of mid QC concentration.
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Table 3-19. 5-HMF recovery in human RBCs.
Concentration
(µM)

R1

R2

R3

Mean

CV%

4

81.2

77.4

81.5

80.0

2.9

10

90.9

91.7

89.4

90.7

1.3

48

69.7

74.0

73.6

72.4

3.2

1903

59.7

59.7

60.1

59.8

0.4
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3.3.3.2 Accuracy

Within-assay accuracy was determined for six replicate measurements at three different
concentrations and at the LLOQ. The DFN value was used as a measure of the accuracy in the
analytical range. The absolute DFN value did not exceed 15% at any of these concentrations
including the LLOQ, as shown in Table 3-20.

3.3.3.3 Precision

Within-run precision was determined for six replicates, shown in Table 3-20, at four
concentrations in the analysis range including the LLOQ. The FDA guidance for industry
“Bioanalytical Method Validation” criteria were considered for acceptance with no more than
15% CV for the selected concentrations and 20% or less as the CV at the LLOQ.

3.3.3.4 Selectivity

As shown in Table 3-20, six different sources of RBCs were analyzed to test for
interferences and to investigate the ability to differentiate and quantify 5-HMF in the presence of
other endogenous components in the extracted RBCs. The ratio of the average area response of
six replicates at the LLOQ concentration to that of six blank sources was 5.1.
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Table 3-20. 5-HMF intra-run accuracy and precision in human RBCs.
Concentration
(µM)

R1

R2

R3

R4

R5

R6

Mean

CV

0

2934

2514

2552

2594

3001

3897

2915

17.9

4

15287

14555

15341

14730

14394

14350

14776

3.0

-3.2

10

42751

43151

42055

43816

43857

42589

43037

1.7

-12.6

48

211185

224117

222822

221966

220153

225901

221024

2.4

-7.8

7598597 7603656 7649638 8279831 8025133 7950308 7851194

3.6

6.0

1903
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DFN%

3.3.3.5 Calibration curve

The relationship between 5-HMF concentration in RBCs and the UV detector response
was modeled by a linear regression algorithm in the range of 4-2379 µM, as demonstrated in
Figure 3-24. Three replicates were used to define the analytical relationship. As evident in Table
3-21, the concentrations in the defined analytical range were within 88.2-114.6% of the nominal
concentrations and did not exceed 3% in their coefficient of variation. These results meet the
acceptance criteria of having at least four of six concentrations within the accuracy and precision
limits including the lowest and highest concentration.
The lowest value in the calibration curve, which is 4 µM, was deemed as the LLOQ. The
response of the blank at the retention time of 5-HMF, was not more than the 20% of the LLOQ
response at the specified retention time. The ratio of the average response of six replicates at the
LLOQ to that of the six sources of thee blanks was 5.1. The average of the analytical results for a
minimum of six replicates at the LLOQ had DFN value of 13.6%. The CV at the LLOQ did not
exceed 3% as a measure of precision. The intercept of the equation was not statistically
significant.
Due to the wide analytical range, a weighing factor of (1/X) was used in the established
linear model. The calibration curve had a significant slope and a non-significant intercept.
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1500
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Figure 3-24. 5-HMF response-concentration curve.
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Table 3-21. 5-HMF standard curve.
Concentration
(µM)

R1

R2

R3

Mean

CV

Average
DFN%

4

15287

14555

15341

15061

2.9

13.6

5

20287

20134

20635

20352

1.3

14.6

24

90157

88275

91153

89862

1.6

-11.8

95

367338

366141

376163

369881

1.5

-11.1

238

995900

1013878

999394

1003057

1.0

-3.3

952

3995286

3827174

4055532

3959331

3.0

-5.0

2379

10763231

10884655

10384749

10677545

2.4

2.6

Value

p-value

Intercept

-4479.3

0.52

Slope
r2

4372.9
0.998

<0.0001

169

3.3.4 5-HMF in Rat, Mouse, and Dog RBCs

An HPLC-UV assay was developed for the determination of HMF in rat, mouse, and dog
RBCs. A descriptive summary of the method is shown in Table 3-22.
To ensure the suitability and reliability of the developed method for the intended
measurements, validation of this analytical method in rat, mouse, and dog RBCs was evaluated
through the following:

3.3.4.1 Accuracy

Within-assay accuracy was determined for six replicate measurements at three different
concentrations and at the LLOQ. The DFN value was used as a measure of accuracy in the
analytical range, as shown in Tables 3-23, 3-24, and 3-25.
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Table 3-22. 5-HMF assay descriptive summary in species RBCs.
Type of assay:

HPLC-UV

Sample preparation:

Solid phase extraction of diluted RBCs by Oasis HLB cartridges (Waters)

Detector:

Shimadzu 10 AV Absorbance Detector

LC pump:

Waters 600E Multisolvent Delivery System

LC column:

Zorbax Rx C18, 80 Ao, 150 mm x 4.6 mm, 5 μm
(Agilent, Serial # USDU010028)

Guard column

C18, 12.5 mm x 4.6 mm
(Agilent, Serial # USCI042710)

Detection:

UV at 285 nm

Autosampler temperature:

4 °C

Flow rate:

0.75 ml/min

Regression algorithm:

Linear, weighted 1/X

Sample volume and matrix:

0.1 ml of RBCs suspension, extracted to 0.5 ml sample

Mobile phase

Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3)

Injection volume:

10 µL

Chromatographic run time:

10 minutes

Calibration curve range:

Mouse: 8.6 – 4757.8 µM, Rat: 8.6 – 4757.8 µM, Dog: 8.6 – 4757.8 µM

Lower limit of quantitation:

Mouse: 8.6 µM, Rat: 8.6 µM, Dog: 8.6 µM

Quality control levels:

Mouse: 19.0, 95.2, 3806.2 µM, Rat: 19.0, 95.2, 3806.2 µM, Dog: 19.0, 95.2,
3806.2 µM
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Table 3-23. 5-HMF intra-run accuracy and precision in mouse RBCs.
Concentration
(µM)

R1

R2

R3

0

1851

2029

1379

8.6

4055

3427

3637

4058

3072

19

9084

8992

8641

11221

95

135741

126266

127200

3806

6437939

6537972

6681089

R4

Mean

CV

1753

19.2

4878

3854

16.3

-492.4

8397

9679

9336

10.9

-46.2

132624

125519

123645

128499

3.6

-14.1

6647384

6923159

6542404

6628325

2.5

0.3

172

R5

R6

DFN%

Table 3-24. 5-HMF intra-run accuracy and precision in rat RBCs.
Concentration
(µM)

R1

R2

R3

0

2686

1215

1174

8.6

26021

23840

26034

24697

24542

19

33723

35661

33846

31389

95

208477

215522

202883

3806

7442537

7419570

7552769

R4

Mean

CV

1692

50.9

24981

25019

3.5

11.6

26440

-

32212

11.1

-24.8

209306

210404

195089

206947

3.4

8.1

7304463

7151040

7679852

7425039

2.5

-0.1

173

R5

R6

DFN%

Table 3-25. 5-HMF intra-run accuracy and precision in dog RBCs.

Concentration
(µM)

R1

R2

R3

0

0

1060

822

8.6

24142

21922

22295

23465

22352

19

44696

45340

43986

42051

95

206939

188630

179375

3806

7445653

6887127

6821685

R4

Mean

CV

627

88.7

23009

22864

3.7

-3.5

46204

46407

44781

3.6

3.0

188713

191056

178310

128499

3.6

2.1

6933841

6663242

7780804

6628325

2.5

-0.1

174

R5

R6

DFN%

3.3.4.2 Precision

Within-run precision was determined for at least five replicates, shown in Tables 3-23, 324, and 3-25 at four concentration levels in the analytical range including the LLOQ. The FDA
guidance for industry “Bioanalytical Method Validation” criteria were considered for acceptance
with no more than 15% coefficient of variation for the selected concentrations and 20% or less as
the CV at the LLOQ.

3.3.4.3 Selectivity

As shown in Tables 3-23, 3-24, and 3-25, pooled RBCs from at least six different sources
were analyzed to test for interferences and to investigate the ability to differentiate and quantify
5-HMF in the presence of other endogenous components in the extracted RBCs.
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3.3.5 Other Matrices

The development of this analytical method involved 5-HMF analysis in neat solution, as
shown in to Table 3-26. In addition, the same method was used in the measurement of 5-HMF in
the ultrafiltrate of human serum albumin and hemoglobin PBS solutions. For each study, a
calibration curve in PBS was analyzed in conjunction with the samples. Samples and calibration
curve standards were injected directly into HPLC. Table 3-27 is showing some of the PBS
calibration curves.
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Table 3-26. 5-HMF standards in neat solution.
Concentration (µM)

R1

R2

R3

Mean

CV

0.08

20280

21533

21900

21238

4

0.40

111678

112737

113100

112505

0.7

0.79

218133

218354

218880

218456

0.2

11.9

3330060

3322928

3319840

3324276

0.2

47.6

13349916

13302739

13323871

13325509

0.2

79.3

21462393

21492723

21453369

21469495

0.1
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Table 3-27. 5-HMF standards in PBS.
Concentration (µM)

R1

R2

R3

R4

Mean

CV

0.2

6312

6764

6904

5165

6286

13

0.8

21454

20635

22599

19085

20943

7

4.0

97756

90331

99556

91037

94670

5

7.9

216324

185712

175796

172020

187463

11

39.6

1142549

958669

837630

866326

951294

14

79.3

2175225

1753218

1687014

1727478

1835734

12
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3.3.6 HMFA in Human Hepatic Cytosol

In order to supplement 5-HMF metabolic stability studies in hepatic cytosol, a method
was developed to qualitatively detect HMFA in human hepatic cytosol incubated with 5-HMF. 5HMF and HMFA peaks overlapped, as shown previously in Figure 3-15, using the above
described method. Consequently, a new mobile phase was prepared of water and methanol, in
which tetrabutylammonium was dissolved. A summary of the method is described in Table 3-28
and a chromatogram showing the peaks of both 5-HMF and HMFA standards in Tris buffer, is
shown in Figure 3-25. Response-concentration curves for 5-HMF and HMFA in buffer are
shown in Figures 3-26 and 3-27, respectively. In addition, the chromatograms of a blank cytosol
and two concentrations of HMFA added to the cytosol are shown in Figures 3-28, 3-29, and 330. As demonstrated in Figure 3-28, a peak in the blank cytosol is present in the retention
window of 5-HMF, and in particular HMFA. However, for a qualitative purpose, the method was
deemed satisfactory. A standard curve of HMFA was investigated in the cytosol and is shown in
Figure 3-31.
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Table 3-28. 5-HMF assay descriptive summary in human hepatic cytosol
Type of assay:

HPLC-UV

Sample preparation:

Dilution of with ice-cold acetonitrile and water.

Detector:

Shimadzu 10 AV Absorbance Detector

LC pump:

Waters 600E Multisolvent Delivery System

LC column:

Zorbax Rx C18, 80 Ao, 150 mm x 4.6 mm, 5 μm
(Agilent, Serial # USDU010028)

Guard column

C18, 12.5 mm x 4.6 mm
(Agilent, Serial # USCI042710)

Detection:

UV at 260 nm

Autosampler temperature:

4 °C

Flow rate:

1 ml/minute

Sample volume and matrix:

100 µl diluted to 800 µl (650 µl water and 50 µl acetonitrile)

Mobile phase

Water-methanol (83:17), 0.2% w/v tetrabutylammonium iodide

Injection volume:

10 µL

Chromatographic run time:

10 minutes
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`

HMFA

5-HMF

Figure 3-25. 5-HMF (0.79 mM) and HMFA (0.90 mM) chromatogram.
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Figure 3-26. HMFA response-concentration curve.
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Figure 3-27. 5-HMF response-concentration curve.
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Figure 3-28. Cytosol blank chromatogram.
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HMFA

Figure 3-29. HMFA standard in hepatic cytosol (0.9 mM)
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HMFA

Figure 3-30. HMFA standard in hepatic cytosol (6.0 mM).
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Figure 3-31. HMFA calibration curve in human cytosol.
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CHAPTER 4
4
5-HMF IN-VITRO METABOLISM IN HEPATIC CYTOSOL OF DIFFERENT SPECIES

4.1

Introduction

Different in-vitro methodologies are used to predict human clearance. An example of that
is recombinant enzymes; however, the artificial nature of this matrix represents a drawback of
the recombinant system (Hallifax 2009). Hepatocytes are considered more physiological and
give an idea about the cumulative metabolic rate for a drug if detoxified by different enzymes.
However, identifying the exact metabolic pathway is challenging with the use of hepatocytes
(Gupta 2006).
In general, metabolic stability studies follow the scheme introduced in Figure 4-1. These
studies investigate the disappearance of the parent drug or the formation of the metabolite
(Houston 2008). Initially, they result in pseudo-zero order kinetics that is estimated over a period
of time (Houston 2008). Non-linear regression modeling is used to estimate the in-vitro
metabolic parameters from the concentration-dependent initial metabolic rate profile. Then the
metabolic parameters are used in the in-vitro intrinsic clearance calculation. Physiological
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scaling variables are used to predict the in-vivo intrinsic clearance value from the in-vitro
intrinsic clearance. This is further extrapolated to organ clearance using different models such as
the well-stirred model to incorporate the hepatic blood flow limitation. The use of well-stirred
model for projecting the hepatic clearance was justified by its mathematical simplicity and
applicability for drugs with low intrinsic clearance (Houston 2008). This model assumes a
uniform distribution of the relevant enzymes in the liver tissues and that merely the unbound
drug fraction is subject to metabolism, which is made available to enzymes by hepatic perfusion
(Houston 2008).
5-HMF structure and the known metabolites indicate its in-vivo oxidation rather than
reduction, which might, otherwise, utilized the aldo/keto reductase enzymes (Marchitti 2008).
Alternatively, aldehyde group oxidation can be carried-out by different enzymes, such as
xanthine oxidase, aldehyde oxidase, and aldehyde dehydrogenase (ALDH) (Marchitti 2008).
Nevertheless, xanthine oxidase, as its names indicates, is involved in the oxidation of purines
(Beedham 1997). Thus, its role in 5-HMF metabolism is assumed to be minimal. On the other
hand, aldehyde oxidase is implicated in the oxidation of N-containing heterocyclic compounds,
such as antiviral drugs (Beedham 1997). Nevertheless, aldehyde oxidase metabolizes other
aromatic aldehydes such as vanillin (Sahi 2008). The other moiety of 5-HMF that is susceptible
to metabolism is the alcohol group, which is most likely metabolized by alcohol dehydrogenase
(ADH) after excluding the other oxidizing enzymes and considering its structural similarity with
ethanol. Table 4-1 lists these oxidizing enzymes and their respective cofactors.
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Figure 4-1. In-vitro-in-vivo extrapolation steps. Adapted from (Hallifax 2009)
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In-Vivo
Prediction

Table 4-1. Oxidative enzymes (Beedham 1997)
Enzyme

Oxidative Reaction

Cofactor

ALDH

Aldehyde oxidation

NAD(P)+

ADH

Alcohol oxidation

NAD+

Aldehyde oxidase

Aldehyde oxidation, C-oxidation of
N-heterocycles

O2

Monoamine oxidase

Oxidative deamination

O2

Flavine monooxygenase

N-oxidation

NADPH, O2

Xanthine oxidase

C-oxidation of purines

NAD+, O2
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Hepatic cytosol was selected for the purpose of predicting the intrinsic clearance of 5HMF in humans and other species for the following reasons:
-

The liver was reported to have high 5-HMF- related radioactivity in mice and rats
after oral administration of 5-HMF (Godfrey 1999).

-

It is a rich resource of ALDH and ADH enzymes (Gupta 2006).

-

Human and other species cytosol is commercially available (Brandon 2003).

-

It is an ethically acceptable medium for investigating enzyme kinetics (Brandon
2003).

-

Studies with hepatic cytosol from different species were carried-out in the PK/PD
laboratory at VCU and the following were demonstrated (Gupta 2006):
-

Successful prediction of in-vivo clearance of other substrates, such as

ethanol and propylene glycol.
-

Demonstration of inter-species differences in hepatic cytosol metabolism.

The metabolism by both ALDH and ADH enzymes can be measured simultaneously
by a simple spectrophotometric method. NADH is measured as a common product for
both enzymes at 340 nm.

The specificity of NADH production is assumed since none of the other oxidizing
enzymes, if present in this system, has the potential to oxidize 5-HMF and produce NADH
simultaneously.
Since NADH is a common product for both of ALDH and ADH enzymes, selective
inhibitors were used to determine the individual contribution of each enzyme. 4-methylpyrazole
and disulfiram were selected as the selective inhibitors for ADH and ALDH, respectively. 4methylpyrazole, known as fomepizole, is used clinically as an antidote to treat alcohol and
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ethylene glycol intoxication (Druteika 2002) (Bestic 2009). 4-methylpyrazole was shown to be a
competitive reversible inhibitor for ADH enzyme (Bestic 2009) (C. D. Cheung 2003) (Plapp
1984). In comparison with ethanol, its affinity for ADH was reported to be approximately 8000
fold greater than that of ethanol (Bestic 2009). Its mechanism of action was found to involve the
formation of a ternary complex involving NAD+, ADH Zinc element, and 4-methylpyrazole
preventing the substrate from the interaction with the enzyme (Bestic 2009). In a study
conducted by Cheung, 38% of the control ADH activity remained in rat liver cytosol after using
1 M of 4-methylpyrazole as the highest inhibitory concentration (C. D. Cheung 2003).
On the other hand, disulfiram (tetraethylthiuram disulfide, Antabuse) is also used
clinically for the treatment of alcoholism by inducing obnoxious effects of drinking, termed as
“aversion therapy” (Kitson 1975) (Shena 2001). Although it is well agreed that these effects are
due to the accumulation of acetaldehyde as a consequence of ALDH inhibition after the
administration of disulfiram (Keung 1993), its mode of inhibition is controversial. The
interaction with ALDH was stated to be a rapid, strong, non-competitive, and reversible
inhibition (A. R. Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde
Dehydrogenases in Acetaldehyde Metabolism 1996). Cheung et. al. used disulfiram as an
inhibitor of ALDH enzyme stating that it is a competitive, reversible inhibitor (C. H. Cheung
2003). On the other hand, when tested with cytoplasmic ALDH of sheep liver, disulfiram caused
an initial inhibition, after which an increase in the inhibition was observed over time, indicating
an irreversible mode of inhibition (Kitson 1975). Cytosolic ALDH is believed to be “disulfiram
sensitive” with a Ki of 13, 15, and 200 nM in hamster, rat, and human, respectively (A. R.
Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde Dehydrogenases in
Acetaldehyde Metabolism 1996).
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In addition to human, the metabolic studies were conducted in mouse, rat, and dog
hepatic cytosol to explore potential differences in 5-HMF metabolism and consequently
disposition among these species. Gupta reported different Km and vmax values ranging between
0.8-14 mM and 0.05-2.8 mmol/min, respectively, for in-vivo ethanol metabolism, mediated by
ADH, in rat, rabbit, dog, and human (Gupta 2006). Cheung and co-workers also observed that
the cytosolic ADH of rodents had a lower metabolic efficiency of ethanol than that of human (C.
D. Cheung 2003). Moreover, interspecies differences in ALDH enzyme were also reported.
Klyosov and co-workers found that human cytosolic ALDH is more acidic than that of rat and
hamster (A. R. Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde
Dehydrogenases in Acetaldehyde Metabolism 1996). In addition, human ALDH appears to be
tetrameric with a molecular weight exceeding 1.5 fold of that in rodents, which is probably
dimeric (A. R. Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde
Dehydrogenases in Acetaldehyde Metabolism 1996). All of these findings emphasize the
complementary role of in-vitro approaches in explaining the results of in-vivo animal studies in
the preclinical phase. Hence, the objective of the proposed in-vitro studies is to mechanistically
investigate 5-HMF disappearance in human hepatic cytosol and to identify and compare the
metabolism of 5-HMF in human, dog, rat, and mouse hepatic cytosol.

.
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4.2

Methods

4.2.1 Materials and Reagents

1. BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
2. 4-Dimethylaminonaphthaldehyde, (DN) Solution:
-

4-Dimethylaminonaphthaldehyde 97% (Aldrich, Milwaukee, WI)

-

BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).

3. Ethanol Solution:
- Ethanol 200 proof, 99.5% (Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
4. Acetaldehyde Solution:
- Acetaldehyde, ACS 99% (Sigma-Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
5. 5-Hydroxymethyl-2-furfural (5-HMF) Solution:
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
6. 4-Methylpyrazole (4-MP) Solution:
- 4-MP, 99% (Sigma-Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
7. Tetraethylthiuram Disulfide (Disulfiram) Solution:
- Disulfiram, purum 97% (Sigma-Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
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8. Liver Cytosol: 10 mg protein/ml (XenoTech, Lenexa, KS):
- human: mixed gender, pool of 50 (Hispanic (8), Caucasian (41), Asian (1), 50 ± 14
years old).
- dog: pooled Beagle males.
- rat: pooled Fischer 344 males.
- mouse: pooled B6C3F1 males.
9. Cytosol Diluent:
- Bovine serum albumin (BSA) (Sigma, St. Louis, MO).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
10. Cofactor Solution, β-Nicotinamide Adenine Dinucleotide (NAD+) Solution:
- NAD+ from yeast (Sigma, St. Louis, MO).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
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4.2.2 Equipment

1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips
(Microman, Rainin Instruments, Oakland, CA).
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West
Chester, PA).
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA).
4. Vortex (Vortex-Genie, VWR, West Chester, PA).
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).
6. pH meter (Corning, Glendale, AZ).
7. Balance (Fisher Scientific A 250, Pittsburgh, PA).
8. Synergy™ 2 multi-mode microplate reader (BioTek, Winooski, VT).
9. Falcon assay plate, 96 reaction wells (VWR, West Chester, PA).
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4.2.3 Preparation of Solutions
- Cofactor solution, β-nicotinamide adenine dinucleotide (β-NAD+) solution
22.3 g of NAD+ (M.W.: 663.43 Da) was dissolved in 3 ml of Tris buffer to prepare 1.4
mM solution.

- Cytosol diluent
BSA (M.W.: 66 kDa) was dissolved in Tris buffer to prepare 0.1% w/v. Solutions were
kept cold during the experiment.

- Cytosol solution
Concentrated cytosol protein solution (10 mg/ml) was mixed with the cytosolic diluents
to prepare a 4 mg/ml solution. For DN concentration-dependency experiments, a 2 mg/ml
solution was prepared. Fresh solutions were prepared and kept cold during the
experiment.

- Substrates solution
Solution at different concentrations of 5-HMF were prepared in Tris buffer. The
measurement of NADH at low substrate concentration was limited by the assay
sensitivity in some cases. In addition, the measurement of NADH at a high substrate
concentration was limited by the solubility of 5-HMF and its high baseline absorbance.
Since the Km for other substrates: ethanol (M.W. 46.07 Da), acetaldehyde (M.W. 44.05
Da), and DN (M.W. 199.25 Da) were reported in the literature, their solutions were
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perpared considering a range of ten-times lower and ten-times higher concentration
relative to their reported Km values, as summarized in Table 4-2.

- Inhibitor solutions
Solution of inhibitors, 4-methylpyrazole (M.W. 82.10 Da) and disulfiram (M.W. 296.54
Da) were prepared to achieve a maximum inhibition of the relevant enzymes taking into
consideration their reported Ki values, as shown in Table 4-3.
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Table 4-2. Selective Substrates.
Substrate

Ethanol

DN

Acetaldehyde

Reported Km

0.7 mM (Gupta
2006)

1.9 nM (A. R. Klyosov
1996)

180 µM (A.
Klyosov 1996)

Concentration
Range

Up to 24 mM

Up to 66 nM

Up to 333 µM in
the presence of
244 µM 4-MP

Structure
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Table 4-3. Selective inhibitors.

4-Methylpyrazole

Disulfiram

Reprted Ki (µM)

0.1-5 (Bestic 2009)

0.2 (A. R. Klyosov 1996)

Concentration range (µM)

0.03-281

0.03-33.8

Structure
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4.2.4 Procedures

Cytosolic protein, NAD+ cofactor, and substrates at different concentrations in Tris buffer
(pH 7.5) were mixed at a final volume of 0.2 ml. The reaction was initiated by the addition of
cytosolic protein solution after allowing the mixture to equilibrate for approximately 5 min.
Then, the increase in the absorbance at 340 nm at 37 °C was monitored over time. The change in
the absorbance was converted to NADH concentration using Beer’s law, that relates the change
in the absorbance to the concentration of absorbing species, as described by Equation 4-1.

∆A = ε × b × ∆c … … … … … … … … … … … … … … … … … … … … … . . … … … … . Equation 4 − 1
Where
∆A: measured absorbance change
ε: the extenction coefficient of NADH at 340 nm
b: pathlenght of the cell
∆c: the concentration change of the absorbing species (NADH)
The change in the concentration of NADH over time represents the velocity at which the
enzyme is forming NADH and simulatenously oxidizing 5-HMF, assuming 1:1 reaction. For
each concentration, the reaction time and the points used for charcterization of the intitial
velocity were selected where a linear increase in the absorbance over time existed, demonstrating
a pseudo-zero order reaction. At each concentration, a minumum of duplicate reactions were
included in the data analysis.
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4.2.5 Optimization Experiments

The incubation conditions for the reaction were optimized through preliminary
experiments. The concentration of the cofactor and the cytosol were selected after several
experiments, so that the initial reaction rate could be observed at a zero-rate order increase in the
absorbance, reflecting the NADH formation.

4.2.6 Concentration-Dependency Studies

These initial velocities were plotted against their corresponding substrate concentrations
and were evaluated using Michaelis Menten kinetics. Michaelis Menten kinetics is characterized
by a maximum velocity and an affinity constant, as shown in Equation 4-2.

vi =

vmax × C
+ v0 … … … … … … … … … … … … … … … … … … … … … … … … … … . Equation 4 − 2
Km + C

Where
vi: the observed velocity
v0: the baseline velocity observed in the absence of the substrate
C: the substrate concentration
vmax: the maximum velocity
Km: the affinity constant

204

The data were fitted to Equation 4-2 using nonlinear regression (SigmaPlot® 10.0, Systat)
to obtain the model parameter estimates. The goodness of fit was evaluated through the
coefficient of determination (r2) values.
In addition, linearization graphing methods, namely: a Lineweaver-Burk (doublereciprocal) plot, a Eadie-Hofstee plot, and a Hanes-Woolf (half-reciprocal) plot, were used to
inspect 5-HMF metabolic reaction in different species hepatic cytosol. The methods are
described in Table 4-4.
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Table 4-4. Linearization graphing methods to assess Michaelis Menten kinetics.
Lineweaver-Burk
(double-reciprocal)

Eadie-Hofstee

Hanes-Woolf (halfreciprocal)

1/v against 1/[S]0 giving
intercepts at 1/vmax and 1/Km

v against v/[S]0 giving
intercepts at vmax and vmax/Km

[S]0/v against [S]0 giving
intercepts at Km/vmax and Km
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4.2.7 Inhibition Studies

Taking into consideration their reported Ki values, different concentrations of inhibitors
of 4-methylpyrazole and disulfiram were used. All reaction components except 5-HMF were
incubated for approximately 15 minutes and 25 minutes with 4-methylpyrazole and disulfiram,
respectively, after which 5-HMF (26 mM) was added. Reactions were run in triplicate and
monitored at 340 nm. In addition, 26 mM of 5-HMF was incubated with 273 µM 4methylpyrazole and 17.4 µM disulfiram, simultaneously, using the same incubation conditions
described previously.
The same approach was used for investigation of the inhibitory effect on ethanol and
acetaldehyde at 1.8 mM and 5.3 mM, respectively. 257 µM of 4-methylpyrazole was used in the
acetaldehyde experiment.
The data were modeled using Equation 4-3 by non-linear regression (SigmaPlot® 10.0,
Systat) to estimate the maximum inhibition, as shown in Equation 4-3. IC50 is the concentration
at which half of the maximum inhibition is achieved.

% inhibition =

Maximum Inhibition × Inhibitor Concentration
… … … … … Equation 4 − 3
IC50 + Inhibitor Concentration
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4.2.8 In-Vitro-In-Vivo Extrapolation

The in-vitro intrinsic clearance (CLintin-vitro) was calculated according to Equation 4-5:

CL𝑖𝑛−𝑣𝑖𝑡𝑟𝑜
=
int

Vmax
… … … … … … … … … … … … … … … … … … … … … … … … … Equation 4 − 5
Km

Where CLintin-vitro is a measure of the innate ability of each milligram of cytosolic protein to clear
a substrate (at concentrations below Km). This in-vitro measure was extrapolated to the in-vivo
intrinsic clearance (CLint) using the cytosolic protein content per gram liver and the total liver
weight. The values of these are listed in Table 4-5 as reported in the literature. CLint refers to the
innate ability of the whole liver cytosol to clear the substrate without flow restrictions.
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Table 4-5. Physiological reference values for mouse, rat, dog, and human (Bogaards 2001) (Gupta 2006).

Cytosolic Protein
Concentration
(mg/g liver)

Liver Weight
(g)

Hepatic Blood
Flow
(ml/min)

Hepatic Blood
Flow
(ml/min/kg)

Body Weight
(kg)

Total Body
Water
(l)

Mouse

83

2.2

9.7

280.2

0.03

0.02

Rat

108

12.5

22.4

89.7

0.25

0.15

Dog

67

320

309

30.9

10

6

Human

45

1799

1502

21.5

70

42

209

In order to scale-up the estimated intrinsic clearance to total body clearance and estimate
the hepatic extraction ratio, the following assumptions were made:
– 5-HMF is subject to oxidative metabolism in hepatic cytosol, only; no other significant
hepatic metabolism, or biliary excretion.
– 5-HMF has negligible renal excretion.
This assumption of negligible biliary and renal excretion was based on the extensive
metabolism reported in different studies with a minimum amount of unchanged 5-HMF excreted
in feces or urine, as discussed in Chapter 1. In addition, the hydrophilic 5-HMF structure with a
small molecular weight implies that 5-HMF is not a substrate for biliary excretion.
CYP-450 is the other potential class of enzymes that might be involved in 5-HMF
metabolism. However, CYP-450 enzyme substrates have affinity in the single micromolar range.
If this is the case with 5-HMF, the enzymes will be saturated at the proposed therapeutic
concentration of 5-HMF (1-2 mM) and their contribution will be minimal to the over metabolism
of 5-HMF.
– 5-HMF has no extrahepatic metabolism.
Extraheptic metabolism was not indicated by the reported studies. In addition, most of the drugs
in the market do not undergo hepatic extraction.
– Fraction unbound of 5-HMF in plasma (fu)= 1.
The hydrophilic 5-HMF structure supports the assumption of insignificant unbound fraction.
Moreover, it was reported that binding to hemoglobin was not affected in the presence or
absence of plasma protein (Abdulmalik 2005).
The hepatic extraction ratio (ERhep) was estimated using the well-stirred model as shown
in Equation 4-5 involving the hepatic blood flow (Qhep):
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ER hep = Q

fu × CLint

hep

+ fu × CLint

… … … … … … … … … … … … … … … … … … … … . … … … . . Equation 4 − 5

In addition, in-vivo intrinsic clearance was used in the calculation of hepatic clearance (CLhep) as
per Equation 4-6:

CLhep = ER hep × Q hep … … … … … … … … … … … … … … … . . … … … … . . … … … . Equation 4 − 6
To estimate the oral bioavailability (Foral) and the elimination half-life (t1/2), the following
were assumed:
– No limitations in gastrointestinal solubility, stability, or permeability.
As discussed in Chapter 1, the solubility of 5-HMF is 48 g/l at 25 °C over a pH range of 1
to 10 (ACS 2009), which means that up to 12 g of 5-HMF can be dissolved in 250 ml of aqueous
media, which is representative to what 5-HMF might be exposed in the gastrointestinal tract.
Probably the highest strength dose will be less than 12 g. Thus, 5-HMF is not expected a
limitation in its solubility.
The calculated logD value of 5-HMF equals -0.45 (ACS 2009) over a pH range of 1-10
and its small molecular weight (MW: 126 D) makes it a candidate for passive diffusion in the
gastrointestinal tract (Hurst 2007). Germond and co-workers reported that 95-100% of the
radioactivity was recovered in urine within 24 hours of oral and intravenous [14C]-5-HMF
administration to rats (Germond 1987). The doses ranged between 0.8-330 mg/kg administered
for two rats at each dose level (Germond 1987). This indicates that≥90% is orally absorbed in
rats. Assuming a similar absorption behavior in human, 5-HMF will have a good permeability in
human gastrointestinal tract.
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– Distribution along total body water compartment (as ethanol), i.e., Vd=0.6 l/kg in all
species.
This assumption was based on the small, neutral, and hydrophilic structure of 5-HMF, as
discussed above, and its similarity to ethanol structure.

ERhep was used in the calculation of oral bioavailability (Foral) as per Equation 4-7.

Foral = 1 − ER hep … … … … … … … … … … … … … … … . . … … … … . … … . … … … . . Equation 4 − 7
The elimination half-life (t1/2) was calculated according to Equation 4-8:

t1/2 =

0.693 × Vdss
… … … … … … … … … … … … … … … … … … … … … … … . … … Equation 4 − 8
CLhep
The predicted 5-HMF elimination half-life was then compared to the half-life reported in

or extrapolated from in-vivo studies. The in-vitro-in-vivo prediction accuracy was evaluated
through calculating the ratio of the predicted value to the observed value.
In addition, 5-HMF AUC∞ was estimated after oral dosing using Equation 4-9 that
involves the oral bioavailability and hepatic clearance assuming the equivalency of the latter to
the total clearance.
AUC∞ =

Foral × Dose
… … … … … … … … … … … … … … … … … … … … … … … . … Equation 4 − 9
CLtot
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The above equation was used in predicting the AUC after 100 mg/kg oral dose
administered in mice. Then, this value was compared to the estimated value from in-vivo study
reported by Abdulmalik and co-workers. Moreover, the predictions were performed for the AUC
after oral administration of 5-HMF for the First-Time in Man (FTIM) Study in a dose-escalating
study with proposed doses (100-10,000 mg).

4.2.9 Detection of HMFA in Human Hepatic Cytosol

Cytosolic protein, NAD+ cofactor, and 5-HMF at 0.8 and 3.2 mM in Tris buffer (pH 7.5)
were mixed at a final volume of 0.2 ml. The reaction was incubated at 36.5±1 °C between 20-80
minutes. The reaction was stopped by the addition of 0.1 ml ice-cold acetonitrile. Then, 0.15 ml
of the mixture was further diluted with 0.65 ml ice-cold water and was subject to HPLC analysis,
as described in Chapter 3.
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4.3

Results

Upon incubation of the selective substrates of ALDH and ADH enzymes, ethanol, DN,
and acetaldehyde with human hepatic cytosol, an increase in the absorbance at 340 nm was
observed. This increase was expected due to the production of NADH in conjunction with
NADH-dependent oxidation of these substrates by ADH and ALDH enzymes. Initial velocities
(vi) were estimated from the slope of the linear portion representing the pseudo-zero order
increase in the absorbance for each concentration within a ten-minute frame during
spectrophotometric monitoring. These initial velocities, when plotted against concentration
resulted in a hyperbolic relationship that was modeled by the Michaelis Menten kinetics by nonlinear regression, as shown in Figures 4-2, 4-3, and 4-4 for ethanol, DN, acetaldehyde.
An increase in the absorption was observed when 5-HMF was incubated with human
hepatic cytosol and it was modeled by non-linear regression, as shown Figure 4-5. The maximum
metabolic capacity and enzyme affinity are summarized in Table 4-6 along with the in-vitro
intrinsic clearance. The in-vitro intrinsic clearance is expressed in µl/min/mg cytosolic protein.
The metabolic activity of ethanol in human hepatic cytosol was inhibited to a higher
extent by 4-methylpyrazole than by disulfiram, as demonstrated in Figures 4-6 and 4-7. On the
other hand, Figure 4-8 shows that acetaldehyde metabolism was inhibited to a great extent by
disulfiram. 5-HMF metabolism was inhibited by both 4-methylpyrazole and disulfiram,
However, the inhibition was larger with disulfiram as shown in Figures 4-9 and 4-10. The
increase in the absorbance diminished in the presence of the two inhibitors. The results of the
inhibition studies are listed in Tables 4-7, 4-8, and 4-9.
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Figure 4-2. Concentration-dependent human hepatic cytosol metabolism of ethanol.
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Figure 4-3. Concentration-dependent human hepatic cytosol metabolism of DN.
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Figure 4-4. Concentration-dependent human hepatic cytosol metabolism of acetaldehyde.
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Figure 4-5. Concentration-dependent human hepatic cytosol metabolism of 5-HMF.
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Table 4-6. Final Michaelis Menten metabolic parameter estimates (SE) for various substrates in
human hepatic cytosol.
Substrate

Ethanol

DN

Acetaldehyde

5-HMF

v0
(nmol/min/mg)

0.13 (0.03)

-

1.8 (0.4)

1.78 (0.15)

vmax
(nmol/min/mg)

0.70 (0.03)

3.6 (0.3)

2.8 (0.6)

33.2 (8.0)

Km (µM)

1.27 (0.23).103

3.5 (1.4).10-3

149 (123)

218 (74).103

CLintin-vitro
(µl/min/mg)

0.55

1.0 X 106

18.8

0.15
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Figure 4-6. Inhibition of NADH-mediated human hepatic cytosol metabolism of ethanol by 4methylpyrazole.
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Figure 4-7. Inhibition of NADH-mediated human hepatic cytosol metabolism of ethanol by
disulfiram.
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Table 4-7. Inhibition metabolism of NADH-mediated human hepatic cytosol of ethanol by 4methylpyrazole and disulfiram (SE).

Maximum inhibition (%)

4-Methylpyrazole

Disulfiram

84.9 (6.9)

40.7 (2.3)
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Figure 4-8. Inhibition of NADH-mediated human hepatic cytosol metabolism of acetaldehyde
by disulfiram.
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Table 4-8. Inhibition of NADH-mediated human hepatic cytosol metabolism of acetaldehyde by
disulfiram (SE).

Disulfiram

92.4 (7.8)

Maximum inhibition (%)
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Figure 4-9. Inhibition of NADH-mediated human hepatic cytosol metabolism of 5-HMF by 4methylpyrazole.
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Figure 4-10. Inhibition of NADH-mediated human hepatic cytosol metabolism of 5-HMF by
disulfiram.
.
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Table 4-9. Inhibition of NADH-mediated human hepatic cytosol of 5-HMF metabolism by 4methylpyrazole and disulfiram (SE).

Maximum inhibition (%)

4-Methylpyrazole

Disulfiram

33.6 (5.1)

59.9 (7.8)
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The increase in the absorption was also observed when 5-HMF was incubated in mouse,
rat, and dog hepatic cytosol: The resulting Michaelis Menten curves for 5-HMF in different
species hepatic cytosol are shown in Figures 4-11, 4-12, 4-13, and the parameters are
summarized in Table 4-10. The estimated v0 in the metabolism of 5-HMF in the mouse and
human hepatic cytosol might indicate the involvement of high affinity/low capacity enzymes in
the metabolism of 5-HMF. In addition, the corresponding linearization graphs are shown in
Figures 4-14, 4-15, 4-16, 4-17, and 4-18 for 5-HMF metabolism in mouse, rat, dog, and human
hepatic cytosol along with ethanol in human hepatic cytosol.
The final IVIVE results are summarized in Table 4-11, including CLintin-vivo, CLmet, ERhep,
Foral, and t1/2. In addition, a half-life comparison between that predicted by IVIVE and that
obtained from in-vivo studies along with the projected AUC(s) after oral administration of 5HMF for the First-Time in Man (FTIM) Study are shown in Tables 4-12 and 4-13.
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Figure 4-11. Concentration-dependent metabolism of 5-HMF in mouse hepatic cytosol.
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Figure 4-12. Concentration-dependent metabolism of 5-HMF in rat hepatic cytosol.
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Figure 4-13. Concentration-dependent metabolism of 5-HMF in dog hepatic cytosol.
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Table 4-10. Final Michaelis Menten metabolic parameter estimates (SE) for 5-HMF in hepatic
cytosol from various animal species.

Mouse

Rat

Dog

Human

v0 (nmol/min/mg)

0.78 (0.24)

1.78 (0.15)

vmax
(nmol/min/mg)

16.2 (1.0)

27.7 (6.8)

14.9 (2.3)

33.2 (8.0)

Km (mM)

37.1 (6.3)

76.6 (32.4)

18.3 (8.0)

218 (74)

CLintin-vitro
(µl/min/mg)

0.44

0.36

0.81

0.15
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Figure 4-14. Linearization graphs for concentration-dependent metabolism of 5-HMF in mouse
hepatic cytosol.
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Figure 4-15. Linearization graphs for concentration-dependent metabolism of 5-HMF in rat
hepatic cytosol.
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Figure 4-16. Linearization graphs for concentration-dependent metabolism of 5-HMF in dog
hepatic cytosol.
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Figure 4-17. Linearization graphs for Concentration-dependent metabolism of 5-HMF in human
hepatic cytosol.
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Figure 4-18. Linearization graphs for concentration-dependent metabolism of ethanol in human
hepatic cytosol.
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Table 4-11. IVIVE for 5-HMF in mouse, rat, dog, and human using physiological variables listed in Table 4-5.

CLint
(ml/min)

CLint
(ml/min/kg)

CLhep
(ml/min)

CLhep
(ml/min/kg)

ERhep
(%)

Foral
(%)

t1/2
(hour)

Mouse

0.08

2.3

0.08

2.3

0.8

99

3.1

Rat

0.49

2.0

0.48

1.9

2.1

98

3.6

Dog

17.4

1.7

16.5

1.7

5.0

95

4.2

Human

12.3

0.18

12.2

0.17

0.8

99

39.7
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Table 4-12. Comparison of IVIVE predictions for 5-HMF with the reported values.

IVIVE Predictions

Mouse

Dog

Human

Literature

t1/2
(hr)

AUC
(mg/ml*min)

t1/2
(hr)

AUC
(mg/ml*min)

Dose

Species

Reference

3.1

44

1.5

26

100 mg/kg
orally

Transgenic
mice

(Abdulmalik
2005)

Male
beagles

(Klimmek
1978)

65-70 yrs
old
women

(Prior 2006)

4.2

2.1

397 mg/kg
infused
over an
hour

39.7

1.2 (for
HMFA
metabolite)

7.5 mg/kg
of 5-HMF
in dried
plum juice
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Table 4-13. Predicted AUC∞ after oral administration of 5-HMF FTIM study.

Dose (mg)

Projected AUC∞ (mg/ml.min)

100

8

300

24

1000

81

3000

244

6000

487

10000

812
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HMFA was detected in human cytosol after incubation of 5-HMF at different
concentrations for different periods. Unfortunately, the peak of HMFA overlapped with a peak
present in the blank, as discussed in Chapter 3. Nevertheless, it is demonstrated in Figures 4-19,
4-20, 4-21, 4-22, and 4-23 that the peak height increased with the increase in the concentration of
5-HMF and with the increase in the incubation period indicating the formation of HMFA in
human hepatic cytosol after the addition of NAD+.
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Figure 4-19. HPLC chromatogram for blank human hepatic cytosol, no 5-HMF added.
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Figure 4-20. HPLC chromatogram for 0.8 mM of 5-HMF incubated in human hepatic cytosol for 20 minutes.
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Figure 4-21. HPLC chromatogram for 0.8 mM 5-HMF incubated in human hepatic cytosol for 40 minutes.
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Figure 4-22. HPLC chromatogram for 3.2 mM 5-HMF incubated in human hepatic cytosol for 20 minutes.

245

Figure 4-23. HPLC chromatogram for 3.2 mM 5-HMF incubated in human hepatic cytosol for 80 minutes.
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4.4

Discussion and Conclusions

The NAD+-dependent oxidation of all ADH/ALDH model-substrates (ethanol,
acetaldehyde, and DN) in human hepatic cytosol were adequately characterized by Michaelis
Menten kinetics as indicated by the goodness of fit of the non-linear regression. This validated
the hepatic cytosolic system and confirmed the presence of active ADH and ALDH enzymes.
The estimated Km values for all these substrates was similar to these reported previously in the
literature, as listed in Table 4.2. Similarly, the NAD+-dependent oxidation of 5-HMF in human
hepatic cytosol was described by Michaelis Menten kinetics, indicating 5-HMF metabolism by
ALDH and ADH enzymes. This was further supported by the observed formation of the
metabolite, HMFA, in human hepatic cytosol.
Overall, low-affinity (Km: 218 mM)/high capacity (vmax: 33.2 nmol/min/mg) metabolism
was observed for 5-HMF relative to ethanol (1.3 mM/0.7 nmoles/min/mg) and DN and
acetaldehyde (3.5 nM/3.6 nmol/min/mg and 149 μM/2.8 nmol/min/mg). However, the Km
estimation for 5-HMF is limited by the fact that 5-HMF concentrations greater than Km could not
be achieved experimentally since the UV absorption saturated the instrument and 5-HMF
solubility was exceeded.
The observed increase in the absorbance is a result of NADH production. Since this a
common product for ALDH and ADH, the following reactions might be involved:

HO
ALDH +

O

HO

O

O

H

O
+NADH

OH
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The effect of the selective ALDH and ADH inhibitors was demonstrated by the inhibition
of ethanol and acetaldehyde metabolism by 4-methylpyrazole and disulfiram, respectively,
ethanol metabolism by ADH was inhibited mainly by 4-methylpyrazole, while acetaldehyde
metabolism by ALDH was inhibited to a large extent by disulfiram.
Relative to the control, the activity of 5-HMF in the presence of disulfiram declined to
40% of the control activity, indicating a significant role of ALDH enzyme in its metabolism. On
the other hand, 5-HMF metabolism was inhibited to a lesser extent (33%) by 4-methylpyrazole.
This suggests that ALDH-mediated oxidation of 5-HMF to HMFA (a human metabolite
identified in-vivo) is the major route of hepatic metabolism.
In concordance with the conclusion of ADH and ALDH-mediated oxidation of 5-HMF,
Modig and co-workers investigated 5-HMF in isolated yeast ADH and ALDH enzymes (Modig
2002). This study involved 5-HMF concentrations up to 32 mM, which is lower than that used in
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this research, and studied NAD+ conversion into NADH. However, the investigators were
interested in 5-HMF interaction with another ALDH and ADH substrate rather than the
characterization of the metabolic parameters for 5-HMF (Modig 2002).
When linearization-graphing methodologies were used to fit ethanol metabolism in
human hepatic cytosol and 5-HMF metabolism in different species hepatic cytosol, the best
linear fits were achieved for ethanol metabolism in human hepatic cytosol and 5-HMF
metabolism in mouse hepatic cytosol. The involvement of multiple enzymes in the metabolism
of 5-HMF might cause the observed deviation from linearity. In our case, it is assumed that the
enzyme involved are both ADH and ALDH. Furthermore, the non-linearity might be due to the
inherent errors in these methods as mentioned below:
– The errors associated with small concentration are exaggerated in the LineweaverBurk (double-reciprocal) due to the use of concentration reciprocal on the x-axis.
In addition to the aggregation of the points at the left side of the plot with high
concentrations.
– The x-axis in the Eadie-Hofstee is not independent since it contains the dependent
variable (velocity).
Furthermore, 5-HMF oxidative metabolism in the hepatic cytosol of mouse, rat, dog, and
human was described well by Michaelis Menten kinetics, with the most precise vmax and Km
estimates observed in the mouse. While vmax values/enzyme capacity in the four animal species
were relatively similar (per mg protein of hepatic cytosol), the enzyme affinity was more
variable - with the highest affinity observed in the dog and the lowest in humans. This suggests
involvement of ALDH and/or ADH in 5-HMF metabolism in all animal species, however, with
quantitative differences in their intrinsic clearance. The highest intrinsic clearance (per kg body
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weight) was predicted for the mouse (2.3 ml/min/kg), while the lowest intrinsic clearance was
predicted for humans (0.18 ml/min/kg). The use of Equation 4-5 to estimate the intrinsic
clearance entails the assumption of therapeutic concentrations lower than the Km value and
similarity between the substrate concentration at the enzyme site and the unbound plasma
concentration (Houston 2008).
Despite the quantitative differences in the intrinsic clearance, in all animal species
studied, 5-HMF is predicted to be subject to low hepatic extraction and thus to show high oral
bioavailability in-vivo. The actual in-vivo oral bioavailability is unknown since no IV reference
dose was administered concurrently with an oral dose.
In-vivo systemic exposure predictions (AUC and t1/2) using the respective IVIVE
parameter estimates in the mouse were within two-fold of those reported for in-vivo exposures
after oral administration of 100 mg/kg of 5-HMF. In dogs, the IVIVE-predicted t1/2 is
approximately two-fold longer than that reported in-vivo after I.V. infusion of 5-HMF (397
mg/kg for 1 hr). In both cases, the IVIVE predictions may have underestimated CLmet for 5HMF, possibly due to other (minor) routes of metabolism, e.g., hepatic mitochondrial oxidation.
Nevertheless, the IVIVE exposure predictions were reasonable for dogs and mice.
On the other hand, the IVIVE-predicted t1/2 for humans is more than 30-fold longer than
the reported plasma t1/2 of the (presumed) primary metabolite, HMFA after oral administration of
approximately 7.5 mg/kg of 5-HMF. This major discrepancy most likely implies a significant
involvement of other hepatic fractions and/or extrahepatic metabolism of 5-HMF in humans,
most likely oxidative, ALDH-mediated metabolism in RBCs (see Chapter 5).
As observed from the IVIVE, all the prediction were underestimated to some extent in
comparison to in-vivo data. Under-prediction is a common issue that is encountered when
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dealing with different in-vitro systems. Considering the average inaccuracy, it was reported that
IVIVE for human microsomes and hypatocytes were 9-fold and 5-fold lower than their
corresponding in-vivo values and were associated with low precision of 30 -150 fold (Houston
2008) (Hallifax 2009). On the other hand, our observation of higher bias in human vs. other
species IVIVE is a common annotation in the literature. The IVIVE was reported to mispredict
rat in-vivo data by 1.4- and 2.2-fold using microsomes and hepatocytes, respectively (Houston
2008). When the repeatability of in-vitro estimates was investigated in hepatocytes, 28%
variation was found using midazolam as a substrate (Hallifax 2009). Unfortunately, a definite
mechanistic understanding of this misprediction is not always available (Hallifax 2009).
In-vivo predictions from in-vitro systems suffers from inaccuracy if the in-vivo data was
collected from a population with different genetic characteristic in comparison to those used in
the generation of the in-vitro data (Hallifax 2009). Both of ALDH and ADH enzymes, involved
in this research, were reported to have extensive polymorphism among ethnic groups (Goedde
1983). The hepatic cytosol is pooled from different donors, which introduces variability in age,
gender, disease, medications, smoking, drinking, and cause of death. In contrast, these variability
factors are well-controlled in the in-vivo studies (Hallifax 2009). In addition, errors from
experimental procedures and extrapolation using the physiological values, which are subject to
inter-individual variability, contribute to random error associated with IVIVE leading to the
uncertainty in the hepatic clearance prediction (Hallifax 2009). For instance, the human cytosolic
protein recovery per gram liver was reported with a significant variation, 45 -134 mg/g liver vs.
78-105 mg/g liver in rats.
In the experiments conducted in this research project, the total added concentration of 5HMF was used and the unbound fraction in the in-vitro system was assumed to be one. This may
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contribute to under-prediction if the drug was non-specifically bound in the hepatic cytosol invitro and was less bound in the physiological system. In addition, diffusion into the subcellular
fraction, increasing or decreasing the concentration available to enzymes, is not accounted for
with the use of hepatic cytosol.
Moreover, the activity of the enzymes might have decreased because of the procedures
associated with liver resection and cellular fractionation (Hallifax 2009). The speed, at which
subcellular fractions are obtained from different species, can be different leading to a variation in
the accuracy of IVIVE among species (Hallifax 2009). Furthermore, endogenous activators or
inhibitors might exist in the physiological setting but not in in-vitro system (Hallifax 2009). In
addition, errors are introduced at the metabolic pharmacokinetics model level due to the inability
to reach saturation due to high background absorbance and substrate solubility (Hallifax 2009).
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CHAPTER 5
5
5-HMF METABOLISM IN HUMAN RBCS

5.1

Introduction

ALDH was first extracted from human erythrocytes by Inoue and co-workers in 1979 as a
tetrameric protein (Inoue 1979). Unfortunately, the literature is sparse with studies investigating
this ALDH enzyme in RBCs. This might be a result of the low number of drugs with an aldehyde
moiety that are administered to humans therapeutically. As discussed in Chapter 1, the ALDH
isoenzyme present in RBCs has similar properties as the ALDH isoenzyme in hepatic cytosol
(Goedde 1983) (Inoue 1979). It was shown by Goedde et al. that the ALDH isoenzyme in RBCs
corresponds to ALDH1 enzyme present in the liver. This fact together with the discrepancy in
the IVIVE prediction with the observed t1/2 (Chapter 4), suggest that 5-HMF may be metabolized
in human RBCs. Consequently, 5-HMF metabolism was investigated in human RBCs.
The same methodology used in studying 5-HMF metabolic stability in the hepatic cytosol
was used to study the metabolism of 5-HMF in human RBCs. NADH production was
spectrophotometrically monitored to investigate 5-HMF oxidation.
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5.2

Methods

5.2.1 Materials and Reagents
1. BD Gentest™ TRIS Buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
2. 5-Hydroxymethyl-2-furfural (5-HMF) Solution:
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
3. Ethanol Solution:
- Ethanol 99.5%, 200 proof (Aldrich, Milwaukee, WI)
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
4. 4-Methylpyrazole (4-MP) Solution:
- 4-MP, 99% (Sigma-Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
5. Tetraethylthiuram Disulfide (disulfiram) Solution:
- Disulfiram, purum 97% (Sigma-Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
6. Human Blood:
- Human: mixed gender, pool of three black females, two black males, and one white
male (35.3 ± 13.5 years).
- Water (BD Bioscience, San Jose, CA).
7. Cofactor Solution, β-Nicotinamide Adenine Dinucleotide (NAD+) Solution:
- NAD+ from yeast (Sigma, St. Louis, MO).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
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5.2.2 Equipment

1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips
(Microman, Rainin Instruments, Oakland, CA).
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West
Chester, PA).
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA).
4. Vortex (Vortex-Genie, VWR, West Chester, PA).
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).
6. pH meter (Corning, Glendale, AZ).
7. Balance (Fisher Scientific A 250, Pittsburgh, PA).
8. Synergy™ 2 multi-mode microplate reader (BioTek, Winooski, VT).
9. Falcon assay plate, 96 reaction wells (VWR, West Chester, PA).
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5.2.3 Preparation of Solutions
- Cofactor solution, β-nicotinamide adenine dinucleotide (β-NAD+) solution
22.3 g of NAD+ (M.W.: 663.43 Da) was dissolved in 3 ml of Tris buffer to prepare 1.4
mM solution.

- Diluted human RBCs
RBCs were obtained after centrifugation of whole blood. The RBCs were lysed and
diluted 625-fold with water on two stages.

- Substrates solution
Solutions of different concentrations (12-142 mM) of 5-HMF (M.W. 126.11 Da) were
prepared in Tris buffer. The estimation of NADH at low substrate was limited by the
assay sensitivity in some cases. In addition, the estimation of NADH at high substrate
was limited by the high baseline absorbance of 5-HMF and its solubility.

- Inhibitors solution
Solutions of inhibitors, 0.03-281 µM 4-methylpyrazole (M.W. 82.10 Da) and 0.03-33.8
µM disulfiram (M.W. 296.54 Da) were prepared to achieve maximum inhibition of the
relevant enzymes taking into consideration their reported Ki, as stated in Chapter 4.
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5.2.4 Procedures

Diluted RBCs, NAD+ cofactor, and 5-HMF at different concentrations were mixed at a
final volume of 0.2 ml. The reaction was initiated by the addition of diluted RBC solutions after
allowing the mixture to equilibrate for approximately 5 minutes. The increase in the absorbance
at 340 nm at 37 °C was monitored over time. The change in the absorbance was converted to an
NADH concentration using Beer’s law, as discussed in the method section of Chapter 4.

5.2.5 Concentration Dependency Studies

When the initial velocities were plotted against their corresponding concentrations, they
did not reach saturation. Consequently, the initial velocities were related to their corresponding
concentrations by the intrinsic clearance, which was represented by the slope.

× C + v0 … … … … … … … … … … … … … … … … … … … … … … … . Equation 5 − 1
vi = CL𝑖𝑛−𝑣𝑖𝑡𝑟𝑜
int
Where
vi: the observed velocity
v0: the baseline velocity observed in the absence of the substrate
C: the substrate concentration
CLintin-vitro: in-vitro intrinsic clearance
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5.2.6 Inhibition Studies

Taking into consideration their reported Ki value, different concentrations of disulfiram
and 4-methylpyrazole were used. All reaction components except for 5-HMF were incubated for
approximately 15 minutes and 25 minutes with 4-methylpyrazole and disulfiram, respectively,
after which 5-HMF, 26 mM, was added. At each concentration, a minimum of duplicate
reactions were considered in the data analysis.
The data were modeled using non-linear regression as discussed in the methods section
of Chapter 4.

5.2.7 In-Vitro-In-Vivo Extrapolation

CLintin-vitro in Equation 5-2 is a measure of the innate ability of each milliliter of RBCs to
clear a substrate. This in-vitro measure was extrapolated to in-vivo clearance (CLRBCs) using the
RBCs fraction of blood (0.4) and the total blood volume (5000 ml) according to Equation 5-2.
Consequently, CLRBCs refers to the innate ability of whole RBCs volume to clear 5-HMF.

CLRBCs = CL𝑖𝑛−𝑣𝑖𝑡𝑟𝑜
× 0.4 × 5000 … … … … … … … … … … … … … … … … … … … . Equation 5 − 2
int
However, in order to scale-up the estimated clearance in RBCs together with the hepatic
clearance to a total body clearance, the following were assumed:
– 5-HMF is subject to oxidative metabolism in hepatic cytosol and RBCs, only; no other
significant hepatic metabolism, or biliary excretion.
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– 5-HMF has negligible renal excretion.
– Fraction unbound of 5-HMF in plasma (fu)= 1.

The bases for these assumptions are stated in Chapter 4. Consequently, Equation 5-3 was
used to estimate the total clearance.

CLtot = CLhep + CLRBC … … … … … … … … … … … … … … … … … … … … … … … … Equation 5 − 3
IVIVE exposure predictions were calculated as described in the methods section of
Chapter 4.

259

5.3

Results

An increase in the absorption was not observed when ethanol was incubated in the RBC
system. This is expected since ADH expression in human RBCs was not reported. On the other
hand, upon the incubation of 5-HMF with diluted RBCs, an increase in absorbance at 340 nm
was observed, indicating the production of NADH in conjunction with 5-HMF oxidation. Initial
velocities (vi) were estimated from the slopes of the linear portion, representing the pseudo-zero
order increase in the absorbance for each concentration within a ten-minute frame of
spectrophotometric monitoring. When these initial velocities were plotted against their
corresponding concentrations, they resulted in a linear relationship that was modeled by linear
regression, as shown in Figure 5-1. The in-vitro intrinsic clearance, expressed in ml/min/ml
RBCs, is shown in Table 5-1. The estimated metabolic activity of 5-HMF was partially inhibited
by disulfiram as demonstrated in Figure 5-2. The parameters of the non-linear regression
inhibition model are shown in Table 5-2.
The IVIVE results are summarized in Table 5-3, including CLRBCs, CLtot, and t1/2. The
predicted half-life by the IVIVE (41 minutes) was 0.6 of that obtained from in-vivo studies (69
minutes) after oral administration of 5-HMF (Prior 2006). In addition, Table 5-4 summarizes the
modified predictions of AUC∞ after oral administration of 5-HMF FTIM study.
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Figure 5-1. Concentration-dependent human RBC metabolism of 5-HMF.
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Table 5-1. Final metabolic parameter estimates (SE) for 5-HMF in human RBC.
1.4 (1.8)

v0 (µmol/min/ml RBCs)
CLintin-vitro (ml/min/ml RBCs)
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Figure 5-2. Inhibition of NADH-mediated human RBC metabolism of 5-HMF by disulfiram.
.
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Table 5-2. Inhibition of NADH-mediated human RBC of 5-HMF metabolism by disulfiram
(SE).
52.6 (3.62)

Maximum inhibition (%)

0.0053 (0.0027)

IC50 (µM)
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Table 5-3. Modified IVIVE predictions for 5-HMF in humans.
CLhep (ml/min)

12

CLRBCs (ml/min)

690

CLtot (ml/min)

702

t1/2 (min)

41.5
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Table 5-4. Modified predictions of AUC∞ for oral administration of 5-HMF FTIM study.

Dose (mg)

Projected AUC∞ (mg/ml.min)

100

0.14

300

0.41

1000

1.4

3000

4.2

6000

8.3

10000

14
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5.4

Discussion and Conclusions

Significant NAD+-dependent oxidation of 5-HMF was observed in RBCs. Overall, lowaffinity metabolism was observed for 5-HMF, where Km estimation for 5-HMF was not possible
due to the fact that 5-HMF concentrations greater than Km could not be achieved experimentally
due to saturation in the instrument response and limitations in 5-HMF solubility.
The failure to observe NAD+-dependent oxidation of ethanol and 5-HMF inhibition by 4methylpyrazole indicated the absence of ADH enzyme in RBCs. On the other hand, 5-HMF
metabolism and inhibition by disulfiram was in concordance with the presence of ALDH in
RBCs, as reported in the literature suggesting ALDH-mediated oxidation of 5-HMF in RBCs.
The use of the slope to estimate the intrinsic clearance entailed the assumption of therapeutic
concentrations lower than the Km value and similarity between the substrate concentration at the
enzyme site and the unbound plasma concentration (Houston 2008).
The IVIVE-predicted t1/2 for humans is similar to the reported plasma t1/2 of the
(presumed) primary metabolite, HMFA after oral administration of approximately 7.5 mg/kg of
5-HMF. This resolves the discrepancy noted in Chapter 4 that suggested the involvement of
extrahepatic metabolism of 5-HMF in humans and led the study of RBC metabolism.
As discussed in Chapter 4, in-vivo predictions from in-vitro systems suffers from
inaccuracy if different genetic characteristic were associated with the in-vivo data population in
comparison to those used in the generation of the in-vitro data (Hallifax 2009). Ueshima et al.
studied ALDH activity in the blood of an individual with normal ALDH1 homozygote after the
addition of 1 mM of acetaldehyde for 14 minutes and found that approximately 80% of the added
acetaldehyde disappeared, while approximately 30% of the acetaldehyde disappeared in the
blood taken from an individual with ALDH1 deficiency (Ueshima 1993). Moreover, errors from
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experimental procedures and extrapolation using blood volume and hematocrit value, which are
subject to inter-individual variability, contribute to IVIVE inaccuracy in this research project.
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CHAPTER 6
6
5-HMF IN-VITRO PROTEIN BINDING

6.1

Introduction

As stated in Section 1.2.2 in Chapter 1, the pharmacological activity of 5-HMF has been
shown to be a consequence of the increased oxygen affinity to hemoglobin upon the formation of
a Schiff adduct between the aldehyde group of 5-HMF and α-valine (Safo 2004). This valine
amino acid is located in the hemoglobin water cavity, as shown in Figure 6-1.
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Figure 6-1. 5-HMF binding to a hemoglobin molecule. (Abdulmalik 2005)
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Likewise, Schiff base formation has been reported between hemoglobin and other
endogenous moieties. An example of a clinically relevant Schiff base adduct with hemoglobin is
HbAIc. The normal blood glucose concentration, 3.6-7.0 mM, is associated with 5.0-8.5%
glycosylated hemoglobin in healthy non-fasting humans (John 1988). Glucose interacts with
hemoglobin, forming a Schiff base that undergoes further rearrangement to form a stable
ketoamine linkage at the amino terminus of the β chain (Higgins 1981) (Bunn 1981). This
interaction results in a slow formation of HbAIc throughout the life cycle of RBCs (Higgins
1981). Moreover, albumin also undergoes non-enzymatic glycosylation (Day 1979). The
principal site for this glycosylation is the lysine amino acid at the 525 position (Garlick 1983).
In 1977, Zaugg et al. investigated Schiff base adducts between aldehydes and hemoglobin
at the amino terminals as a potential approach to decrease HbS polymerization (Zaugg 1977). In
that study, 31 compounds with carbonyl groups were incubated with a 20% RBC suspension,
whole blood, and 6% of cell free hemoglobin (Zaugg 1977). The compounds included twenty
five aromatic aldehydes, most of which were benzaldehyde derivatives, such as salicylaldehyde,
vanillin, and carboxybenzaldehydes (Zaugg 1977). In addition, four aliphatic aldehydes were
studied, namely, glyceraldehydes, cyclohexanecarbxaldehyde, glucose, and valeraldehyde
(Zaugg 1977). Although Schiff base is reversible, it is considered as a relatively stable adduct
since it could be characterized by isoelectric focusing (Zaugg 1977). A hemoglobin molecule
with a Schiff base is slightly more anionic than the unmodified hemoglobin. These studies
showed that aromatic aldehydes have higher affinity towards hemoglobin (typical association
constant (KA) value of 220 M-1) than aliphatic aldehydes (typical KA value of 70 M-1) (Zaugg
1977). These observed association constants are higher than those obtained for small amine
molecules, possibly due to water exclusion by the microenvironment that hemoglobin tetramer
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provides favoring the formation of adduct (Zaugg 1977). In general, ketones and aliphatic
aldehydes (including glucose) binding to hemoglobin did not affect oxygen affinity (Zaugg
1977).
It is noteworthy, that 5 mM of o-vanillin demonstrated 75% left shift of the control P50
value in 20% suspension of normal erythrocytes. This result was followed-up by Abraham and
coworkers, where they incubated different concentrations (2.5, 5, and 10 mM) of vanillin in
whole blood with homozygote sickle hemoglobin (Abraham 1991). With all of the above
concentrations more than 85% of HbS molecules were modified to adducts with vanillin in less
than an hour without affecting the hydration of RBCs (Abraham 1991). Nevertheless, vanillin
was found to possess low oral bioavailability, which hindered its development (C. L. Zhang
2004).
This chapter presents the results of in-vitro binding studies of 5-HMF to human HbA and
HSA. Time–dependency studies were designed to characterize the protein interaction and to
estimate the appropriate rate constants, while concentration-dependency studies were performed
to estimate the binding affinity and capacity of these proteins.
Various methods can be used to perform the physical separation of bound and unbound
concentration of drugs to protein. Equilibrium dialysis is a commonly used method that employs
semipermeable membrane, with a suitable molecular cutoff, to separate two chambers (Cheng
2004). The plasma spiked with the drug is added to one of the chambers while the other chamber
contains a buffer. Despite its widespread use, equilibrium dialysis takes is time-consuming,
which might be problematic to unstable drugs (Pacifici 1992). In addition, non-specific binding
of the drug to the apparatus and volume shift between the compartments are disadvantages of
equilibrium dialysis (Pacifici 1992).
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HPLC using immobilized HSA is a recently developed method that can be used to
determine protein binding (Cheng 2004). However, this method is hindered by the availability of
the column and the drug since a large amount of drug is needed for the analysis (Cheng 2004).
Ultrafiltration uses a semipermeable membrane and forces the plasma or buffer with the
unbound (ultrafiltrate) into a separate compartment using centrifugation that causes a pressure
gradient (Bowers 1984). As with other protein binding determination methodologies, it suffers
from non-specific binding to the instrument and membrane. In addition, centrifugation is usually
performed at room temperature, which might disturb the equilibrium that might have been
initiated at 37 °C (Pacifici 1992).
As a simple and rapid technique in protein binding determination, ultrafiltration was used
in this study. Non-specific binding was determined in the absence of proteins to overcome this
disadvantage. The molecular weight of HSA and Hb were considered in selecting the cutoff of
the semipermeable membrane to avoid protein leakage. The temperature of the centrifuge was set
to 37 °C.
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6.2

Methods

6.2.1 Materials and Reagents

1. Phosphate-Buffered Saline (PBS), pH 7.4:
- Phosphate-buffered saline tablets, pH 7.4 (Sigma, St. Louis, MO).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
2. Human Hemoglobin Solution:
- Human hemoglobin lyophilized powder (Sigma, St. Louis, MO).
- Phosphate-buffered saline, pH 7.4.
3. Human Serum Albumin Solution (Sigma, St. Louis, MO):
- Human hemoglobin, fatty acid free, lyophilized powder (Sigma, St. Louis, MO).
- Phosphate-buffered saline, pH 7.4.
4. 5-Hydroxymethyl-2-furfural (5-HMF) Solution:
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
5. Mobile Phase for 5-HMF Assay Method:
- 93.5% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
- 6.2% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ).
- 1% Acetic acid glacial, > 99% (Sigma, Milwaukee, WI).
- 0.3 % Tetrahydrofuran HPLC grade (Burdick and Jackson, Morristown, NJ).
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6. SPE Conditioning:
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
7. SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4:
- Phosphate-buffered saline tablets, pH 7.4 (Sigma, St. Louis, MO).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
8. SPE Eluting Solution: 50% Methanol:
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
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6.2.2 Equipment

1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips
(Microman, Rainin Instruments, Oakland, CA).
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West
Chester, PA).
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA).
4. Vortex (Vortex-Genie, VWR, West Chester, PA).
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).
6. pH meter (Corning, Glendale, AZ).
7. Balance (Fisher Scientific A 250, Pittsburgh, PA).
8. Centrifuge 5804-R (Eppendorf, Hauppauge, NY).
9. Amicon® Ultra-4 centrifugal filter units with Ultracel-10 and Ultracel-50 membranes
(Millipore, Billerica, MA).
10. Glass vials with caps, 1 ml (Waters, Milford, MA).
11. UV detector (Shimadzu, AV-10, Columbia, MA).
12. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA).
13. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA).
14. 717 plus autosampler (Waters, Milford, MA).
15. 600 Multisolvent controller (Waters, Milford, MA).
16. Empower 2 software (Waters, Milford, MA)
17. Forma Scientific incubator.
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6.2.3 Preparation of Solutions

– Mobile Phase for 5-HMF Assay Method (1 L)
935 ml water, 62 ml methanol, 10 ml acetic acid glacial, and 3 ml
tetrahydrofuran were mixed to prepare the mobile phase.

– 5-Hydroxymethyl-2-furfural Solution (5-HMF)
5-hydroxymethyl-2-furfural (M.W.: 126.11 Da) was dissolved in PBS.

– Phosphate-buffered Saline (PBS), pH 7.4
One tablet of phosphate-buffered saline was added to 200 ml of water.

– SPE Eluting Solution: 50% Methanol
25 ml of methanol was mixed with 25 ml of water.

– Human Hemoglobin Solution
Human hemoglobin powder (M.W.: 64,677 Da) was dissolved in PBS.

– Human Serum Albumin Solution
Human serum albumin powder (M.W.: 66,478 Da), was dissolved in PBS.
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6.2.4 Procedures

5-HMF was added to human serum albumin or hemoglobin solutions in PBS at different
concentrations. The solution was incubated at 36.5 ± 1 °C. Two milliliter samples were
transferred to Amicon® Ultra-4 and centrifuged (5,000 rpm) for 20 minutes at 36.5 ± 1 °C. 50
kDa and 10 kDa were chosen as the molecular cut-off values for the membranes used in the
ultrafiltration of human serum albumin and hemoglobin solutions, respectively. The ultrafiltrate
was transferred to HPLC for analysis to quantitate the unbound 5-HMF concentrations (UC). The
difference between the initial concentration and the measured 5-HMF concentration was
assumed to represent the total 5-HMF binding to both the protein and the ultrafiltration system
(TB). Non-specific binding was determined, in unicate, after ultrafiltration of 5-HMF solutions
in the absence of proteins (NSB).
The chemical stability of 5-HMF was investigated at 36.5 ± 1 °C for 30 hours; where
samples of 5-HMF solution at 16 µM in PBS were analyzed by HPLC in unicate. In all of the
experiments, calibration curves of 5-HMF in PBS (0.2 – 80 µM) were established in PBS in
parallel with the analysis of the samples in various experiments in order to estimate the unbound
concentration of 5-HMF.

6.2.4.1 Time-Dependency Studies

5-HMF was pre-incubated in the suspension of RBCs containing HbS in the experiments
reported by Abdulmalik. This was justified by the notion that Hb adduct needed some time to
form (Abdulmalik, 2005). This rationale triggered this research to investigate time-dependency
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in 5-HMF binding to hemoglobin. Therefore, studies were conducted with 5-HMF in
concentrations ranging from 8 µM to 0.3 mM, incubated in Hb (217 μM) or HSA (63 and 202
μM) solutions in PBS at 37°C. Serial samples (unicate, mostly) for up to 30 hours were taken
and ultra-filtered using the Amicon® Ultra-4 centrifugal filter unit with Ultracel-10 and Ultracel50 membranes for Hb and HSA, respectively, by centrifugation for 20 minutes at 5,000 rpm at
37 °C.

6.2.4.2 Concentration-Dependency Studies

Studies were conducted with various concentrations of 5-HMF ranging from 5 µM to 5
mM and incubated in Hb (217 μM) or HSA (63 and 202 μM) solutions at 37 °C. Duplicate
samples at 24 hours (Hb solution) and 6 hours (HSA solution) were taken and ultrafiltered.
Unbound 5-HMF concentrations were measured by HPLC. Specific binding was estimated after
the correction for non-specific binding using the equations discussed in the Data Analysis
section.
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6.2.5 Data Analysis

The general scheme for the binding reaction, which leads to the formation of 5-HMF
Schiff base adduct with the amino group of a protein (human hemoglobin or serum albumin), is
described by Figure 6-2. In this scheme, k1 is the Schiff base formation rate constant, following
second-order kinetics, while k-1 is the adduct degradation constant that follows first-order
kinetics (Ge 1997). Any rearrangement of the aldimine bond in 5-HMF adduct to a stable
covalent bond (as it is the case for glucose) was assumed to be negligible.
The rate of change in the concentration of the adduct [Adduct] at any time in the binding
reaction is estimated according to Equation 6-1:

d[Adduct]
= k1 × [5HMF](t) × [Protein ](t) − k −1 × [Adduct](t) … … … … . . Equation 6 − 1
dt
where
[5HMF](t): the concentration of free 5-HMF at time (t)

[Protein](t): the concentration of free protein at time (t)

[Adduct](t): the concentration of the adduct between 5-HMF and the protein at time (t)
In these studies, free (i.e. unbound) 5-HMF at a certain time point (t i ), namely

[5HMF](t i ), was measured using the validated HPLC method. On the other hand, Equations 6-2
and 6-3 were used to estimate the adduct formed, [Adduct](t i ), and the concentration of free
protein, [Protein](t i ), at the relevant time point, t i :
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[Adduct](t i ) = [5HMF](t 0 ) − [5HMF](t i ) … … … … … … … … … … … … … … … … Equation 6 − 2
[Protein](t i ) = [Protein](t 0 ) − �[5HMF](t 0 ) − [5HMF](ti )� … … … … … … … Equation 6 − 3
where [5HMF](t 0 ) and [Protein](t 0 ) are the initial concentrations of 5-HMF and the protein,

respectively. At equilibrium, the rate of change is zero, as described by Equations 6-4 and 6-5:

k1 × [5HMF]eq × [Protein]eq = k −1 × [Adduct]eq … … … … … … … … … … … … Equation 6 − 4
KA =

[Adduct]eq
k1
=
… … … … … … … … … … … … … … … … … . . Equation 6 − 5
[5HMF]eq × [Protein]eq
k −1

where KA is association equilibrium constant, while [5HMF]eq , [Protein]eq , and [Adduct]eq are
the concentrations of free 5-HMF, free protein, and protein adduct, respectively, at equilibrium.

As a measure of affinity, the dissociation constant, K D , can be estimated, as an inverse of

KA as described by Equation 6-6:

KD =

1
… … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … Equation 6 − 6
KA
After performing the non-linear regression of the time dependency studies, the final

estimates for the forward and backward rate constants (k1 and k-1) were used to estimate an
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apparent first-order equilibration rate constant, keq (assuming that 5-HMF concentrations are
lower than the protein concentration, i.e., [5-HMF]<<[Protein]) as described in Equation 6-7.

k eq = k −1 + (k1 × [Protein]t 0 ) … … … … … … … … … … … … … … … … … … . … Equation 6 − 7
keq (apparent first-order rate constant) was estimated for 7.9 and 19.8 μM 5-HMF
incubated with Hb and HSA, respectively, using the rate constant estimates. keq was compared to
the actual rate constant, kobs, obtained from the slope when the natural logarithmic value for
difference between the adduct concentration at steady-state (Css) and the concentration of the
adduct at different time points (Ct), i.e. (ln (Css-Ct)), was plotted against time.
In addition, the final estimates of the rate constants were compared to those reported for
glucose and the equilibration rate for 5-HMF-Hb adduct was extrapolated to physiological blood
concentrations of Hb (2.3 mM) and the expected clinically relevant concentrations of 5-HMF (12 mM). In addition, the overall results of this study were put in context with the previously
reported data (Abdulmalik 2005).
In the data analysis performed, specific binding (SB) was estimated from the nominal
concentration (NC) and nonspecific binding (NSB), as follows:
Total Concentration Bound (TB) = NC – Ultrafiltrate (=Unbound) Concentration (UC)
Specific Binding (SB) = TB - NSB
Fraction Specifically Bound (fSB) = SB/(NC – NSB)
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Figure 6-2. Schiff base interaction between 5-HMF and protein.
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6.2.6 Modeling

For all models, goodness of fit was assessed by r2. Parameter estimates are reported along
with their standard errors.

6.2.6.1 Time-Dependency Studies

6.2.6.1.1 INITIAL ESTIMATES

To obtain initial estimates for the rate constants, shown in Figure 6-3, Equation 6-1 was
combined with Equation 6-5. The reaction was rewritten as shown in Equations 6-9 and 6-10
using KA and k-1 to express k1.

d[Adduct]
= k −1 × K A × [5HMF](t) × [Protein](t) − k −1 × [Adduct](t) … Equation 6 − 8
dt
d[Adduct]
= k −1 × (K A × [5HMF](t) × [Protein](t) − [Adduct](t)) … … … Equation 6 − 9
dt

The above differential equation was approximated by Equations 6-10 and 6-11:

∆[Adduct]
= k −1 × (K A × [5HMF](t) × [Protein](t) − [Adduct](t)) … … … Equation 6 − 10
∆t
B = k −1 × A … … … … … … … … … … … … … … … … … … … … … … … … … … … … . . Equation 6 − 11
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Where B represents the left side of the equation and A is the right side of the equation divided by
k-1.
An initial estimates of KA was obtained according to Equation 6-5 by measuring the
steady state concentration of 5-HMF and estimating the steady-state concentration of the adduct
and the protein in accordance with Equations 6-2 and 6-3. Consequently, k1 was estimated using
Equation 6-5.

6.2.6.1.2 FINAL ESTIMATES

Equation 6-1 describes the rate of adduct formation using forward and backward reaction
rate constants. However, the adduct was not directly measured experimentally, alternatively,
unbound 5-HMF was measured. Therefore, nonlinear regression, (Scientist®, version 2.1,
Micromath), was fitted to the data across initial 5-HMF concentrations, and the initial model
estimates (k1 and k-1) were optimized using non-linear regression using Equation 6-12.

d[5HMF]
= k −1 × [Adduct](t) − k1 × [5HMF](t) × [Hb](t) … … … … … … … . Equation 6 − 12
dt
The above equation assumes that all of the lost 5-HMF is involved in the adduct formation after
the correcting for the NSB. The final model parameter estimates were compared to those
reported for the Schiff adduct of glucose and Hb. The built Scientist model is shown in Appendix
C.
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6.2.6.2 Concentration-Dependency Studies

After correction for nonspecific binding, specific binding was used to estimate steadystate binding affinity (KD) and the maximum binding capacity or that which can be attained at a
very high concentration of 5-HMF (binding capacity, Bmax) by nonlinear regression (SigmaPlot®
10.0, Systat), using the hyperbolic relationship described by Equation 6-13. Bmax was expressed
as a molar ratio of 5-HMF bound to the total protein.

CB =

Bmax × Cu
… … … … … … … … … … … … … … … … … … … … … … … … … … . . Equation 6 − 13
K D + Cu

Where saturable binding was not observed, linear regression was employed using Equation 14.

CB = SB × Cu + Y0 … … … … … … … … … … … … … … … … … … … … … … . . … … Equation 6 − 14
where CB is 5-HMF concentration bound to the protein, SB is the specific binding coefficient, Y0

is the y-axis intercept, and Cu is the concentration of unbound 5-HMF.
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6.3

Results

6.3.1 Non-Specific Binding Studies

In the hemoglobin study, non-specific binding to Amicon® Ultra-4 centrifugal filter units
with Ultracel-10 membrane was fitted to a quadratic equation, as shown in Figure 6-3. This
model was used to estimate the specific binding to hemoglobin at different concentrations. On
the other hand, non-specific binding to Amicon® Ultra-4 centrifugal filter units with Ultracel-50
membrane was fitted to a linear equation, as shown in Figure 6-4. This model was used to
estimate the specific binding to albumin at different concentrations. The goodness of fit of these
models was assessed through the coefficient of determination r2 as shown the corresponding
figures.

6.3.2 Time-Dependency Studies

The concentration of 5-HMF was constant when incubated in PBS in the absence of
protein for 30 hours, as shown in Figure 6-5, indicating that it was chemically stable under the
experimental conditions. However, 5-HMF concentration decreased in the ultrafiltate when
incubated in the protein (Hb or HSA) solutions as demonstrated in Figures 6-6, 6-7, 6-8, 6-9, 610, 6-11, 6-12. The extent of decrease was higher in the presence of hemoglobin in comparison
to serum albumin, as demonstrated in Figures 6-6 and 6-10. Since only a small fraction of 5HMF was bound to albumin, the y-axis scale in Figures 6-9, 6-10, and 6-11 was changed to make
the decrease in the free concentration of 5-HMF more visible.
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Figure 6-3. Non-specific binding of 5-HMF in Amicon® Ultra-4 centrifugal filter units with
Ultracel-10 membrane.
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Figure 6-4. Non-specific binding of 5-HMF in Amicon® Ultra-4 centrifugal filter units with
Ultracel-50 membrane.

289

0.000016

5-HMF Concentration (M)

0.000012

0.000008

0.000004

0.000000
0

10

20
Time (hrs)

Figure 6-5. 5-HMF (16 µM) stability in PBS.
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Figure 6-6. Time-dependency of 5-HMF (7.9 µM) binding to hemoglobin (217 µM).
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Figure 6-7. Time-dependency of 5-HMF (63 µM) binding to hemoglobin (217 µM).
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Figure 6-8. Time-dependency of 5-HMF (397 µM) binding to hemoglobin (217 µM).
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Figure 6-9. Time-dependency of 5-HMF (37 µM) binding to HSA (202 µM).
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Figure 6-10. Time-dependency of 5-HMF (7.9 µM) binding to HSA (63 µM).
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Figure 6-21. Time-dependency of 5-HMF (20 µM) binding to HSA (63 µM).
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Figure 6-12. Time-dependency of 5-HMF (150 µM) binding to HSA (63 µM).
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30.00

It appears from Figure 6-6 that equilibrium between 5-HMF and hemoglobin was
achieved in this experiment. According to Equation 6-5, the average of last two points were used
in estimating the equilibrium constant (KA) for the purpose of obtaining the initial estimates as
follows:
=

2.86 (0.08)
× 106
3.60 (0.08) × 214 (0.08)
= 3711 ± 128 M-1

After that, the data from the experiment shown in Figure 6-7 were used for the purpose
of obtaining an initial estimate of the backward constant (k-1) as per Equation 6-11.
Consequently, the slope, 0.099 ± 0.025 hr-1, in Figure 6-13 represents k-1 for 5-HMF binding to
hemoglobin. This approach in estimating k-1 and k1 was previously reported by (Ge 1997). The
values of A and B are shown in Table 6-1. The initial estimate for k1 was calculated using
Equation 6-5:
= 3711 (128) X 0.099 (0.025)
= 367 ± 93.6 M-1hr-1

The same approach was used in obtaining initial estimates for the rate constants of 5HMF binding to human serum albumin. The equilibrium between 5-HMF and albumin was
achieved in the experiment shown in Figure 6-10. Consequently, the initial estimate of KA for 5HMF binding to human serum albumin was:
=

0.09 (0.03)
× 106
6.87 (0.03) × 62.9 (0.03)
= 208 ± 69 M-1
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Plotting Equation 6-11, as shown in Figure 6-14, k-1 was obtained from the slope and
estimated to be 0.61 ± 0.12 hr-1. The values of A and B are shown in Table 6-2. Using Equation
6-5, k1 was estimated
= 208 (69) X 0.61 (0.12)
= 127 ± 49 M-1hr-1

The initial estimates of the rate constants for both human hemoglobin and serum albumin
binding were optimized through non-linear regression across various concentrations. The final
parameter estimates of Equation 6-12 are shown in Table 6-3.
The final estimates of 5-HMF binding to hemoglobin were used to fit the experimental
data at three different 5-HMF initial concentrations. The fitted lines vs. the observed data are
shown in Figures 6-15, 6-16, 6-17.
When the natural logarithmic value for the adduct concentration yet to be formed , i.e. ln
(Css-Ct), was plotted against the incubation time for 5-HMF with human hemoglobin and serum
albumin, as shown in Figures 6-18 and 6-19, respectively, the observed rate constants (kobs)
were 0.194 ± 0.09 hr-1 and 0.66 ± 12 hr-1, while the t1/2 (=0.693/ kobs) was equal to 3.58 hours
and 1.1 hours for hemoglobin and albumin, respectively. kobs is equivalent to the product of the
forward and backward rate constants according to Equation 6-7. Consequently, the final estimate
of the rate constants (k1 and k-1) were used to calculate keq for hemoglobin and albumin. As
shown in Table 6-4, the estimated keq were similar to their corresponding kobs values.
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Table 6-1. Estimation of A and B for Hb-5-HMF adduct using Equation 6-11.

Time
(hr)

Free 5-HMF,
[5-HMF](t)
(μM)

Adduct
Formed
[Adduct](t)
(μM)

Free Hb,
[Hb](t)
(μM)

“A”
(KA*[Hb](t)
*[5-HMF](t)) [Adduct](t)

“B”
∆[5-HMF](t)/
∆t
(μM/hr)

0

60.43

0

217.2

0.4

58.75

1.68

215.5

47.1

4.59

1.2

55.53

4.90

210.6

43.7

3.86

3.0

49.03
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Figure 6-13. Initial estimate of k-1 for 5-HMF binding to hemoglobin using Equation 6-11.
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Table 6-2. Estimation of A and B for HSA-5-HMF adduct using Equation 6-11.

Time
(hr)

Free 5-HMF,
[5-HMF](t)
(μM)

Adduct
Formed
[Adduct](t)
(μM)

Free HSA,
[HSA](t)
(μM)

“A”
(KA*[HSA](t)
*[5-HMF](t)) [Adduct](t)

“B”
∆[5-HMF](t)/
∆t
(μM/hr)

0.2

19.7

0

63.0

1.1

19.1

0.6

62.4

0.26

0.60

2.8

18.9

0.8

61.6

-0.31

0.17

5.2

18.7

1.0

60.5

-0.61

0.08
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Figure 6-14. Initial estimate of k-1 for 5-HMF binding to albumin using Equation 6-11.
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Table 6-3. Final model parameter estimates for 5-HMF with HSA and Hb.
k1 (M-1hr-1)

k-1 (hr-1)

KA (M-1)

KD (mM)

Human Serum Albumin

523 ± 274

0.769 ± 0.502

680 ± 569

1.5 ± 1.2

Human Hemoglobin

414 ± 35

0.107 ± 0.026

3879 ± 998

0.26 ± 0.07
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Figure 6-15. Observed vs. fitted concentration of 5-HMF (7.9 µM).
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Figure 6-16. Observed vs. fitted concentration of 5-HMF (63 µM).
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Figure 6-17. Observed vs. fitted concentration of 5-HMF (397 µM).
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Figure 6-18. Apparent first-order decline in (Css-Ct) to estimate kobs for 5-HMF (7.9 μM)
binding to hemoglobin (217 μM).
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Figure 6-19. Apparent first-order decline in (Css-Ct) to estimate kobs for 5-HMF (19.8 μM)
binding to human serum albumin (63 μM).
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Table 6-4. Apparent first-order decline rate constant (SD) estimated from the data vs. that
obtained from the model.
Data kobs (hr-1)

Model keq (hr-1)

Human Serum Albumin

0.66 (0.12)

0.80 (0.67)

Human Hemoglobin

0.19 (0.09)

0.20 (0.05)
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6.3.3 Concentration-Dependency Studies

After correction for non-specific binding using the equations discussed in Section 6.2.5,
specific binding to human hemoglobin and albumin was estimated, as summarized in Tables 6-5
and 6-7. Specific binding to hemoglobin and albumin was plotted against the unbound
concentration, as shown in Figures 6-20 and 6-21. The data points represent the average of the
duplicate samples and the error bars represent their associated standard deviation (hard to
visualize due to their small value). The parameter estimates of 5-HMF- hemoglobin and 5-HMFalbumin binding models, are summarized in Tables 6-6 and 6-8 along with the standard error of
these estimates.
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Table 6-5. 5-HMF bound to hemoglobin at different initial 5-HMF concentrations ([Hb]= 217 µM, n=2 per concentration, mean
(SD)).

Nominal
5-HMF
Concentration
(µM)

Ultrafiltrate (UC)
Concentration (µM)

NSB
(µM)

Specific Binding
(µM)

Fraction
Specifically
Bound%

Bound
5-HMFmol/
Hbmol

4.76

3.12

0.758

0.882

22.1

0.004

14.3

8.72 (0.037)

1.85

3.70 (0.04)

29.8

0.017 (0.0002)

42.8

11.7 (0.279)

8.80

22.3 (0.28)

65.6

0.103 (0.001)

119

62.9 (0.983)

10.5

45.5 (0.98)

42.0

0.209 (0.005)

357

224 (2.60)

29.1

104 (2.6)

31.8

0.480 (0.012)

714

487 (1.34)

64.3

163 (1.3)

25.1

0.751 (0.006)

5952

4170

1455
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7.29

1.51
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Figure 6-20. 5-HMF specific binding to human hemoglobin.
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Table 6-6. Final parameter estimates of 5-HMF binding to hemoglobin (217 µM).
Value (SE)
Parameter
Concentration (µM)

Molar Ratio

Bmax

370 (6.93)

1.7 (0.03)

KD (µM)

577 (32.0)

577 (32.0)

r2

0.993

0.993
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Table 6-7. Concentration-dependency of 5-HMF binding to human serum albumin. ([HSA]= 202 µM, n=2 per concentration, mean
(SD)).
Nominal
5-HMF
Concentration
(µM)

Ultrafiltrate (UC)
Concentration
(µM)

NSB
(µM)

Specific Binding
(µM)

Fraction
Specifically
Bound%

Bound
5-HMFmol/
HSAmol

12

8.8 (0.2)

1

2.9 (0.07)

32

0.014 (0.0003)

37

33 (1)

2

1.7 (0.05)

5.0

0.008 (0.0003)

74

66 (1)

4

3.7 (0.07)

5.6

0.018 (0.0003)

222

177 (6)

12

33 (1.1)

19

0.17 (0.005)

667

521 (52)

36

110 (11)

21

0.55 (0.05)

2000

1588 (189)

107

306 (36)

19

1.5 (1.8)
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Figure 6-21. 5-HMF specific binding to human serum albumin.
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Table 6-8. Final parameter estimates of 5-HMF binding to human serum albumin (202 µM).

Value (SE)
Parameter
Concentration (µM)

Molar Ratio

SB

0.197 (0.005)

0.001 (0.00002)

Y0 (µM)

-1.82 (3.37)

-0.009 (0.016)

r2

0.998

0.998
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6.4

Discussion and Conclusions

Under the experimental conditions of the binding experiments, 5-HMF was chemically
stable at 37 °C for at least 30 hours – allowing the assessment of time-dependent binding. On the
other hand, binding of 5-HMF to both proteins, namely Hb and HSA, showed the expected time
dependency, reflecting the “transiently covalent” nature of this Schiff base binding reaction. The
time-dependency studies showed that the binding of 5-HMF to its target site of action, Hb, was
characterized by a time-dependent binding reaction with a high affinity and selectivity to Hb
relative to HSA. Hb had over 5-fold higher equilibrium association constant for 5-HMF than that
with human serum albumin, as shown in Table 6-3, indicating that 5-HMF is a high affinity
substrate for Hb.
Upon the comparison of the estimated rate constants with those estimated for glucose
binding to hemoglobin (Higgins 1981), as shown in Table 6-9, 5-HMF has a faster rate constant
of adduct formation (k1= 0.9 M-1 hr-1 for glucose vs. 414 M-1hr-1 for 5-HMF ). In contrast, 5-HMF
has a slower rate constant of the adduct degradation (k-1= 0.33 hr-1 for glucose vs. 0.11 hr-1 for 5HMF) and this coincides with the duration of action shown in Figure 1-8, Chapter 1. In addition,
the affinity constant (KD) for 5-HMF binding to Hb is 10-fold higher than that observed for a
typical aromatic aldehyde (Zaugg 1977), listed in Table 6-9, which is consistent with the fact that
5-HMF has a better in-vitro pharmacological activity when compared to other structurallyrelated aromatic aldehydes (Safo 2004). Besides, because 5-HMF has a faster rate constant of
Hb-adduct formation than glucose, while it has a slower rate constant of Hb-adduct degradation,
5-HMF has more than a 1,000-fold larger association constant, i.e., much higher affinity for Hb
than glucose. Again, this is consistent with the observation that aromatic aldehydes (similar to 5HMF) have higher affinity than aliphatic aldehydes (glucose) (Zaugg 1977).
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At a relatively low concentrations of human serum albumin, 63 µM, only a small fraction
of 5-HMF was bound to serum albumin (approximately 20% of total binding). On the other
hand, non-specific binding was quite high (approx. 80% of total binding), which may have
prevented better characterization of HSA binding to 5-HMF. However, at a higher human serum
albumin concentration, 202 µM, binding to human serum albumin showed a non-saturable
pattern. Abdulmalik et al, implied that 5-HMF does not have significant binding to plasma
proteins (Abdulmalik 2005). This might be due to the fact that serum albumin has a lower
physiological blood concentration compared to hemoglobin (0.6 vs. 2.3-5.3 mM), which makes
hemoglobin have higher capacity of binding than that of serum albumin in addition to its higher
affinity.
Both time-dependency and (steady-state) concentration-dependency studies resulted in
similar affinity (KD) estimates for Hb (0.26 mM vs. 0.59 mM). In addition, the Bmax value for Hb
is consistent with approximately two moles of 5-HMF bound per mole of hemoglobin. This
observation was expected, since each Hb molecule has two 5-HMF binding sites, one at each αchain of the hemoglobin molecule, i.e., α-valine (Safo 2004).
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Table 6-9. Hemoglobin binding rate constants (SD) to different substrates.
Substrate

k1 (M-1hr-1)

k-1 (hr-1)

KD (mM)

Reference

Aliphatic aldehydes
(Typical)

14

(Zaugg 1977)

Aromatic aldehydes
(Typical)

5

(Zaugg 1977)

(Higgins 1981)

Glucose

0.9 (0.2)

0.33 (0.04)

367 (91)

5-HMF

414 (35)

0.11 (0.03)

0.26 (0.07)
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As shown in Table 6-4, the predicted first rate-order equilibrium constants for 5-HMF
binding with Hb and HSA, (keq) were 102% and 121% of the observed constants (kobs),
respectively, obtained from the decline in the concentration of the adduct to be formed (Css-Ct).
A good estimate of keq, is expected if the initial Hb concentration is much higher than 5-HMF
concentration; thus, the free Hb concentration remains relatively constant during the
binding/unbinding reaction.
At the physiological Hb concentration in whole blood, the presumed effective
concentrations of 5-HMF (i.e., 1-2 mM, exceeding KD, i.e., beginning to saturate Hb binding
sites) are expected to show fast association with, but slow dissociation from Hb, resulting in
prolonged persistence of the Hb adduct (t1/2eq of 0.7 hrs). Thus, this unique drug-receptor
interaction may lead to a prolonged in-vivo PD effect.
Overall, these in-vitro findings are consistent with the results from an in-vivo PK study in
transgenic mice, which received single, oral 5-HMF doses of 50 to 200 mg/kg (Abdulmalik
2005). There was an initial lag-time observed between in-vivo plasma concentrations of 5-HMF
and the “modified” Hb (adduct) concentrations, semi-quantitatively determined by Hb gel
electrophoresis – consistent with the time-dependent binding of 5-HMF to hemoglobin, as shown
in Figure 1-10, Chapter 1.Moreover, the results of an accompanying in-vitro study, assessing
hypoxia-induced RBC sickling after 1 hour pre-incubation and immediate addition of 5-HMF (5
mM) demonstrated that pre-incubation enhanced the antisickling effects of 5-HMF relative to
direct addition, as shown in Figure 1-8, Chapter 1 - consistent with time depending binding and
an equilibration half-life of 0.7 hours, as reported above.
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CHAPTER 7
7
IN-VITRO DISPOSITION IN HUMAN BLOOD

7.1

Introduction

As discussed in Chapters 5 and 6, 5-HMF is subject to human hemoglobin and serum
albumin binding, as well as being metabolized in human RBCs. Consequently, studies were
carried-out to investigate 5-HMF concentration changes in the presence of blood proteins and
enzymes at their physiological concentration. The studies were performed in RBC hemolysate
suspension and in whole blood. Models were built combining both binding and metabolism
processes to examine their ability in predicting the free concentration of 5-HMF and the fraction
bound to hemoglobin, its site of action. In addition, studies were designed to verify whether the
validated HPLC method in Chapter 3 is measuring the total concentration of 5-HMF (bound and
unbound fractions) or only the free (unbound) fraction. Moreover, this project aimed to explore
the sensitivity of 5-HMF metabolism to inhibitors in order to estimate the contribution of RBC
metabolism to the observed 5-HMF disappearance rate in human blood.
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7.2

Methods

7.2.1 Materials and Reagents

1. Milli-Q® Water (Virginia Commonwealth University, PK/PD Laboratory).
2. 4-Methylpyrazole (4-MP) Solution:
- 4-MP, 99% (Sigma-Aldrich, Milwaukee, WI).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
3. Tetraethylthiuram Disulfide (Disulfiram) Solution:
- Disulfiram, purum 97% (Sigma-Aldrich, Milwaukee, WI).
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA).
4. Human Blood:
From a single female caucasian individual.
5. Phosphate-Buffered Saline (PBS), pH 7.4:
- Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
6. Phosphate-Buffered Saline (PBS), pH 7.4:
-Sodium phosphate dibasic (Sigma, St. Louis, MO).
-Potassium phosphate (Sigma, St. Louis, MO).
-Sodium chloride (Sigma, St. Louis, MO).
-Potassium chloride (Sigma, St. Louis, MO).
-Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
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7. 5-Hydroxymethyl-2-furfural (5-HMF) Solution:
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
8. Mobile Phase for 5-HMF Assay Method in Plasma and RBCs:
- 93.5% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
- 6.2% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ).
- 1% Acetic acid glacial, > 99% (Sigma, Milwaukee, WI).
- 0.3 % Tetrahydrofuran HPLC grade (Burdick and Jackson, Morristown, NJ).
9. SPE Conditioning:
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
10. SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4:
- Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).
11. SPE Eluting Solution: 50% Methanol:
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ).
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory).

324

7.2.2 Equipment
1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips
(Microman, Rainin Instruments, Oakland, CA).
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West
Chester, PA).
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA).
4. Vortex (Vortex-Genie, VWR, West Chester, PA).
5. Eppendorf vials (VWR, West Chester, PA).
6. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).
7. pH meter (Corning, Glendale, AZ).
8. Balance (Fisher Scientific A 250, Pittsburgh, PA).
9. Centrifuge 5804-R (Eppendorf, Hauppauge, NY).
10. Amicon® Ultra-4 centrifugal filter units with Ultracel-10 membrane (Millipore, Billerica,
MA).
11. Oasis HLB cartridge, 1 cc/ 30 mg (Waters).
12. Glass vials with caps, 1 ml (Waters, Milford, MA).
13. UV detector (Shimadzu, AV-10, Columbia, MA).
14. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA).
15. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA).
16. 717 plus autosampler (Waters, Milford, MA).
17. 600 Multisolvent controller (Waters, Milford, MA).
18. Empower 2 software (Waters, Milford, MA).
19. Forma Scientific incubator.
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7.2.3 Solution Preparation

– Mobile Phase for 5-HMF Assay Method in Plasma and RBCs (1 L)
935 ml water, 62 ml methanol, 10 ml acetic acid glacial, and 3 ml
tetrahydrofuran were mixed to prepare the mobile phase.

– 5-Hydroxymethyl-2-furfural Solution (5-HMF) Stock Solution (381 mM)
48 mg of 5-hydroxymethyl-2-furfural, M.W.: 126.11 Da, was dissolved in 1 ml of
PBS.

– Phosphate-buffered Saline (PBS), pH 7.4
One tablet of phosphate-buffered saline was added to 200 ml of water.

– SPE Eluting Solution: 50% Methanol
25 ml of methanol was mixed with 25 ml of water.
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7.2.4 Procedures

Human blood was collected from a healthy female volunteer using heparinized vacutainer.

7.2.4.1 Total vs Free 5-HMF Concentration in Hemolyzed RBCs.

After centrifuging the whole blood, plasma layer was removed and RBCs were washed
with PBS. RBCs were re-suspended in Milli-Q® water (0.4 RBCs: 0.6 water) and hemolyzed by
centrifugation. Concentrated PBS mixture was added to the hemolyzed RBCs together with 5HMF to achieve a concentration of 2 mM of 5-HMF. The suspension was then incubated at
36.5±1 °C for approximately 3 hours. Two sets, each with duplicate samples, taken at different
time points, were analyzed by the validated HPLC method after extracting the samples using
either solid phase extraction as described in Chapter 3 or by ultrafiltration using Amicon® Ultra.

7.2.4.2 5-HMF Metabolism in Hemolyzed RBCs.

Hemolyzed RBCs were processed using the same approach stated above. However, water
was replaced by 4-methylpyrazole and disulfiram solution in Milli-Q® water (0.4 RBCs: 0.6
inhibitors solution). The final concentrations of 4-methylpyrazole and disulfiram were 375 µM
and 40.5 µM, respectively. After incubation for 30 minutes, 5-HMF was added to the mixture to
achieve a concentration of 2 mM and the suspension was incubated at 36.5±1 °C for
approximately 3 hours. Duplicate samples, taken at different time points, were analyzed by the
validated HPLC method using solid phase extraction as described in Chapter 3.
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7.2.4.3 5-HMF in Whole Blood

5-HMF was incubated in whole blood and RBC suspension at concentrations of 2 mM
and 0.3 mM at 36.5 ± 1 °C over 2 hours. Duplicate samples, taken at different time points, were
analyzed by the validated HPLC method after separating plasma and RBCs using centrifugation
for 12 minutes at 3500 rpm, 3 °C.

7.2.5 Data Analysis and Modeling Assumptions

The first-order rate constants (k) for the disappearance of 5-HMF in different studies
were obtained as the negative value of the slope when the natural logarithmic values of 5-HMF
concentrations were plotted vs time. Consequently, the half-life (t1/2) was estimated using
Equation 7-1:

t1/2 =

0.693
… … … … … … … … … … … … … … … … … … … … … … … … … … … … … Equation 7 − 1
k

These rate constants and half-lives were compared to:

1. Verify the fraction of 5-HMF measured by the validated HPLC method, where the
samples were extracted using solid phase extraction. Only the unbound fraction of
5-HMF was assumed to survive sample extraction using ultrafiltation.
2. Investigate the sensitivity of 5-HMF metabolism in RBCs to inhibition by disulfiram
and 4-methylpyrazole.
3. Explore any difference in 5-HMF decline-rate between plasma and RBCs.
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In the non-linear regression carried-out for 5-HMF disappearance in human blood, the
concentration of hemoglobin was fixed, considering that the average hematocrit in females is
42% and is associated with an Hb concentration of 14 g/dl (Dixon 1997) (Rhoades 1996). In this
study, the hematocrit was adjusted to 40% and the Hb concentration was assumed to be 13.3
g/dl. Having a molecular weight of 64,677 g/mol, the concentration of Hb in this study was
equivalent to 2.06 mM.
The intrinsic clearance was estimated in Chapter 5 as 0.35 ml/min/ml RBCs, which is
equivalent to 21 ml/hr/ml RBCs. In this part of the research project, studies were carried-out in
whole blood or in RBCs suspension. Hence, the RBCs intrinsic clearance was diluted with PBS
or with plasma. With the RBCs accounting for approximately 40% in these matrices, the
metabolic activity of the enzymes was decreased by a factor of 2.5. Accounting for this dilution
factor, the intrinsic clearance was scaled by the volume of RBCs in the body resulting in a
metabolic rate constant of 8.3 hr-1, which was used as an initial model parameter. The data of the
ultrafiltrate of the RBCs hemolysate was selected for modeling purposes since it is believed to
reflect the free fraction of 5-HMF.
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7.2.6 Modeling

In blood, 5-HMF is subject to simultaneous hemoglobin binding and enzyme metabolism
in RBCs, as shown in Figure 7-1. Considering these processes, Equation 7-2 was used to
simulate the change of free 5-HMF in RBCs over time as follows:

d[5 − HMF]
=
dt

−k met [5HMF](t) + k −1 × [Adduct](t) − k1 × [5HMF](t) × [Hb](t) … … … Equation 7 − 2
where
[5HMF](t): the concentration of free 5-HMF at time (t)

[Protein](t): the concentration of free protein at time (t)

[Adduct](t): the concentration of the adduct between 5-HMF and the protein at time (t)

k met : the metabolic rate constant

Moreover, 5-HMF might be prone to binding to RBCs membrane. Hence, a factor was
added to account for this binding in the initial concentration of 5-HMF available for hemoglobin
binding and metabolism in RBCs. This value was estimated using the difference between the
nominal and the observed initial 5-HMF concentration. The simulation was performed assuming
four scenarios:
Scenario (1): 5-HMF binding to hemoglobin is the sole contributor to 5-HMF
disappearance over time.
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Scenario (2): Concurrent metabolism and binding of 5-HMF contribute to 5-HMF
disappearance over time.
Scenario (3): In the third scenario, the metabolic rate constant was re-estimated since it is
assumed to involve higher inter-individual variability than hemoglobin
binding.
Scenario (4): In whole blood: in addition to hemoglobin binding and RBC metabolism,
5-HMF can bind to serum albumin. Consequently, a second term in the
initial conditions of the model was added to account for human serum
albumin binding.
The parameters used in the simulation are summarized in Table 7-1. The model
parameters were used in the simulations of 5-HMF free concentration in RBC hemolysate
suspension and whole blood using non-linear regression of Equation 7-2. Scientist non-linear
regression models are shown in Appendix C.
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Figure 7-1. Concurrent 5-HMF binding and metabolism in blood.
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N Hb
H

+ H2 O

Table 7-1. Model parameters.
Parameter

Scenario (1)

Scenario (2)

Scenario (3)

Scenario (4)

HB0 (M)

0.00206

0.00206

0.00206

0.00206

HMF0 (M)

0.002

0.002

0.002

0.002, 0.0003

k1 (M-1hr-1)

414

414

414

414

k-1 (hr-1)

0.107

0.107

0.107

0.107

kmet (hr-1)

0

8.3

0.174

0.174

khsa

0

0

0

0.2
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7.3

Results

The concentrations of 5-HMF over time in the RBC hemolysates, which were analyzed
using solid phase extraction and by ultrafiltration, are shown in Figure 7-2. In addition, the
concentrations of 5-HMF in the presence of inhibitors, are shown in Figure 7-3. The
concentration of 5-HMF in the samples prepared by ultrafiltraton and that prepared by solid
phase extraction were found to be similar. The same was observed when 5-HMF concentration
was compared in the presence of inhibitors and in their absence. In addition, the concentration of
5-HMF over time when incubated in whole blood is shown in Figures 7-4 and 7-5. For all of
these studies, the first-order disappearance rate constant and the half-life are summarized in
Table 6-2.
The simulation for hemoglobin binding using the physiological concentration of
hemoglobin is shown in Figure 7-7. When the metabolism process was added to the process, the
fitted line underestimated the observed concentrations as shown in Figure 7-8. Upon optimizing
the metabolic rate constant, the kmet was estimated as 0.174 ± 0.047 hr-1 and the fit is shown in
Figure 7-9.
When the optimized metabolic and binding parameters were used in the simulation of 5HMF in whole blood, it fitted better to the data of higher 5-HMF concentration, 2 mM, than that
of the lower concentration, 0.3 mM, as demonstrated in Figures 7-10 and 7-11.
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Figure 7-2. Decline in 5-HMF concentration (2 mM) in RBC hemolysate measured after SPE or ultrafiltration.
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Figure 7-3. Decline in 5-HMF concentration (2 mM) in RBC hemolysate in the presence or absence of inhibitors.
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Figure 7-4. Decline in 5-HMF concentration (2 mM) in whole blood.

337

150

0.0004

0.0010
Plasma
Concentration (M)

Concentration (M)

Plasma

RBCs
0.0002

0.0000

RBCs
0.0001

0.0000
0

20

40

60

80

0

Time (min)

20

40
Time (min)

Figure 7-5. Decline in 5-HMF concentration (0.3 mM) in whole blood.
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Figure 7-6. Decline in 5-HMF concentration (2 mM) in RBCs of whole blood and RBCs hemolysate suspension.
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Table 7-2. Disappearance rate constants (SD) and t1/2 of 5-HMF in various matrices.

Presence of
Inhibitors

k (hr-1)

t1/2 (hour)

r2

0.67 (0.02)

1.0

0.99

0.76 (0.04)

0.9

0.99

0.72 (0.03)

1.0

0.99

0.58 (0.17)

1.2

0.80

2.8 (0.17)

0.3

0.99

Plasma (2 mM)

1.0 (0.10)

0.7

0.97

Plasma (0.3 mM)

2.9 (0.38)

0.2

0.95

Matrix

Sample Preparation

Ultrafiltration
Absent

Hemolysate
Suspension (2 mM)

Present
RBCs of Whole
Blood (2 mM)
RBCs of Whole
Blood (0.3 mM)

SPE
Absent
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Figure 7-7. Simulated 5-HMF free concentration in RBCs hemolysate using Scenario (1) with no metabolism included.
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Figure 7-8. Simulated 5-HMF free concentration in RBCs hemolysate using Scenario (2) including kmet= 8.3 hr-1.
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Figure 7-9. Simulated 5-HMF free concentration in RBCs hemolysate using Scenario (3) including kmet= 0.174 hr-1.
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Figure 7-10. Simulated 5-HMF free concentration (2 mM) in RBCs of whole blood using Scenario (4) including HSA binding.
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Figure 7-11. Simulated 5-HMF free concentration (0.3 mM) in RBCs of whole blood using Scenario (4) including HSA binding.
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7.4

Discussion and Conclusions

Due to the small difference in the concentration between 5-HMF in the ultrafiltrate and 5HMF exposed to solid phase extraction, it seems that the extraction method developed in Chapter
3 is unable to dissociate the bound 5-HMF from proteins and that HPLC determination reflects
mainly the free, i.e. the unbound, fraction of 5-HMF. This is further supported by the similar rate
constants for 5-HMF decline, shown in Table 7-2. In addition, there was no significant difference
in 5-HMF concentrations (or the determined decline rate constants) measured in the presence of
inhibitory concentrations of the inhibitors, as discussed in Chapter 4, and 5-HMF concentrations
measured in their absence. This indicates the absence of significant metabolic activities that are
sensitive to these inhibitors. The metabolic enzymes might have their activity decreased or
diminished during the experiment.
The rate constant for 5-HMF decline in the plasma was higher than that for 5-HMF
decline in the RBCs. This might be attributed to a higher rate of distribution of 5-HMF from the
plasma into the RBCs compartment in comparison to the redistribution rate. Higher capacity of
RBCs for 5-HMF versus that of the plasma may justify this difference in the distribution and
redistribution rates.
However, the higher rate constant for 5-HMF decline with lower initial 5-HMF
concentration was not expected. At the concentration of hemoglobin employed in these studies,
saturation of its binding sites is not anticipated at 2 mM. On the other hand, binding of 5-HMF to
blood components (other than hemoglobin) is assumed to be instantaneous, hence, it contributes
only to the initial decline of 5-HMF but not to the decline of 5-HMF over time. This might not be
true with low concentrations of 5-HMF that can show some time-dependency in its 5-HMF
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binding and increase the overall observed rate of 5-HMF decline over time. This coincides with
what is demonstrated in Figure 7-12, where the model initially underpredicts the free 5-HMF
concentration and overpredict it later in the experiment for the 0.3 mM 5-HMF concentration.
The simulations showed that 5-HMF binding to hemoglobin alone overestimated the free
concentration of 5-HMF in RBCs hemolysate suspension. This might be attributed to
modifications in the binding kinetics in the physiological setting that is affected by the unique
environment of RBCs, conformational changes of hemoglobin, and/or 5-HMF binding to other
proteins, such as RBC membranes.
On the other hand, the 5-HMF free concentration was underpredicted in the simulations
including concurrent RBC metabolism. The two simulation scenarios indicated that 5-HMF
metabolism may have existed in the matrix, however, not to the extent observed in the metabolic
studies discussed in Chapter 5. Here, the optimized metabolic rate constant was significantly
lower than that estimated from the RBC metabolism studies in Chapter 5. This observation
coincides with the absence of inhibitor activity due to the loss of enzyme viability during the
study. In addition, the metabolic studies in Chapter 5 were performed in a blood pooled from
different individuals, while in this study the blood was taken from a single Caucasian female.
Consequently, the activity of the enzyme might be different in these two studies. This is further
supported by Table 7-3. As demonstrated in this table, the activity of ALDH enzyme in RBCs
varies between individual as much as 10 fold. In addition, as stated in Chapter 1, 1 out of 16
persons had a deficiency in RBCs ALDH enzyme. Hence, this may have contributed to the
failure of observing significant metabolism in the current study. Moreover, Equation 7-2 assumes
that the activity of enzymes remains fully functional over the incubation time, which might not
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be the case. Furthermore, the cofactor for the metabolic enzymes might have diminished during
the period of the experiment.
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Table 7-3. Erythrocyte ALDH activity in mU/ml (Goedde 1983)
Number of Individuals
Erythrocyte ALDH Activity
(mU/ml)

Healthy Controls

Alcoholics

Psychiatric Patients
(Non-Alcoholic)

0.3

9

41

6

0.9

29

17

3

1.5

23

6

13

2.1

5

1

9

2.7

1

0

3

349

As shown in Figures 7-10 and 7-11, the fit using the optimized parameters matches
the observed data for the 2 mM of 5-HMF incubated in whole blood, which validates the
optimized model parameter estimates. On the other hand, the fit was less perfect for the 0.3
mM concentration of 5-HMF incubated in whole blood. This discrepancy was explored
above through the discussion of the rate constant for 5-HMF decline over time.
The inclusion of albumin binding in the initial conditions of the model assumes that
a steady-state (equilibrium) was instantaneous. While this might be valid in the case of 2
mM, this might not be the case with lower concentrations such as 0.3 mM. In addition, in
the model, the factor correcting for RBCs membrane binding was estimated at 2 mM
concentration rather than at 0.3 mM.
Overall, the built model demonstrated a persistence of the adduct concentration in
the RBCs in comparison to the free concentration of 5-HMF in plasma. Consequently, the
plasma concentration of 5-HMF does not reflect the concentration of 5-HMF in its
biophase in contrast to the assumption made to most of the drugs in the market. Due to the
time-dependency in 5-HMF binding to hemoglobin, there is a lag time between the peak
plasma concentration and the peak adduct concentration. In addition, the covalent bond in
the adduct will hinder the clearance of the bound 5-HMF leading to the persistence of the
pharmacodynamics effects of 5-HMF.
Since binding and metabolic parameters were not obtained in an in-vivo settings,
the following factors may contribute to a different behavior of 5-HMF when compared to
in-vitro studies:
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1. The unique environment of RBCs, including the presence of organic phosphate 2,3diphosphoglycerate (2,3-DG), cationic, and anionic species might affect the
binding and the metabolic reactions. It was reported that the presence of 2,3-DG,
CO, CO2, and O2 affected the rate constants for the Schiff base in HbA1c Invalid
source specified..
2. Inter-individual variation in hemoglobin concentration.
3. Genetic variation in the metabolic enzymes.
4. Sample preparation used in the analysis might disturb the equilibrium of binding
and metabolism.
5. Conformational changes of hemoglobin upon oxygenation and deoxygenation,
which makes the binding site for 5-HMF more or less accessible Invalid source
specified..
6. 5-HMF might be bound to other proteins. Lens crystalline, peripheral nerve
proteins, and erythrocytes membranes are examples of proteins that are susceptible
to Schiff base adduct formation with aldehydes Invalid source specified. (Bucala
1982).
7. The cofactor steady-state concentration in the physiological setting might be
different from that used in the conducted-studies.
Nevertheless, the parameters obtained from the performed studies were able to
describe 5-HMF behavior in blood. Accordingly, 5-HMF free concentration and that bound
to its site of action can be acceptably predicted using Equation 7-2.
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In a human body, 5-HMF is exposed to metabolism by the liver and RBCs. This
metabolism is not expected to undergo saturation since the determined Km value in hepatic
cytosol (218 mM) was much higher than the proposed therapeutic concentration (1-2 mM).
Likewise, the metabolism in the RBCs was not saturated with 5-HMF concentration up to
142 mM. Consequently, non-linear PK of 5-HMF in the plasma are not expected due to 5HMF metabolism. On the other hand, 5-HMF binding to hemoglobin is saturable due to
the finite binding sites to 5-HMF, which are equivalent to the concentration of Hemoglobin
dimmers (4.6 mM in blood). Consequently, 5-HMF binding to hemoglobin result in nonlinear PK of 5-HMF in plasma (supra-propotional) at high concentration of 5-HMF.
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CHAPTER 8
8
OVERALL RESULTS AND CONCLUSIONS

In this research project, the available literature on the physiochemical properties,
pharmacokinetics, and pharmacodynamics of 5-HMF was reviewed. 5-HMF is found
constitutively in food and is an adulteration product in honey, beer, fruit juice, and glucose
infusion solutions (Janzowski 2000) (Godfrey 1999). Although 5-HMF was administered
orally to human in three clinical studies, its PK properties were not described (Prior 2006)
(Matzi 2007) (M. P. Murkovic 2006). In different species, 5-HMF was shown to be
extensively metabolized and the metabolites were mainly excreted in urine (Godfrey 1999)
(Germond 1987). On the other hand, gaps were identified in human pharmacokinetics.
Consequently, this research project was carried out to explore the differences in 5-HMF
pharmacokinetics between and among species and to estimate its oral bioavailability.
An HPLC assay method for the quantitation of 5-HMF in neat solution, human
plasma, and human RBCs was developed and validated. 5-HMF was detected using UV
absorbance at 285 nm. The mobile phase was mainly aqueous with more than 90% water
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in addition to acetic acid, methanol, and tetrahydrofuran. The mobile phase had a flow rate
of 0.75 ml/minute through C18 guard and analytical columns.
The experimental conditions needed to investigate 5-HMF metabolism in human
hepatic cytosol were optimized to determine the metabolic pathways of the oxidative
metabolism of 5-HMF. NADH production was monitored at 340 nm as an indicator of 5HMF oxidative metabolism. In human hepatic cytosol, selective substrates validated the
presence of active ALDH and ADH enzymes. In addition, selective inhibitors
demonstrated that 5-HMF was metabolized by ALDH enzyme and to a lesser extent by
ADH enzyme in human hepatic cytosol.
In addition to human hepatic cytosol, oxidative metabolism was also demonstrated
in mouse, rat, and dog hepatic cytosol and was described by Michaelis Menten kinetics.
The in-vitro metabolic capacities (per mg protein of hepatic cytosol) were relatively similar
in mouse, rat, and dog hepatic cytosol. On the other hand, affinities were more variable with the highest affinity observed in the dogs and the lowest in humans. Consequently,
quantitative differences were predicted in the intrinsic clearance (per kg body weight)
among species with the lowest intrinsic clearance in humans.
In-vitro-in-vivo extrapolations of 5-HMF metabolism in mouse, rat, dog, and
human hepatic cytosol were performed and compared with published data. In all animal
species studied, 5-HMF is predicted to be subject to low hepatic extraction and clearance
and show high oral bioavailability in-vivo. In-vivo systemic exposure predictions using the
respective in-vitro-in-vivo extrapolations parameter estimates in mouse and dog were
reasonable and were within two-fold of those reported for in-vivo exposures. On the other
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hand, the in-vitro-in-vivo extrapolated t1/2 for humans was more than 30-fold longer than
the reported plasma t1/2 of the (presumed) primary metabolite, HMFA, after oral
administration of 5-HMF. This major discrepancy implied the involvement of extrahepatic
metabolism of 5-HMF in humans.
In-vitro 5-HMF metabolism was observed in human RBCs. Nevertheless,
metabolic saturation was not achieved in that system due to experimental limitations. The
intrinsic clearance was determined from the slope of the velocities vs. the concentration.
The failure to observe NAD+-dependent oxidation of ethanol and 5-HMF inhibition by 4methylpyrazole indicated the absence of ADH enzyme in RBCs. 5-HMF clearance by
RBCs, estimated through in-vitro-in-vivo extrapolations, was added to the hepatic
clearance, estimated previously from human hepatic cytosol, resulting in a total 5-HMF
clearance in human. The in-vitro-in-vivo extrapolated half-life was similar to the reported
plasma t1/2 of the (presumed) primary metabolite, HMFA, after oral administration of 5HMF. This resolved the discrepancy observed in human hepatic cytosol studies.
Time-dependency was observed in 5-HMF binding to human hemoglobin and to a
lower extent in 5-HMF binding to serum albumin. The kinetics of this binding indicated a
fast binding reaction rate with a slow dissociation rate. When 5-HMF binding to
hemoglobin was compared to glucose binding to hemoglobin, 5-HMF had a faster rate
constant of Hb-adduct formation than glucose, while it had a slower rate constant of Hbadduct degradation. At physiological Hb concentrations in whole blood, 5-HMF is
expected to show fast association with, but slow dissociation from Hb, resulting in
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prolonged persistence of the Hb adduct (t1/2eq of 0.7 hrs). Thus, this unique drug-receptor
interaction may lead to a prolonged in-vivo PD effect.
When the steady-state concentration-dependent kinetics were investigated, 5-HMF
showed saturable binding to human hemoglobin and non-saturable binding to serum
albumin. In the physiological environment, the serum albumin concentration in blood is
lower than hemoglobin, which makes hemoglobin have a higher capacity and affinity of
binding to 5-HMF than serum albumin.
A PK model that combined both hemoglobin and serum albumin binding together
with RBCs metabolism of 5-HMF to describe its disposition in blood was developed. The
fit using the optimized parameters matched the observed data for the 2 mM of 5-HMF
incubated in whole blood, validating by that the optimized model parameters. Accordingly,
5-HMF free concentration and that bound to its site of action can be acceptably predicted
using the developed PK model. In addition, the model demonstrated a persistence of the
adduct concentration in the RBCs in comparison to the free concentration of 5-HMF in
plasma. Consequently, the plasma concentration of 5-HMF does not reflect the
concentration of 5-HMF in its biophase due to the time-dependency in 5-HMF binding to
hemoglobin and the covalent bond in the adduct leading to the persistence of the
pharmacodynamics effects of 5-HMF.
Nevertheless, since binding and metabolic studies were not carried-out in an in-vivo
setting, a discrepancy might be observed in the behavior of 5-HMF in-vivo when compared
to in-vitro studies findings.
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As a conclusion, 5-HMF was found to be a low-affinity ALDH/ADH substrate in
hepatic cytosol and appears to be oxidatively metabolized primarily by ALDH in humans.
Across animal species, 5-HMF is expected to be a low-hepatic-extraction-ratio drug with
low hepatic first-pass effect and high oral bioavailability. In addition, 5-HMF is
metabolized in humans RBCs (presumably by ALDH). The presumed effective
concentrations of 5-HMF are expected to show fast association with, but slow dissociation
from its drug target, hemoglobin, which may lead to a prolonged in-vivo PD effect.
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Table A- 1. Ethanol concentration-dependency metabolic curve in human hepatic cytosol.
Concentration (mM)

Velocity (nmol/min/mg)

0.000

0.112 (0.013)

0.255

0.256 (0.008)

0.510

0.363 (0.023)

1.53

0.496 (0.032)

3.06

0.613 (0.013)

6.12

0.708 (0.031)

12.2

0.736 (0.001)

24.5

0.835 (0.042)
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Table A- 2. DN concentration-dependency metabolic curve in human hepatic cytosol.

Concentration (nM)

Velocity (nmol/min/mg)

0.000

0.083 (0.199)

3.30

2.03 (0.110)

8.25

2.07 (0.082)

24.8

3.21 (1.94)

66.0

3.46 (0.543)
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Table A- 3. Acetaldehyde concentration-dependency metabolic curve in human hepatic
cytosol.
Concentration (µM)

Velocity (nmol/min/mg)

4.12

1.92 (0.309)

12.4

2.39 (0.317)

37.0

2.08 (0.424)

111

2.62 (1.13)

333

4.38 (2.24)

33333

4.41 (0.603)
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Table A- 4. 5-HMF concentration-dependency metabolic curve in human hepatic cytosol.

Concentration (mM)

Velocity (nmol/min/mg)

0.000

1.86 (0.622)

1.50

2.01 (0.155)

3.01

2.40 (0.340)

6.02

2.23 (0.050)

12.0

3.78 (0.723)

24.1

4.89 (0.297)

48.1

7.90 (0.584)

96.3

11.9 (0.918)
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Table A- 5. 5-HMF concentration-dependency metabolic curve in mouse hepatic cytosol.

Concentration (mM)

Velocity (nmol/min/mg)

0.000

0.815 (0.511)

1.50

1.49 (0.284)

3.01

2.02 (0.357)

6.02

2.83 (1.13)

12.0

4.48 (1.98)

24.1

7.78 (1.12)

48.1

9.54 (0.633)

96.3

12.6 (2.83)
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Table A- 6. 5-HMF concentration-dependency metabolic curve in rat hepatic cytosol.

Concentration (mM)

Velocity (nmol/min/mg)

6

2.49 (0.682)

12

2.34 (0.788)

16

7.07 (2.69)

24

5.67 (0.637)

32

7.23 (1.71)

48

10.7 (2.59)

64

13.8 (1.35)

96

14.9 (2.13)
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Table A- 7. 5-HMF concentration-dependency metabolic curve in dog hepatic cytosol.

Concentration (mM)

Velocity (nmol/min/mg)

0.000

1.36 (1.25)

1.50

2.28 (0.819)

3.01

4.31(3.98)

6.02

4.47 (3.10)

12.0

4.02 (0.482)

24.1

8.43 (1.97)

48.1

9.90 (0.259)

96.3

13.4 (1.61)
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Table B- 1. Time-dependency of 5-HMF (0.0000079) binding to hemoglobin (0.000217
M).
Time (hours)

Unbound 5-HMF (M)

0

0.0000065

2.6

0.0000046

6.8

0.0000043

25

0.0000035

30

0.0000037
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Table B- 2. Time-dependency of 5-HMF (0.000063 M) binding to hemoglobin (0.000217
M).
Time (hours)

Unbound 5-HMF (M)

0

0.000060 (0.00000002)

0.40

0.000059 (0.00000043)

1.2

0.000056 (0.00000025)

3.0

0.000049 (0.00000005)

3.9

0.000046

6.5

0.000043
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Table B- 3. Time-dependency of 5-HMF (0.000397 M) binding to hemoglobin (0.000217
M).
Time (hours)

Unbound 5-HMF (M)

0.03

0.000296

1.0

0.000264

3.0

0.000250

6.0

0.000216
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Table B- 4. Time-dependency of 5-HMF (0.000037 M) binding to albumin (0.000202 M).
Time (hours)

Unbound 5-HMF (M)

0.07

0.000034

0.58

0.000032

1.3

0.000032

3.0

0.000031
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Table B- 5.Time-dependency of 5-HMF (0.0000079 M) binding to albumin (0.000063 M).
Time (hours)

Unbound 5-HMF (M)

0.0

0.00000696

2.6

0.00000691

6.8

0.00000687

24.9

0.00000691

30.2

0.00000684
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Table B- 6.Time-dependency of 5-HMF (0.0000198 M) binding to albumin (0.000063 M).
Time (hours)

Unbound 5-HMF (M)

0.0

0.0000197

0.4

0.0000197

1.1

0.0000191

2.8

0.0000189

5.2

0.0000187
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Table B- 7. Time-dependency of 5-HMF (0.000150 M) binding to albumin (0.000063 M).
Time (hours)

Unbound 5-HMF (M)

0.03

0.000143

0.97

0.00013

3.0

0.000128

6.1

0.000135

8.7

0.000138

25

0.000137
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// In-Vitro 5-HMF Binding to Hemoglobin
// Version 1.0
// JV, TO, July 29, 2009
//
// Assuming bimolecular, reversible interaction
// concentrations in M
// k1 in M*hr-1
// k-1 in hr-1
//
IndVars: T
DepVars: HMF, Hb, HbHMF
Params: k1, kmin1, Hb0, HMF0
// Diff Equations
HMF'=kmin1*HbHMF-k1*Hb*HMF
HbHMF'=k1*Hb*HMF-kmin1*HbHMF
// Mass Balance
Hb=Hb0-HbHMF
// IC
t=0
HMF=HMF0
HbHMF=0

***
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// In-Vitro 5-HMF in RBC suspension
// Version 1.0
// JV, TO, Dec 27, 2009
//
// Assuming bimolecular, reversible interaction
// concentrations in M
// k1 in M*hr-1
// k-1 in hr-1
// kmet in hr-1
// kmembrane in fraction
//
IndVars: T
DepVars: HMF, Hb, HbHMF, HMFmet
Params: k1, kmin1, Hb0, HMF0, kmet, kmembrane
// Diff Equations
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF
HbHMF'=k1*Hb*HMF-kmin1*HbHMF
HMFmet'=kmet*HMF
// Mass Balance
Hb=Hb0-HbHMF
// IC
t=0
HMF=HMF0-kmembrane*HMF0
HbHMF=0
HMFmet=0
***
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// In-Vitro 5-HMF in Blood
// Version 1.0
// JV, TO, Dec 28, 2009
//
// Assuming bimolecular, reversible interaction
// concentrations in M
// k1 in M*hr-1
// k-1 in hr-1
// kmet in hr-1
// kmembrane and khsa in fraction
//
IndVars: T
DepVars: HMF, Hb, HbHMF, HMFmet
Params: k1, kmin1, Hb0, HMF0, kmet, kmembrane, khsa
// Diff Equations
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF
HbHMF'=k1*Hb*HMF-kmin1*HbHMF
HMFmet'=kmet*HMF
// Mass Balance
Hb=Hb0-HbHMF
// IC
t=0
HMF=HMF0-kmembrane*HMF0-khsa*HMF0
HbHMF=0
HMFmet=0
***
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